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Natural killer T (NKT) cells are a subset of T cells that recognizes and is activated by 
glycolipid antigens. Glycolipids, specifically -galactosylceramides, are a primary focus 
due to their ability to modulate immune responses based on interactions with NKT cells. 
KRN7000, the first synthetic glycolipid shown to potently activate NKT cells, has been the 
foundation of structure-activity relationship (SAR) studies, providing insight to how 
glycolipids interact with components of the immune system to elicit specific responses. A 
glycolipid can produce a Th1 and/or Th2 response from NKT cells. A primary goal of many 
researchers is to produce a potent glycolipid, but also one that selectively induces a Th1 
response.  
Various modifications have been made to the structure of KRN7000 to monitor changes 
in activity. 7DW8-5 is a potent, Th1 biasing glycolipid that emerged from such efforts. 
Another modification to KRN7000 was replacing galactose with several disaccharide 
counterparts. Certain disaccharides have been shown to increase Th1 responses in 
whole cell assays. Therefore, this thesis describes novel analogs of 7DW8-5 that have 
been developed in an attempt to produce a potent, Th1 biased biological response. 
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Chiral amines are abundant in pharmaceutically interesting compounds including drugs 
currently on the market. One method of generating chiral amines is through nucleophilic 
addition into chiral N-sulfinyl imines and other substituted imines. One major flaw in this 
method is that the synthesis of N-substituted imines is not trivial. Some methods require 
highly reactive species or form insoluble byproducts that are not viable for large-scale 
process chemistry set ups. Transimination has been shown to form N-alkyl substituted 
ketimines from a ketiminium salt and alkyl amine. This thesis presents the first use of 
transimination to form chiral N-sulfinyl ketimines under optimal conditions. Ketiminium 
salts were also used to generate a library of N-phosphinyl, -tosyl, and –carbamoyl 
ketimines under mildly basic conditions with good to excellent yields.  
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CHAPTER 1 
Synthesis of -Galactosylceramide Analogs  
for Th1 Biased iNKT Cell Activation 
 
1.1 INTRODUCTION 
1.1.1 Natural Killer T Cells 
 
Natural killer T (NKT) cells are members of both the innate and adaptive immune system. 
The T cell receptors (TCRs) of NKT cells recognize lipid antigens presented by CD1d 
proteins on the surface of antigen presenting cells (APCs). It has been shown that 
genetically engineered mice deficient in CD1d fail to develop NKT cells. As a result, the 
immune system is unable to protect against common infections, and the mice do not 
survive. This result indicates the absolute necessity of these cells to the immune system.1 
NKT cells can further be classified into two distinct groups: Type I and Type II. Type I 
NKT cells express an invariant T cell receptor (iNKT cells) whereas Type II express a 
diverse set of TCRs. Although the most abundant NKT cells in humans are Type II, Type 
I NKT cells have been studied more extensively with lipid antigen activators.2 
 
1.1.2 Glycosphingolipids 
Glycosphingolipids (GSLs) are a class of amphiphilic natural products. Due to both their 
polar and nonpolar nature, these compounds are found in the cell membranes of both 
prokaryotes and eukaryotes.3 The name glycosphingolipids denotes the general structure 
of this class of compounds. They contain a polar sugar head with two lipid tails 
characterized as a fatty acyl chain and sphingoid base. The two lipid tails together are 
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referred to as a ceramide (Fig. 1.1a). Glycosphingolipids can be further characterized by 
the arrangement of the glycosidic linkage, the degree of saturation on the sphingoid base, 
as well as which sugar is present on the polar head. The anomeric substituent can be 
either in the  or  disposition. For D-sugars, which are most commonly found in nature, 
when the anomeric substituent is axial, it is considered alpha (), because it is anti to the 
C5” substituent. When the C1” and C5” substituents are syn in D-sugars, they are 
considered beta () (Fig. 1.1b). The same nomenclature applies when there are more 
than one sugar present on the glycolipid. Di- and tri-saccharide glycolipids have also been 
isolated. Although the sphingoid base can vary, there are three very common types: 
phytosphingosine, sphinganine, and sphingosine. Phytosphingosine is an amino triol,  
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 whereas sphinganine is an amino diol with the C4 hydroxyl in phytosphingosine replaces 
with a proton. The C4 hydroxyl is eliminated in sphingosine with an alkene between the 
C4 and C5 (Fig. 1.1c). Following the nomenclature for glycosphingolipids, the compound 
in Figure 1.1a can also be called an -Galactosylceramide ( -GalCer), due to the 
anomeric carbon position and galactose sugar head. The first natural glycosphingolipid 
isolated and characterized was a -GalCer with a sphingosine base (Fig. 1.1d).4 Like the 
natural product in Figure 1.1d, most naturally occurring glycosphingolipids are -linked, 
with the predominant sugars being galactose or glucose.5 However, -GalCers have also 
been isolated and are of great pharmaceutical interest.  
 
1.1.3 KRN7000 
In 1993, Kirin Brewery, a subsidiary of Kirin Holdings Company in Japan, reported the 
activity of several isolated glycosphingolipids, termed agelasphins, from the marine 
sponge Agelus maritianus.6 Agelasphin-9b was a potentially interesting natural product,  
because it was shown to have anti-tumor activity in B-16 melanoma mice (Fig. 1.2a). 
Using agelasphin-9b as a lead compound, structure-activity relationship (SAR) studies 
were performed.7  
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Because agelasphin-9b’s activity was measured on the isolated natural product, Morita 
et al. also sought to synthesize the glycolipid to ensure that the compound’s activity was 
not due to unknown natural product impurities. Luckily, both the isolated and synthesized 
natural product had the same reactivity, confirming the glycolipid’s biological effect. In 
generating agelasphin-9b, however, the synthetic chemists noted how difficult it was to 
establish a terminal branched methyl in the sphingoid base. Therefore, while performing 
SAR studies, they generated a library of compounds similar to agelasphin-9b, differing in 
C-3, C-4, and the length of the sphingoid base (n), while monitoring the effect of a linear 
sphingoid base versus branched. They also sought to observe the effect of substitution 
on C-2’ as well as the length of the acyl chain (m). Including agelaphin-9b, they reported 
the activity of twenty glycolipid analogs where X, Y, and Z in Figure 1.2b was either a 
hydroxyl group or a proton, the acyl chain length ranged from thirteen to twenty-five 
carbons, and the sphingoid base ranged from eleven to eighteen carbons.  
When monitoring tumor growth inhibition in B16 melanoma bearing mice, no difference in 
effect was observed between branched and linear sphingoid bases. When comparing the 
length of the linear sphingoid base (C-11, C-15, C-18, C-19, and C-20), it was found that 
the eighteen carbon sphingoid base had the most inhibitory activity. Another murine assay 
was performed to measure lymphocyte proliferation (LP). The researchers found that 
when there were no alcohols on the sphingoid base, no LP is observed. It was also noted 
that a similar LP response was observed in the 3,4-dihydroxy and 3-hydroxy analogs. 
These results led the researchers to conclude that, although the 3-OH was necessary for 
biological activity in mice, the 4-OH may not be. In the same murine assays, it was also 
found that a longer acyl chain (C-25) had the best results and the 2’-OH did not play an 
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important role, if any, in biological activity. The glycolipids with promising biological activity 
were then carried forward into human umbilical cord blood (hUCB) assays. Interestingly, 
compounds with 3,4-dihydroxy sphingoid bases performed better than 3-hydroxy. This 
result indicated that the 4-OH may play a more important role for activity in human cells 
than it does in mice biological activity. The results of the SAR study are summarized in 
Table 1.1. 
Putting all the results together led to a simplified and synthetically accessible glycolipid, 
KRN7000 (Fig. 1.2c). KRN7000 was chosen as the desirable candidate to carry forward 
into clinical trials.8 Since its development, KRN7000 has remained the gold standard for 
glycolipid activity of which all other glycolipid analogs are compared to. 
 
1.1.4 Glycosphingolipid Mechanism of Action 
When agelaspin-9b and other glycolipid analogs were first found to be tumor growth 
inhibitors, the mechanism of action was not fully understood. In 1997, it was discovered 
that glycolipids, such as KRN7000, are CD1d-restricted activators of NKT cells via TCRs.9 
When glycosphingolipids were exposed to antigen presenting cells (APCs), more 
specifically CD1d proteins on the cells, they were found to follow an immunological 
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pathway. A glycosphingolipid is considered an antigen by the immune system, and this is 
recognized by APCs. APCs contain CD1d proteins on the surface of the cell which bind 
lipid antigens. The long hydrophobic tails of the ceramide fit into an active site of CD1d 
forming a binary complex. Mice CD1d proteins contain two hydrophobic pockets, termed 
A’ and F’, that are laced with hydrophobic amino acid residues. The fatty acyl chain docks 
into the A’ pocket, whereas the sphingoid base resides in F’. Due to difficulties isolating 
the human CD1d (hCD1d)/glycolipid binary complex, only the murine binary complex has 
been reported (Fig. 1.3a).10  
 
Alcohols on the sugar and sphingoid base of KRN7000 also interact with CD1d via 
hydrogen bonding which further stabilizes the binary complex (Fig. 1.3b).11 The 2”-OH of 
galactose participates in hydrogen bonding with Asp151 on CD1d, and the 1-O and 3-OH 
of phytosphingosine hydrogen bond with polar amino acids Thr154 and Asp80, 
respectively. As mentioned previously, the 4-OH of KRN7000 is required for increased 
activity in human cells, but no significant interaction has been observed in the murine 
(binary) or human (ternary) crystal structures.  
CD1d
Figure 1.3. Crystal stucture of murine CD1d/KRN7000 binary complex
a. Ceramide residing in the A’ and F’ pockets. b. Hydrogen bonding between 
galactose and murine CD1d amino acid residues
b
acyl
chain
sphingoid 
base
sugar heada
CD1d
sugar head
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Invariant TCRs (invTCRs) on the surface of 
iNKT cells recognize binary complexes 
(APC/GSL) presented by the APC to form the 
ternary complex (APC/GSL/NKT). Because 
KRN7000 protrudes out of the APC 
minimally, few interactions between 
galactose and the TCR have been observed 
in both mice and human NKT cells. A crystal 
structure of the ternary complex solved by 
Rossjohn and co workers highlights the interactions between glycosyl alcohols on 
KRN7000 and a human TCR on an NKT cell (Fig. 1.4).12 The 3”-OH and 4”-OH on 
galactose interact with the CDR3 and CDR1 loop on the TCR, respectively. The amino 
acid sequences of these loops are conserved between mice and human TCRs. Key 
interactions occur between the 3”-OH and Arg95 on CDR3 and between the 4”-OH 
and Ser30 on the CDR1 loop. These hydrogen bonding interactions contribute to the 
overall stability of the ternary complex. This indicates the importance of the 4”-OH and 3”-
OH on galactose for TCR interaction.  
Once the ternary complex is formed, NKT cells are stimulated. Glycolipids can promote 
both a Th1 and Th2 response, which results in the development and release of various 
cytokines (Fig. 1.5).13 The Th1 response is characterized by the production of interferon-
gamma (IFN), interleukin 2 (IL-2), and tumor necrosis factor (TNF), among others. These 
cytokines cause a pro-inflammatory response, which in turn fights infections and tumor 
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growth. Conversely, the Th2 response is considered anti-inflammatory, and the Th2 
cytokines, IL-4, IL-10, and IL-13, prevent autoimmune diseases from developing.  
 
1.1.5 Th1 and Th2 Biasing Effects  
Because glycolipids were first shown to have tumor growth inhibiting effects, efforts have 
continued to modify the structure of glycolipids, such as KRN7000, to produce the optimal 
anti-tumor biological response. Due to the antagonistic effects of the Th1 and Th2 
responses, the target glycolipid therapy would invoke an ideal balance of Th1 versus Th2. 
Although promoting a Th1 response can result in the treatment of infections and tumors, 
too much stimulation of Th1 cytokines results in autoimmune disease development. 
Similarly, although a Th2 response can counteract autoimmune disorders, an excess of 
Th2 cytokines can lead to allergic inflammatory diseases.14 Despite KRN7000’s ability to 
induce an immune response, it has been largely a failure in clinical trials for the treatment 
of metastatic cancer.15 This result is thought to be due to the stimulation of both a Th1 
and Th2 response, which negates the overall effectiveness of the treatment. Therefore, 
for a glycolipid cancer therapy to be successful, it is critical to elicit the perfect balance of 
Figure 1.5. NKT cell activation by a glycolipid can produce various biological responses.13
 9 
both immune responses to achieve the desired result. Unfortunately, the optimal Th1/Th2 
ratio is not fully understood, and as a result, researchers continue to seek a glycolipid that 
can produce enough of a biased Th1 response to have a significant and positive biological 
effect, while also inducing an adequate Th2 response so as to not cause harm.  
 
1.1.6 Structural Modifications to KRN7000  
Because KRN7000 showed greater potency than most synthetically obtained GSLs but 
had poor Th1 selectivity, many groups have sought to modify KRN7000 in order to 
maintain potency yet produce a polarizing Th1 effect.  
 
1.1.6.1 Acyl Chain Modifications 
As mentioned previously, the first source of glycolipid recognition by CD1d is at the lipid 
tails of the ceramide in the hydrophobic A’ and F’ pockets. Therefore, Yamamura and co 
workers explored the effect of the hydrocarbon chain length on the sphingoid base. 
Despite the objective of biasing a Th1 response, one analog with a truncated sphingoid 
base resulted in a Th2 cytokine profile.16 This glycolipid, termed OCH, was not as potent 
as KRN7000, but was interesting nonetheless (Fig. 1.6). Due to its Th2 biasing nature, it 
was shown to activate NKT cells in mice and treat autoimmune encephalomyelitis, the 
murine equivalent of multiple sclerosis. Soon after, another glycolipid was reported to be 
less potent than KRN7000, but more Th2 biasing (C20:2).17 C20:2 was similar to 
KRN7000 in the sphingoid base, but contained a skipped diene in the shortened acyl 
chain.  
The first glycolipid to show a significant Th1 cytokine profile was -C-GalCer, which differs 
from KRN7000 solely at the anomeric position with a methylene replacing the anomeric 
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ether.18 Although it was shown to have a stronger Th1 biased response in B16 melanoma 
mice assays, it later failed in human lymphocyte studies.19 Similar to C20:2, more SAR 
studies were performed on the acyl chain of KRN7000. It wasn’t until aromatic moieties 
were incorporated into the acyl chain that a Th1 cytokine profile was observed again. In 
2006, Wong and co workers reported a library of glycolipids with acyl chains of varying 
length and aromatic rings.20 Although they examined the effect of heteroaromatics such 
as pyridine, thiophene, and furan, most interesting were the glycolipids with shortened 
hydrocarbon tails with a terminal phenyl group (see Fig. 1.6). These glycolipids were 
shown to bias a Th1 response by about 2:1 based on the levels of IFN- and IL-4 
measured. Docking studies with hCD1d revealed similar interactions in the F’ pocket 
observed with phytosphingosine of KRN7000. Significantly different from KRN7000 were 
the interactions with aromatic amino acid residues in the A’ pocket observed in the 
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modeling program, Autodock 3.0, employed for docking studies (Fig. 1.7).21 These 
interactions included pi stacking between the phenyl rings on the glycolipids with a chain 
length of five and seven carbons and the phenol of Tyr73. Similarly, pi interactions 
between the GSL with ten carbons and Trp40 were also noted. Shorter aromatic acyl 
chains had few significant interactions in the A’ pocket.  
In biological assays, these aromatic substituted compounds had greater anti-cancer 
activity than KRN7000 in breast and lung cancer models.22 This biological result could be 
due to the aromatic analogs demonstrating up to an 80-fold greater binding affinity to 
CD1d than KRN7000, implying the 
more stable the binary complex, 
the more Th1 biasing.23 Another 
aromatic glycolipid that contained 
eight carbons in the acyl chain with 
a terminal p-fluorophenyl group 
was examined. It was shown to 
have the highest number of van 
der Waals contacts in the A’ pocket. Based on these results, it was determined that 
aromatic substituents on the acyl chain promote a beneficial IFN-/IL-4 ratio and fine tune 
the Th1/Th2 response.  
One additional important analog with an acyl chain modification has been examined by 
Wong and co workers. In 2010, 7DW8-5, with ten carbons and a terminal p-fluorophenyl 
group on the acyl chain, was reported to have potential as a vaccine adjuvant (see Fig. 
1.6).24 An adjuvant is an immunological agent that promotes the immune response to a 
Figure 1.7. Superimposed results of docking studies with
hCD1d and glycolipids with terminal aromatic moieties.
CD1d
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vaccine. As a result, the adjuvant increases the efficacy of said vaccine by producing a 
greater number of antibodies for longer-lasting immunity. Because -GalCers are proven 
to boost immunological activity, they have been examined as potential vaccine 
adjuvants.25 7DW8-5 produces a much greater Th1 response than KRN7000 with 
significantly more IFN- and IL-2 production. 7DW8-5 also has a drastically lower half 
maximal effective concentration (EC50) value against human iNKT cells than KRN7000: 
0.38 nM and 54 nM respectively. EC50 is an operational value measured for potential 
drugs. It refers to the concentration of a drug required to induce a response that is halfway 
between the baseline and maximal measurement of a biological response.26 EC50 is 
typically used to measure how potent a drug is. A low (sub-nanomolar) EC50 indicates a 
more effective drug, because it takes a smaller dose to induce the same result. 
Furthermore, 7DW8-5 has a much lower dissociation constant (Kd) to invTCRs than 
KRN7000. Once again, the lower the Kd value, the greater the binding affinity. Overall, 
7DW8-5 exhibited a greater Th1 response at much lower concentrations than KRN7000, 
suggesting it is a promising therapeutic agent with multiple functions. 
 
1.1.6.2 Sphingoid Base Modifications 
As mentioned in the SAR study of agelaphin-9b, Morita and co workers investigated the 
effect of the 4-OH on glycolipids. Surprisingly, the twenty analogs examined in the SAR 
study did not include a sample of KRN7000 with a sphinganine sphingoid base. Analogs 
missing the 4-OH, had varied sphingoid base and acyl chain lengths that did not match 
KRN7000. Therefore, the sphinganine analog of KRN7000 had remained unexamined for 
quite some time. In 2004, the Howell group reported various methods of accessing 
 13 
sphinganine-type sphingoid bases (aminodiols).27 At the time, these syntheses were 
much simpler than generating phytosphingosine, which has since become commercially 
available for a reasonable cost. As a result of that work, the Howell group reported the 
first synthesis of both KRN7000 and OCH analogs containing a sphinganine base in 2005 
(Fig. 1.8).28 Biological assays using immortalized NKT cells revealed that 1 (AH03-1) and 
2 had comparable activity to their phytosphingosine counterparts. AH03-1 elicited a 
strong Th1 response in mice 
but did not perform as well in 
human cell lines. These results 
confirm what Morita and co 
workers observed that the 4-
OH may not be crucial to a 
glycolipid’s activity in mice, but 
plays a larger role in human 
CD1d docking. There continues to be conflicting reports about the importance of 4-OH in 
the sphingoid base. Pipelier and co workers generated KRN7000 analogs with 3-fluoro 
and 3,3-difluoro substitutions. Both analogs were 4-deoxy, and they argued their analogs 
work as well as KRN7000 in human NKT cell models.29 Analogs without any functional 
group at C3 or C4  were not investigated due to reports of their inactivity.30 Glycolipids 
containing an unsaturated sphingosine base have also been investigated but these 
compounds are typically -GalCers and -GlcCers and interact with the immune system 
in a different manner.31  
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1.1.6.3 Carbohydrate Modifications 
As with the other components of a GSL, the sugar head has also been modified for SAR 
studies. Disaccharide analogs of -GalCers are of interest partially due to the isolation 
and characterization of naturally occurring di-glycosylated GSLs (Fig. 1.9a). 3a-c and 
4a,b were isolated from an unknown Japanese marine sponge and Stylissa frabeliformis 
respectively.32  Compounds 3a-c are di-glycosylated GSLs with an  glycosidic linkage 
between two galactoses at C1” and C2”. Therefore, they are considered (1-2) 
glycolipids. Following the same nomenclature, 4a and 4b are (1-2, 1-3) GSLs. Not 
surprisingly, 4a and 4b had diminished immunological activity, which could be rationalized 
by a loss in the H-bonding of 3”-OH with the TCR shown in Figure 1.4. GSLs 3a-c were 
examined for their effects on mixed lymphocyte reaction (MLR) and murine spleen cell 
proliferation. MLR is a pharmaceutical safety assay where different lymphocyte 
populations are mixed together with the compound of interest and the cellular reaction is 
recorded. The purpose of the assay is to measure how T cells react to certain species.33 
Although this assay does not indicate exactly how the glycolipids are activating NKT cells, 
 it serves as a starting point to see if a compound if active at all and whether or not it 
should be carried forward for more extensive studies. Compounds 3b and 3c had 
comparable activity in the MLR assay, whereas 3a was significantly less potent. This 
result was somewhat perplexing considering 3a has just two fewer carbons in the acyl 
chain than 3b. Spleen cell proliferation studies also showed a much weaker response to 
3a. These results indicate that the length of the hydrocarbon acyl chain plays a role in the 
activity of the glycolipid, and the longer the chain, the better the activity; as shown with 
3b, 3c, and KRN7000.  
 15 
In 1997, the Kirin Brewing Company once again reported on the activity of KRN7000-type 
glycolipids.9 This time, they explored the activity of disaccharide analogs of KRN7000. 
In 2001, the glycolipids were sent to Kronenberg and co workers, who reported the cellular 
processing of the disaccharide analogs of KRN7000 (Fig. 1.9b).34 Following the naturally-
occuring agelasphin analogs, they reported the (1-2) analog of KRN7000. Because the 
(1-3) was previously found to be inactive, they investigated an (1-6) analog instead. 
One purpose of the study was to observe what kind of antigen processing, if any, the 
disaccharides underwent in the presence of cellular enzymes such as -galactosidase, a 
sugar-cleaving enzyme. In an APC-free T cell stimulation assay, KRN7000 and (1-6) 
GalCer were able to stimulate IL-2 production by NKT cells whereas (1-2) GalCer was 
not. This test uses mouse CD1d coated plates to examine whether the lipid antigens 
require internalization and cellular processing to activate NKT cells or if they can just bind 
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to CD1d and cause an immunological response. Because (1-2) GalCer resulted in no 
IL-2 release, it must require some degree of processing. Interestingly, they observed NKT 
cell stimulation in assays with CD1d on APCs and (1-2) GalCer, indicating that the 
presentation of (1-2) GalCer to the TCR may occur after CD1d is internalized directed 
to antigen processing compartments in the APC. To test this hypothesis, a fluorescent 
assay was employed where they were able to observe CD1d immunolocalized in APCS 
using Bodipy-labelled pepstatin. Conversely, KRN7000 and (1-6) GalCer were not 
internalized upon formation of the binary complex. Similarly, when Bafilomycin A1 (Baf), 
an inhibitor that prevents cellular uptake of macromolecules, was introduced, both 
KRN7000 and (1-6) GalCer promoted IL-2 production, whereas (1-2) GalCer had no 
reaction. To confirm (1-2) GalCer internalization, an analogous assay was performed 
where APC and (1-2) GalCer were incubated together; then, Baf was introduced. IL-2 
production was observed, meaning (1-2) GalCer was internalized before Baf could 
inhibit it, and the GSL was able to activate NKT cells. Finally, an in vitro assay was 
performed to mimic in vivo conditions. -Galactosidase was introduced to the system to 
examine what cellular processing was required for (1-2) GalCer activity. They observed 
a dose-dependent increase of IL-2 and IFN- production, mimicking antigen processing 
in APCs. What was most fascinating however, was that upon (1-2) GalCer trafficking 
and processing, the IL-2 and IFN- production was greater than that of KRN7000. The 
results of this extensive study suggest that certain GSLs can be internalized and undergo 
cellular processing by co-opting metabolic pathways that typically serve another function 
in the cell. From an SAR standpoint, it was notable that (1-2) GalCer was more potent 
and more Th1 biasing than KRN7000 after such processing occurred.  
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Glycolipid analogs with C6” modifications have also been investigated. This type of GSL 
was first used for labelling studies where the fluorescent handle was anchored onto C6”. 
In 2002, Savage and co workers reported the synthesis of KRN7000 analogs with C6” 
amides and sulfonamides linked to fluorescent probes (Fig. 1.10).35 The purpose of the 
experiment was to follow the GSLs’ pathway to activating NKT cells, but what was 
ultimately interesting from an SAR standpoint is that these C6” modifications did not 
disrupt the GSL-induced production of IL-2.  
 Following this trend, the Savage group then reported the activity of C6” amides 7a and 
7b (Fig. 1.11).36,37 GSLs 7a and 7b are C6” N-acetylated analogs of KRN7000, but 7b 
also contains an olefin in 
the acyl chain. These GSLs 
were shown to be more 
potent and Th1 polarizing 
than KRN7000 during in 
vitro and in vivo studies. 
Thus, for the last decade, 
synthesis groups have 
been derivatizing the C6” 
alcohol of KRN7000 with 
various functional groups.  
Trappeniers and et al. reported a handful of C6” amide and carbamate analogs 8a-d and 
9a-e.38 While 8a had no agonistic effect, 8b-d caused decreased production of IL-4 (a 
Th2 cytokine) while still stimulating a reasonable amount of IFN-. This trend was thought 
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to be due to favorable electron withdrawing effects on the phenyl ring. The CF3 substituent 
on 8d was thought to be why the GSL had such a positive cytokine profile with IFN- 
production similar to that of KRN7000. The C6”-carbamate class of GSLs were found to 
be Th1 skewing with 9e resulting in the highest concentration of IFN- produced. It 
outperformed KRN7000 in assays with both human peripheral blood mononuclear cells 
(PBMCs) and human iNKT cells.39 This naphthyl-carbamate has been studied more 
extensively and is now generally referred to as NU--GalCer.  
 In 2013, the Mori group investigated the effects of ethers at C6” as well as a C6” proton 
and fluorine.40 Their glycolipids (10a-e) stimulated mice NKT cells in vivo  to produce 
more IFN- than KRN7000 while resulting in the same concentrations of IL-4. 
Interestingly, 10a had a better cytokine profile than 10b-c despite there only being a one 
and two carbon difference 
among the three compounds. 
Because 10d-e resulted in 
more Th1 cytokine production 
than the ethers, the 
researchers hypothesized that 
a smaller, hydrophobic group at 
C6” induces a greater Th1 bias. 
This conclusion seems to 
contradict the promising activity 
of NU--GalCer, which, based 
on their theory, should not be a 
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potent Th1 inducer.  The Mori group class of GSLs (10a-e) however, have only been 
tested in mice models, which could account for the opposing conclusions of C6” effects.  
 
1.1.6.4 Combining KRN7000 Modifications 
The Howell group has continuously focused on modifying KRN7000 to produce the 
optimal cytokine response. One approach has been to combine the various structural 
modifications done to KRN7000 that have shown promising Th1 bias (Fig. 1.12). The 
effects of C6” esters have been examined on GSLs containing both phytosphingosine 
and sphinganine sphingoid bases (11a-d). The (1-2) GalCer with a sphinganine base 
and C6” ester were also explored. The glycolipid 11b, also referred to as AH10-7, is of 
great interest to the group due to its excellent immunostimulatory activity in both mice and 
human cell lines. AH10-7 is one of the few examples of two modifications having a 
synergistically enhancing Th1 skewing effect. The glycolipid is able to promote more IFN-
 production and less IL-4 production in human CD1d knock in (hCD1dKI) mice. This 
assay involves replacing the coding sequence for the mouse CD1d gene with the 
orthologous human CD1d gene, in order to monitor iNKT cell activation in what is 
considered a partially humanized mouse.41 In crystal structure studies of the ternary 
complex, it was found that the hydrocinnamoyl ester of AH10-7 interacted with amino 
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acids on mCD1d. These interactions are thought to strengthen AH10-7 and mCD1d 
binding, thus stabilizing galactose for recognition by the NKT cell via the TCR. The 
disaccharide series, AH15-5 and AH15-6 are still undergoing preliminary biological 
studies by the Porcelli group at The Albert Einstein School of Medicine. 
 
1.1.7 Target Glycolipids: SAR of 7DW8-5  
As mentioned previously, 7DW8-5 produced a better cytokine profile than KRN7000. 
Although 7DW8-5 has undergone some SAR studies, the modifications were made 
primarily to the terminal fluorophenyl group.42 Wong and co workers explored the addition 
of substituted biphenyl systems on the acyl chain but found that in most cases, single 
phenyl rings such as 7DW8-5 performed best. They also explored the effects of a 
truncated sphingoid base (C8) with a terminal phenyl ring. In these analogs, they found 
CD1d docking to be greatly diminished. Therefore, to better improve the activity of 7DW8-
5, six target analogs were designed that incorporate various structural modifications 
shown to improve the activity of KRN7000 (Fig. 1.13). This strategy was chosen based 
on two arguments. A deductive argument: if these modifications make KRN7000 more 
potent and Th1 biasing, and 7DW8-5 is more potent and biasing than KRN7000, then the 
same modifications to 7DW8-5 will produce an even more potent and Th1 biasing 
response than all the previous analogs. A crystal structure-based argument: by 
incorporating the same C6” esters into 7DW8-5, perhaps the same amino acid 
interactions would occur that promote the Th1 skewed response seen in AH10-7.   
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The analogs chosen to investigate are a combination of modifications performed by the 
Howell group and others. Based on the work of Prigozy et al., (1-2) 7DW8-5 (13) was 
chosen for examination primarily for the promising activity displayed by (1-2) GalCer 
upon cellular trafficking and processing. Inspired by the Th1 biasing effect observed in 
the Howell group’s AH03-1 and AH10-7, glycolipids containing a sphinganine base with 
and without C6” esters were chosen for investigation 14a (AH17-3), 14b (AH17-2), and 
15 (AH17-1). C6” phenyl esters of 7DW8-5 were also explored (16a and 16b).  
 
Although many SAR studies have been performed on KRN7000, only a limited SAR 
study has been done on 7DW8-5. Therefore, structural modifications on the sugar head 
and sphingoid base of 7DW8-5 were performed to promote a more potent and Th1 
skewing response with the goal of developing a promising anti-cancer agent or vaccine 
adjuvant.  
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1.2 RESULTS AND DISCUSSION 
1.2.1 Research Objectives 
The goals of this study were to synthesize the following glycolipid analogs 
for an improved Th1 biasing NKT cell response  
1. (1-2) Disaccharide of 7DW8-5, 13 
2. Sphinganine/C6” ester analogs of 7DW8-5, 14a/b 
3. Sphinganine analog of 7DW8-5, 15 
4. C6” ester analogs of 7DW8-5, 16a/b 
 
1.2.2 Synthesis of Glycolipid 13 
1.2.2.1 Retrosynthetic Strategy for Glycolipid 13 
The retrosynthetic strategy for 13 is summarized in Figure 2.1. The final target compound 
can be achieved through a glycosylation between sugar donor 17 and ceramide acceptor 
19. Following the protocol developed by Yanke Liang in the Howell lab, compound 17 
was accessible in five steps from purchased tri-O-acetyl galactal (18).43 Ceramide 19 
could be generated in four steps from commercially available phytosphingosine (20) by 
making minor adjustments to procedures and protecting group strategies used in the 
Howell group. 
 23 
 
 
 
1.2.2.2 Synthesis of Sugar Donor 17  
Because the sugar donor (17) for AH15-7 is a disaccharide, two different sugars had to 
be synthesized and linked. The synthesis of 17 began with a thiophenol substitution on 
the anomeric acetate of -D-pentaacetyl galactose 21 in the presence of boron trifluroide 
diethyl etherate (Scheme 1.1).44 The remaining acetates were then cleaved under basic 
conditions, and the alcohols were protected with benzyl groups using standard methods, 
giving 23 in 72% yield over two steps. Benzyl-protected sugar 23 is one of the 
glycosylation partners for 17. The synthesis of the other monosaccharide (24) began with 
tri-O-acetylgalactal (18). The corresponding epoxide was formed by generating 
dimethyldioxirane (DMDO) in situ. Subsequent cleavage by nuclephilic ring opening using 
thiophenol gave 24 in two steps.45 Compounds 23 and 24 were chosen as glycosyl donor 
and acceptor, respectively, based on the armed/disarmed approach of glycosylations to 
prevent self-glycosylation. Acetylated sugars are considered disarmed, while benzylated 
Figure 1.14. Retrosynthetic approach for 13
O
OH
HO
HO
O C13H27
OH
OHNH
O
O
O
HO
HO
HO
OH
(CH2)10 F
HO C13H27
OTBS
OTBSNH
(CH2)10O
+
O
OBn
BnO
BnO
O
SPh
O
OBn
BnO
BnO
BnO
F
O
OAcAcO
AcO
NH2
OH
OH
C13H27HO
13 17
18
19
20
 24 
sugars are armed due to electronic effects (electron withdrawing and donating 
respectively).46 It would be highly unfavorable for an electron-rich sugar to couple with 
another electron-rich sugar. Therefore, successful glycosylations require one reactant to 
be electron-donating (glycosyl donor) and the other to be electron-withdrawing (glycosyl 
acceptor) in order to ensure the most favorable electronic effects. Coupling 23 and 24 
using NIS and silver triflate produced disaccharide 25 with no -disaccharide detected via 
nuclear magnetic resonance (NMR). Once again, following the armed/disarmed theory, 
the acetates were cleaved with sodium methoxide in methanol, and the alcohols were 
then re-protected with benzyls to form armed disaccharide 17.43  
 
1.2.2.3 Synthesis of Ceramide Acceptor 19 
The synthesis of ceramide acceptor 19 required preparation of the acyl chain for coupling 
to the sphingoid base. The fatty acyl chain of 7DW8-5 was accessed in three steps 
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(Scheme 1.2). First, a Sonagashira coupling reaction between 4-fluoroiodobenzene and 
10-undecynoic acid resulted in coupled alkyne product, which was then reduced to the 
alkane (26) via hydrogenation with palladium on carbon in 80% yield over two steps.47 
Although Sonagashira coupling is not a clean reaction and tends to form byproducts, it 
was found that the overall yield was improved when purification occurred after reducing 
the alkyne. Therefore, the Sonagashira crude material was filtered through celite to 
remove the palladium reagent and then carried over to the next step. Activated p-
nitrophenyl (PNP) ester 27 was prepared in excellent yield through a Steglich 
esterification using N,N’-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine 
(DMAP).48 N-acylation was performed on phytosphingosine (20) with 27 under mildly 
basic conditions with consistently excellent yields. All alcohols were then protected with 
TBS, and the primary alcohol in 29 was selectively de-protected using TFA in water to 
access 19 in 80% yield.43  
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1.2.2.4 Glycosylation and Final Steps for AH15-7 
Unfortunately, the glycosylation between ceramide acceptor 19 and glycosyl donor 17 
was low yielding with very poor  selectivity. This result was thought to be due to 
electronic effects mentioned previously in the armed/disarmed theory. Silyl ethers are not 
good electron-withdrawing groups to promote a favorable glycosylation. As a result, the 
protecting group strategy had to be modified to promote good electronic effects. 
In the first reported synthesis of 7DW8-5 by Wong and co workers, they performed the 
glycosylation between a benzoyl- and Boc-protected phytosphingosine to great success. 
This strategy was chosen so that they could incorporate different acyl chains in a final 
step. Following their lead, it was decided that protecting the alcohols of the ceramide with 
benzoyls would provide adequate electron withdrawing effects to promote a successful 
glycosylation. Typically, this method is done first by selectively protecting the primary 
alcohol with a bulky trityl protecting group, then protecting the secondary alcohols with 
benzoyls. Under acidic conditions, the trityl can be cleaved while the ester protecting 
group (Bz) remain. Both protection reactions are primarily performed under basic 
conditions using DMAP and pyridine.49 However, when this strategy was attempted with 
28, both reactions were low yielding and inconsistent. Therefore, following a different 
method, the reactions were slightly modified by using a different base and solvent (31 in 
Scheme 1.3).50 The combination of triethylamine (Et3N) and ethyl acetate (EtOAc), 
seemed to improve the reaction slightly, but once again, the results were inconsistent. 
Eventually it was observed through crude NMR analysis, that trityl protection was 
proceeding with 100% conversion. When subjected to column chromatography however, 
only starting material was isolated. Therefore, it was concluded that the trityl group was 
 27 
cleaved during purification due to the slightly acidic nature of silica gel in column 
chromatography. This problem was overcome by neutralizing the column prior to loading 
the crude material. Then, the reactions resulted in significantly higher isolated yields with 
more consistent success. Finally using 10-camphorsulfonic acid (CSA), the trityl group 
was cleaved while maintaining secondary alcohol protection to achieve ceramide 
acceptor 30 in 73% yield.50 
 
With both ceramide and sugar in hand, the final glycosylation could be performed Using 
NIS/AgOTf as the activator and methylene chloride as the solvent, protected glycolipid 32 
was achieved in 60% yield with no -isomer detected (Scheme 1.4). Finally, the benzoyl 
protecting groups were cleaved using sodium methoxide in 88% yield. Hydrogenolysis 
provided AH15-7 in 90% yield.  
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1.2.3 Synthesis of C6” Ester Analogs 14a and 14b 
1.2.3.1 Retrosynthetic Strategy for Glycolipids 14a/b 
The retrosynthetic approach for the sphinganine-containing C6” ester analogs of 7DW8-
5 is summarized in Figure 1.15. Glycosylation was planned between a sugar donor (33) 
and sphingoid base acceptor 34. Although glycosylation with a ceramide acceptor was 
shown to work very well previously (Scheme 1.4), the glycosylation had to performed with 
the sphingoid base for these analogs in order to cleave the benzylidene protecting group 
after glycosylation. Intermediate 43 is a result of cleaving both the benzylidene and Boc 
protecting groups in one step.  Following a method reported by the Howell group, 
sphingoid base acceptor 34 can be achieved in six steps from commercially available 
Boc-L-serine (35). Benzylidene-protected sugar 33 can be accessed from 22 (see 
Scheme1.1) in three steps through a known procedure. This sugar was chosen for 
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glycosylation for late-stage installation of structural diversity at the C6” alcohol. The goal 
was to protect the C6” alcohol for as long as possible for a divergent synthesis of the C6” 
ester analogs. Therefore, only one glycosylation would have to be performed, and the 
material could be split in half for two analogs. Sugar 33 is also a beneficial intermediate, 
because the 4,6-benzylidine protecting group has been extensively studied and methods 
have been developed for selectively cleaving it to expose the C4” or C6” alcohol. As a 
result, the benzylidine protected sugar was chosen to take advantage of the high C4” 
versus C6” selectivity and the ability to generate analogs late in the synthesis. 
 
1.2.3.2 Synthesis of Sugar Donor 33 
The synthesis of donor 33 began with thiophenyl sugar 22 (Scheme 1.5). Upon treatment 
with sodium methoxide in methanol, the acetate protecting groups were cleaved. The C4” 
and C6” hydroxyls were subsequently protected with benzaldehyde dimethyl acetal (36). 
The two remaining alcohols were protected with benzyls to achieve benzylidene-modified 
benzyl-protected sugar 33 with good yields.51 The synthesis of 33 was performed on a 
large scale (>20 g) by Dr. Divya Chennamadhavuni of the Howell lab, and the compound 
was shared with the group members.52 
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1.2.3.3 Synthesis of Sphingoid Base 34 
The first step towards accessing 33 involves converting Boc-L-serine (35) to the 
corresponding Weinreb amide 37 (Scheme 1.6). Double deprotonation of 37 using two 
equivalents of isopropylmagnesium chloride as a sacrificial base allowed for a Grignard 
reaction using pentadecylmagnesium bromide to generate ketone 38 in 74% yield. 
Pentadecylmagnesium bromide was generated by combining 1-bromopentadecane with 
magnesium turnings in refluxing tetrahydrofuran (THF). Protection of the primary alcohol 
in 38 with tert-butyldiphenylsilyl chloride (TBDPSCl) gave 39 in 95% yield. The ketone 
then underwent diastereoselective reduction using lithium tri-tert-butoxyaluminum hydride 
to provide the secondary alcohol (40) in 97% yield. The reaction is clean, rarely requires 
purification, and the other diastereomer was never observed. Alcohol 40 was then 
protected using sodium hydride and benzyl bromide (41). The primary alcohol was 
selectively de-protected upon treatment with tetrabutylammonium iodide (TBAF) in THF, 
giving 34 in 91% yield.28  
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1.2.3.4 Glycosylation and Final Steps for The Synthesis of AH17-2 and 
AH17-3 
Compounds 33 and 34 were coupled under the established conditions (Scheme 1.7). 
Unfortunately, with a sphingoid base instead of a ceramide, the yield was low, and  
selectivity was only 1:1. The  isomer was isolated in 20% yield and carried forward. 
Using 1M borane-tetrahydrofuran complex and scandium triflate, the benzylidene was 
selectively cleaved on the C6” alcohol.53 Under these conditions, the Boc protecting group 
was also cleaved (42). For this reason, the glycosylation had to be performed on the 
sphingoid base. It was observed in a previous attempt that the reaction conditions not 
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only cleaved carbamates and acetals, but also amide bonds. Therefore, when 
glycosylation occurred on the ceramide acceptor, the acyl chain was also removed when 
the benzylidene cleaving reaction was run. Armed with this knowledge, the synthetic 
strategy utilized the reaction conditions to expose both the C6” alcohol and C2 amine.  
N-acylation with 27 was performed under basic conditions to access 44 in 73% yield. 
Because amines are much more nucleophilic than alcohols, there was no concern over 
esterification of the C6” alcohol. With only a few steps left, 44 was split into two aliquots 
to generate the two target glycolipids. Upon esterification with phenylacetic acid under 
Steglich conditions, 45a was formed in 79% yield, and global deprotection using 
Pearlman’s catalyst gave AH17-3 in 70% yield. Starting at 44 again, Steglich esterification 
using hydrocinnamic acid gave 45b in 94% yield. Finally, cleavage of the benzyls gave 
AH17-2 in 99% yield. 
 
1.2.4 Synthesis of Sphinganine Analog of 7DW85 (15) 
1.2.4.1 Retrosynthetic Strategy for AH17-1 
Because the synthesis of AH17-1 was occurring at the same time as AH17-2 and AH17-
3, it was simpler to perform the glycosylation on sphingoid base 34 and sugar 23 due to 
the availability of these advanced intermediates in the lab (Figure 1.16). The synthesis of 
both 23 and 34 have been described previously (Schemes 1.1 and 1.6, respectively). 
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1.2.4.2 Glycosylation and Final Steps Towards AH17-1 
Glycosylation of sphingoid base 34 with 23 was performed under the same conditions 
described previously. Similar to the former glycosylations with a sphingoid base, the yield 
was moderate with a 2:1  ratio. This result is most likely due to electronic effects from 
protecting groups (benzyl-protected alcohol on the sphingoid base). The  isomer was 
isolated in 35% yield and carried forward (46 in Scheme 1.8). Boc-amine 46 was de-
protected using TFA to access the free amine in 77% yield. In the presence of pyridine, 
the amine underwent N-acylation with PNP ester 27 (see Scheme 1.2) to yield glycoside 
47. N-Acylation reactions continue to be an ongoing problem in the lab when the previous 
reaction is cleaving Boc with trifluoroacetic acid (TFA). One thought as to why the reaction 
is low yielding is due to pH effects. The reaction with TFA is acidic, and the work up 
involves neutralizing the crude material with a base (aqueous sodium bicarbonate). If the 
reaction is not properly neutralized prior to the next step, the reaction may not proceed. 
Interestingly, it was found that when Boc was cleaved under milder conditions and the 
crude material was purified via column chromatography (23 in Scheme 1.7), N-acylation 
proceeded with good to excellent yields. That method however, was not performed on 46 
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to achieve 47. Global de-protection was accomplished by hydrogenolysis, providing 
AH17- 1 in 99% yield.  
 
1.2.5 Synthesis of C6” Ester Analogs of 7DW8-5 (16a and 16b) 
1.2.5.1 Retrosynthetic Approach to 16a and 16b 
The plan was to prepare targets 16a and 16b in the same manner as the other C6” esters 
(14a and 14b) with a glycosylation between 33 and protected phytosphingosine 48 (Fig. 
1.17). The synthesis of sugar donor 33 was described in Scheme 1.5. Sphingoid base 48 
can be accessed in five steps from phytosphingosine (20) by following literature 
procedures. Once again, structural diversity at the C6” position is installed after 
glycosylation.  
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1.2.5.2 Synthesis of Glycosyl Acceptor 48 
When looking at which protecting group strategy should be employed for 48, the entire 
glycolipid synthesis had to be considered. Although benzoyl protecting groups would 
ensure good electronic effects for glycosylation (48b), they are esters and would have to 
be removed prior to esterification of the C6” alcohol. TBS protecting groups resulted in 
poor glycosylation results in section 1.2.2.4, however, they can usually be cleaved in 
acidic conditions which won’t affect the C6” ester (48a). For this reason, 48a was chosen 
as the glycosyl acceptor. Unfortunately, in one of the last steps of the synthesis when the 
TBS groups had to be removed, no reaction was observed (Scheme 1.9). When both 
TBAF and TFA methods were employed, only starting material was recovered even when 
the reaction was allowed to run for days with high equivalents of the cleaving reagent.  
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 Therefore, it was determined that the benzoyl-protection was the best route. When 
looking at 48b, it was tempting to perform the same protecting group strategy used in 
Scheme 1.3 where the primary alcohol was protected with trityl and the secondary 
alcohols were protected with benzoyls. Subsequent selective de-protection of the primary 
alcohol and protection of the free amine would give the desired sphingoid base. This 
protecting group strategy resulted in the greatest glycosylation yield and -selectivity (AH 
15-7). Encouraged by the previous success, the Trt/Bz protecting group strategy was 
employed. Unfortunately, the sphingoid base synthesis was not as straightforward as 
anticipated. First, the free amine in phytosphingosine was protected with Boc under 
standard conditions without purification required (49). Trityl protection was attempted 
under the conditions shown in Scheme 1.3 with Et3N and EtOAc. No product was isolated, 
and only starting material was recovered (Scheme 1.10a). This result was thought to be 
due to solubility issues; while ceramide 28 was soluble in EtOAc, sphingoid base 49 was 
not. Therefore, another trityl protection method was employed with DMAP and pyridine.49  
Although the average yield for this reaction was low, the material was carried forward with 
benzoyl protections. As noted, the trityl group can be and was cleaved serendipitously 
during purification on the mildly acidic column (48b). Once again, the average yield was 
too low to establish this method as a reliable way to make the desired sphingoid base 
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(Scheme 1.10b). As a result, a new approach had to be considered. The primary alcohol 
was protected with TBDPSCl (51); then the secondary alcohols were protected with 
benzoyl groups (52).54 When using typical silyl ether cleaving conditions TBAF/THF, 
however, no desired product was isolated. Instead, a benzoyl-migration to the primary 
alcohol was observed (Scheme 1.10c). As a result, TFA had to be used to cleave both 
the TBDPS and Boc protecting groups. Subsequent Boc protection of the amine resulted 
in 48b with a modest yield of 40% over two steps (Scheme 1.10d). Although the route 
was much longer than anticipated, grams of 48b were obtained in this method which is 
more than suitable for glycosylation. 
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1.2.5.3 Glycosylation and Final Synthesis of 16a and 16b 
The final steps for 16a and 16b are similar to Scheme 1.8 with slight differences to 
account for the phytosphingosine base (Scheme 1.11). The standard glycosylation 
between 42 and 48b resulted in glycoside 53 with a good yield in terms of glycosylation 
reactions. The benzylidene and Boc were cleaved using boron tetrahydrofuran complex 
and scandium triflate to expose the C6” alcohol and C2 amine (54). N-acylation with 27 
resulted in glycolipid 55. For this reaction sequence, the benzoyl protecting groups had 
to be removed prior to esterification at C6” (56). Benzoyl protecting groups are also esters; 
therefore, the conditions required to cleave benzoyl, would also cleave the newly installed 
C6” ester.  Once again, the glycolipid preceding esterification was split into two portions 
for Steglich esterfications with phenylacetic acid and hydrocinnamic acid (57a and 57b, 
respectively). Both esterifications were low yielding, which was thought to be due to the 
two secondary alcohols available for esterification. Although the primary alcohol is the 
most available sterically, in both reactions, column purification resulted in product, impure 
unreacted starting material, and doubly esterified glycolipids. This step was the reason 
why the TBS-protecting group strategy was chosen first in order to prevent esterification 
at the secondary alcohols. However as mentioned in section 1.2.5.2, the TBS groups 
caused problems later in the synthesis that made it impossible to continue. Hydrogenation 
of 57a and 57b resulted in the final C6” ester-modified analogs of 7DW8-5, 16a and 16b.  
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1.2.6 Preliminary Biological Results 
All six glycolipids have been sent to the Albert Einstein School of Medicine for biological 
testing. Of the glycolipids sent, AH17-1, AH17-2, and AH17-3 have been tested with 
murine CD1d in B6 cells. IL-2 production was measured 24 hours after addition of the 
glycolipid solution at varying concentrations (Fig. 1.18a). These compounds are the 
sphinganine analogs of 7DW8-5 with and without C6” esters. AH17-4 is 7DW8-5 that has 
been synthesized in the Howell lab. When comparing the sphinganine-containing 
compounds’ activities to 7DW8-5, all three analogs are less potent. In Figure 1.18b, the 
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glyocolipids were examined in human peripheral blood mononuclear cells (PMBCs). Once 
again, all analogs were less potent than 7DW8-5. This result is thought to be partially due 
to solubility problems. Because AH17-2 and AH17-3 have two fewer alcohols than 7DW8-
5, they are less polar and therefore don’t dissolve in water or DMSO as well. These 
compounds are being tested in aqueous, cellular environments; therefore, water solubility 
is essential. AH17-1 is more active than the C6” esters but still less potent than 7DW8-5. 
Because AH17-1 is only lacking one alcohol in comparison to 7DW8-5, it is more soluble 
in water than the C6” esters, which could explain the higher potency. It’s important to 
note, however, that although these trends could be partially due to solubility, it doesn’t 
give any insight into how the glycolipids are interacting with CD1d or NKT cells, which is 
much more difficult to elucidate. As mentioned, these compounds are in the preliminary 
stage of testing, and one result alone is not indicative of a compound’s activity. Although 
these results don’t seem promising, the phytosphingosine-containing analogs have not 
been tested yet and are anticipated to perform better. Further studies are currently being 
performed in Dr. Steven Porcelli’s lab at Albert Einstein School of Medicine. 
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1.2.7 Conclusions 
Six analogs of 7DW8-5 have been reported for the purpose of activating iNKT cells for 
Th1 cytokine production. The structural modifications performed on 7DW8-5 were 
selected based on alterations done to KRN7000 that was shown to skew towards a Th1 
response. Although initial biological testing showed very little activity in analogs AH17-1, 
AH17-2, and AH17-3, these compounds are in the very early stage of examination. The 
remaining analogs presented have not yet been investigated for their biological activity. 
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1.3 EXPERIMENTAL  
General experimental. Methylene chloride (DCM), dimethylformamide (DMF), pyridine, 
chloroform (CHCl3) and toluene were dried over CaH2. THF was purified by a J. C. Myer 
Solvent Dispensing system. All reactions, unless specified, were conducted under an 
atmosphere of N2. Where appropriate, control of temperature was achieved with a solid 
CO2/acetone bath, a Cryocool CC-100 II immersion cooler, an ice-bath or a heated oil 
bath. Phytosphingosine was purchased from Evonik, and -D-galactose pentaacetate 
was purchased from Carbosynth. All other commercially available reagents were 
purchased from Sigma-Aldrich, Acros, TCI Alfa-Aesar or Oakwood. 
1H NMR spectra were recorded at 400 MHz and/or at 500 MHz and calibrated to the 
residual CHCl3 peak at 7.26 ppm. The following abbreviations are used for peak 
multiplicities: br s (broad singlet), s (singlet); d (doublet); t (triplet); q (quartet); quintet 
(quin); m (multiplet); dd (doublet of doublets); ddd (doublet of doublet of doublets); dt 
(doublet of triplets). 13C NMR spectra were recorded at 100MHz and/or at 125 MHz and 
calibrated to the CDCl3
 
peak at 77.23 ppm. Chemical shifts are reported in units of parts 
per million (ppm). Coupling constants, J, are reported in Hertz (Hz). Infrared (IR) spectra 
were recorded on an FT-IR spectrophotometer and are reported in cm-1. High-resolution 
mass spectra were obtained on an AccuESI instrument at the University of Connecticut. 
Specific rotations []D
 
were obtained on a JASCO P-2000 polarimeter, using the sodium 
D-line as a source, and the concentration (c) is expressed in g per 100 mL. Flash 
chromatography was performed on Silica Gel, 40 microns, 32-63 flash silica. Thin layer 
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chromatography was performed on silica gel (Silica Gel 60 F254) glass plates, and the 
compounds were visualized by UV and/or 5% phosphomolybdic acid in ethanol.  
 
(2S,3S,4R)-2-Amino-N-(11-(4-fluorophenyl)undecanoyl)1-O-[2-O-(-D-galacto-
pyranosyl)--D-galactopyranosyl]octadecan-1,3,4-triol (13)  
(2S,3S,4R)-2-Amino-1-O-[2-O-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-3,4,6-tri-O-
benzyl--D-galactopyranosyl]-3-(O-benzyl)-N-(11-(4-fluorophenyl)undecanoyl)octa-
decan-1,3,4-triol (32) (0.035 g, 0.027 mmol) was dissolved in MeOH/CHCl3 (v/v 1:4, 2.2 
mL) under N2. Pd(OH)2/C (0.134 g) was added, and the reaction vessel was purged with 
H2. The reaction mixture was stirred for 5 h under a H2 balloon. It was then filtered through 
celite, and the celite pad was rinsed with MeOH/CHCl3 (v/v 1:1, 10 mL). The filtrate was 
concentrated, and the crude product purified via flash column chromatography on silica 
gel (DCM/MeOH 80:20) to give 13 as a white film (0.022 g, 90%): []25D +83 (c 0.05, 
MeOH); IR (neat) 3330 (br), 2923, 2853, 1510, 1070 cm-1; 1H NMR (400 MHz, 
MeOD/CDCl3)  7.13 (m, 2H), 6.94 (m, 2H), 5.03 (d, J = 3.0 Hz, 1H), 5.02 (d, J = 2.8 Hz, 
1H), 4.15 (m, 2H), 3.93 (m, 3H), 3.86–3.70 (m, 10H), 3.59 (m, 1H), 3.39 (m, 2H), 2.58 (t, 
J = 7.5 Hz, 2H), 2.23 (t, J = 7.6 Hz, 2H), 1.60 (m, 6H), 1.27 (m, 34H), 0.89 (t, J = 6.6 Hz, 
3H); 13C NMR (125 MHz, CDCl3)   174.1, 160.8 (dC-F, J = 240.9 Hz), 138.1 (dC-F, J = 2.9 
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Hz),  129.2 (dC-F, J = 7.6 Hz), 114.3 (dC-F, J = 20.9 Hz), 97.5, 97.0, 74.7, 73.6, 71.7, 70.7, 
70.3, 69.7, 69.6, 69.4, 68.5, 68.1, 67.0, 61.6, 61.2, 49.8, 35.8, 34.6, 31.5, 31.2, 31.1, 29.3, 
29.2, 29.2, 29.1, 29.1, 29.0, 28.9, 28.7, 25.6, 25.5, 22.1, 13.2; HRMS (ESI) for 
C47H83FNO14 (M + H)+ m/z calcd: 904.5798. Found: 904.5763. 
 
(2S,3R)-2-Amino-N-(11-(4-fluorophenyl)undecanoyl)-1-O-(6-O-phenylacetoyl--D-
galactopyranosyl)octadecan-1,3-diol (14a)  
(2S,3R)-2-Amino-1-(2,3,4-tri-O-benzyl-6-phenyl-acetoyl--D-galactopyranosyl)-3-(O-
benzyl)-N-(11-(4-fluorophenyl)undecanoyl))octadecan-1,3-diol (45a) (0.008 g, 0.007 
mmol) was dissolved in CHCl3/MeOH (1:4 v/v, 0.5 mL) under N2. Pd(OH)2/C (0.010 g) 
was added, and the reaction vessel was purged with H2. The reaction mixture was 
stirred overnight under a H2 balloon. The reaction mixture was diluted with MeOH (2 
mL) and CHCl3 (1 mL) then filtered through celite. The celite was rinsed with MeOH and 
DCM (1:5 v/v, 10 mL). The crude product was purified via flash column chromatography 
on silica gel (DCM/MeOH 95:5) to give 14a as a white film (0.004 g, 70%): []25D –45 (c 
0.04, DCM); IR (neat) 3370 (br), 2922, 2852, 1734,1645 cm-1; 1H NMR (400 MHz, 
CDCl3)   7.31 (m, 4H), 7.11 (m, 3H), 6.95 (m, 2H), 6.80 (d, J = 8.5 Hz, 1H), 6.24 (d, J = 
O
O
C14H29
HN
OH
O (CH2)10
HO
HO
HO
O
F
O
Ph
 45 
8.2 Hz, 1H), 4.88 (d, J = 3.6 Hz, 1H), 4.41 (dd, J = 11.6, 6.2 Hz, 1H), 4.21 (dd, J = 11.5, 
7.0 Hz, 1H), 4.10 (m, 1H), 4.00 (m, 1H), 3.93–3.73 (m, 5H), 
3.59 (dd, J = 10.6, 4.6 Hz, 1H), 2.56 (t, J = 7.6 Hz, 2H),2.96–2.56 (br, 4H), 2.21 (m, 2H), 
1.57 (m, 6H), 1.26 (m, 40H), 0.88 (t, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3) 
 173.2, 171.8, 161.2 (dC-F, J = 254.6 Hz), 138.4 (dC-F, J = 8.6 Hz), 129.6 (dC-F, J = 7.7 
Hz), 129.3, 128.7, 127.8, 127.3, 114.9 (dC-F, J = 20.9 Hz), 113.9, 99.8, 73.3, 70.5, 69.2, 
68.9, 68.7, 68.3, 63.3, 52.3, 41.2, 37.4, 37.1, 36.9, 35.1, 34.7, 32.8, 31.9, 31.6, 30.0, 
29.7, 29.6, 29.5, 29.4, 29.2, 27.4, 27.1, 26.7, 26.0, 25.8, 25.5, 24.5, 22.7, 19.7, 14.1; 
HRMS (ESI) for C49H79FNO9 (M + H)+ m/z.  calcd: 844.5741. Found: 844.5771. 
 
(2S,3R)-2-Amino-N-(11-(4-fluorophenyl)undecanoyl)-1-O-(6-O-hydrocinnamoyl--
D-galactopyranosyl)octadecan-1,3-diol (14b) 
(2S,3R)-2-Amino-(2,3,4-tri-O-benzyl-6-hydrocinnamoyl--D-galactopyranosyl)-3-(O-
benzyl)-N-(11-(4-fluorophenyl)undecanoyl)octadecan-1,3-diol (45b) (0.008 g, 0.007 
mmol) was dissolved in CHCl3/MeOH (1:4 v/v, 0.5 mL) under N2. Pd(OH)2/C (0.010 g) 
was added, and the reaction vessel was purged with H2. The reaction mixture was 
stirred overnight under a H2 balloon. It was then diluted with MeOH (2 mL) and CHCl3 (1 
mL) and filtered through celite. The celite was rinsed with MeOH and DCM (1:5 v/v, 10 
mL). The filtrate was concentrated, and the crude product was purified via flash column 
O
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chromatography on silica gel (DCM/MeOH 95:5) to give 14b as a white film (0.006 g, 
99%): []25D –30 (c 0.08, DCM); IR (neat) 3353 (br), 2923, 2853 1737,1639 cm-1; 1H 
NMR (400 MHz, CDCl3)  7.16 (m, 2H), 7.11 (m, 3H), 7.00 (m, 2H), 6.94 (m, 2H), 6.70 
(d, J = 8.2 Hz, 1H), 4.73 (d, J = 3.7 Hz, 1H), 4.13 (m, 1H), 3.97 (m, 1H), 3.80 (m, 2H), 
3.66 (m, 1H), 3.60 (dd, J = 10.0, 3.3 Hz, 1H), 3.56 (m, 3H),  3.47 (m, 1H), 2.83 (t, J = 
7.7 Hz, 2H), 2.55 (t, J = 7.8 Hz, 2H), 2.45 (t, J = 7.5 Hz, 2H), 2.09 (t, J = 7.0 Hz, 2H), 
1.50–1.30 (m, 8H), 1.25 (m, 36 H), 0.88 (t J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)  
 174.2, 173.2, 161.1 (dC-F, J = 243.0 Hz), 140.2, 138.5 (dC-F, J = 3.0 Hz), 129.6 (dC-F, J 
= 7.7 Hz), 128.5, 128.2, 126.3, 114.8 (dC-F, J = 21.0 Hz), 99.7, 71.6, 70.2, 70.0, 69.1, 
68.9, 68.8, 68.5, 68.5, 67.7, 63.6, 53.2, 41.7, 36.5, 35.7, 35.1, 34.1, 31.9, 31.6, 30.9, 
30.8, 29.7, 29.5, 29.5, 29.4, 29.4, 29.3, 29.2, 25.9, 25.8, 22.6, 14.0; HRMS (ESI) for 
C50H81FNO9 (M + H)+ m/z.  calcd: 858.5895. Found: 858.5914. 
 
 (2S,3R)-Amino-N-(11-(4-fluorophenyl)undecanoyl)-1-(-D-galactopyranosyl)octa-
decan-1,3-diol (15) 
(2S,3R)-2-Amino-1-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-3-(O-benzyl)-N-(11-
(4-fluorophenyl)undecanoyl)octadecan-1,3-diol (47) (0.008 g, 0.008 mmol) was dissolved 
in CHCl3/MeOH (1:4 v/v, 1.0 mL) under N2. Pd(OH)2/C (0.010 g) was added, and the 
reaction vessel was purged with H2. The reaction mixture was stirred overnight under a 
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H2 balloon. It was then diluted with MeOH (2 mL) and CHCl3 (1 mL) and filtered through 
celite. The celite was rinsed with MeOH and DCM (1:5 v/v, 10 mL). The filtrate was 
concentrated, and the crude product was purified via flash column chromatography on 
silica gel (DCM/MeOH 90:10) to give 15 as a white film (0.005 g, 100%): []21D +70 (c 0.1, 
1:1 v/v DCM/MeOH); IR (neat) 3304 (br), 2920, 1751 cm-1; 1H NMR (500 MHz, 
CDCl3/MeOD)  7.33 (d, J = 8.8 Hz, 1H), 6.76 (m, 2H), 6.57 (m, 2H), 4.50 (d, J =  3.7 Hz, 
1H), 3.55 (m, 2H), 3.55 (m, 1H), 3.44–3.42 (m, 3H), 3.40–3.37 (m, 4H), 3.24 (m, 1H), 2.20 
(t, J = 7.6 Hz, 2H), 1.85 (t, J = 7.5 Hz, 2H), 1.22 (m, 6H), 0.90 (m, 38H), 0.51 (t, J = 6.5 
Hz, 3H); 13C NMR (125 MHz CDCl3, MeOD)  174.4, 160.8 (dC-F, J = 241.0 Hz), 138.0 
(dC-F, J = 3.8 Hz), 129.2 (dC-F, J = 7.8 Hz), 114.2 (dC-F, J = 21.3 Hz), 99.5, 70.5, 70.3, 69.8, 
69.3, 68.6, 67.2, 61.2, 53.5, 35.9, 34.6, 33.5, 31.4, 31.2, 29.2, 29.1, 29.1, 29.1, 29.0, 28.9, 
28.8, 28.7, 25.5, 25.2, 22.1, 13.2; HRMS (ESI) for C41H73FNO8 (M + H)+ m/z.  calcd: 
726.5320. Found: 726.5346. 
 
(2S,3S,4R)-2-Amino-N-(11-(4-fluorophenyl)undecanoyl)-1-O-(6-O-phenylacetoyl--
D-galactopyranosyl)octadecan-1,3,4-triol (16a) 
(2S,3S,4R)-2-Amino-1-(2,3,4-tri-O-benzyl-6-phenylacetoyl--D-galactopyranosyl)-N-(11-
(4-fluorophenyl)undecanoyl)octadecan-3,4-diol (57a) (7 mg, 0.006 mmol) was dissolved 
in EtOH/CHCl3 (4:1 v/v, 0.5 mL) and purged with N2 under stirring. Pd(OH)2/C (50 mg) 
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was added, and the reaction vessel was purged with H2. The reaction mixture was 
stirred overnight under a H2 balloon. It was then flushed with N2 and filtered through 
celite. The celite pad was rinsed with DCM (5 mL) and MeOH (5 mL), and the filtrate 
was concentrated under reduced pressure. The crude material was purified via flash 
chromatography on silica gel (DCM/MeOH 95:5). Glycolipid 16a was isolated as a white 
film (4 mg, 80% yield); []25D –18 (c 0.08, DCM/MeOH 60:40); IR (neat) 3326, 2926, 
2851, 1624, 1578 cm-1; 1H NMR (500 MHz, CDCl3/MeOD 2:1 v/v)   7.01 (m. 4H), 6.83 
(m, 3H), 6.64 (m, 2H), 6.52 (m, 1H), 4.59 (d J = 3.8 Hz, 1H), 3.97 (m, 2H), 3.89 (m, 1H), 
3.84 (m, 2H), 3.78 (m, 1H), 3.55 (m, 1H), 3.49 (dd, J = 10.0, 3.8 Hz, 1H), 3.42 (dd, J = 
9.9, 3.5 Hz, 1H), 3.35 (m, 2H), 3.27 (m, 1H), 2.28 (t, J = 7.5 Hz, 2H), 1.91 (t, J = 7.5 Hz, 
2H), 13C NMR (125 MHz, CDCl3/MeOD 2:1 v/v)   173.9, 143.4, 129.3 (dC-F, J = 7.5 Hz), 
128.9, 128.2, 127.4, 126.8, 114.4 (dC-F, J = 20.9 Hz), 113.6, 99.2, 74.1, 71.7, 69.7, 69.1, 
68.5, 63.9, 40.7, 36.1, 34.7, 33.3, 31.6, 31.3, 30.5, 29.3, 29.3, 29.1, 29.0, 28.8, 25.5, 
25.3, 24.6, 22.3, 13.4; HRMS (ESI) for C49H79FNO10 (M + H)+ m/z.  calcd: 861.5770. 
Found: 861.6141. 
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(2S,3S,4R)-2-Amino-N-(11-(4-fluorophenyl)undecanoyl)-1-O-(6-O-hydrocinnamoyl-
-D-galactopyranosyl)octadecan-1,3,4-triol (16b) 
(2S,3S,4R)-2-Amino-1-(2,3,4-tri-O-benzyl-6-hydrocinnamoyl--D-galactopyranosyl)-N-
(11-(4-fluorophenyl)undecanoyl)octadecan-3,4-diol (57b) (8 mg, 0.007 mmol) was 
dissolved in EtOH/CHCl3 (4:1 v/v, 0.6 mL) and purged with N2 under stirring. Pd(OH)2/C 
(50 mg) was added, and the reaction vessel was purged with H2. The reaction mixure 
was stirred overnight under a H2 balloon. It was then flushed with N2 and filtered through 
celite. The celite pad was rinsed with DCM (5 mL) and MeOH (5 mL), and the filtrate was 
concentrated under reduced pressure. The crude material was purified via flash 
chromatography on silica gel (DCM/MeOH 95:5). Glycolipid 16b was isolated as a white 
film (5 mg, 83% yield); []20D –13 (c 0.1, DCM/MeOH 60:40); IR (neat) 3329 (br), 2925, 
2852, 1625, 1509 cm-1; 1H NMR (500 MHz, CDCl3/MeOD 2:1 v/v)   7.07 (m, 2H), 7.00 
(m, 2H), 6.92 (m, 3H), 6.75 (m, 2H), 6.62 (d, J = 7.6 Hz, 1H), 4.71 (dd, J = 3.6, 3.6 Hz, 
1H), 4.05 (d, J = 5.6 Hz, 2H), 3.77 (m, 2H), 3.68 (m, 4H), 3.63 (m, 1H), 3.57 (m, 4H), 3.52 
(dd, J = 9.9, 3.2 Hz, 1H), 3.47 (m, 2H), 2.74 (t, J = 8.7 Hz, 2H), 2.47 (t, J = 8.0 Hz, 1H), 
2.38 (m, 3H), 1.42 (m, 4H), 1.07 (m, 36H), 0.68 (t, J = 6.7 Hz, 3H); 13C NMR (125 MHz, 
CDCl3/MeOD 2:1 v/v)   174.5, 174.0, 161.5, 140.2, 129.5 (dC-F, J = 7.8 Hz), 128.3, 128.1, 
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127.6, 126.1, 114.6 (dC-F, J = 20.9 Hz), 113.8, 99.4, 74.4, 71.9, 70.5, 69.9, 68.6, 68.4, 
60.5, 53.3, 37.1, 36.3, 35.5, 34.9, 33.5, 32.8, 32.3, 32.1, 31.7, 31.4, 30.6, 30.5, 29.9, 29.6, 
29.5, 29.5, 29.3, 29.2, 29.0, 27.7, 27.2, 26.9, 26.3, 26.2, 26.0, 25.7, 25.3, 13.7; HRMS 
(ESI) for C50H81FNO10 (M + H)+ m/z.  calcd: 874.5844. Found: 874.5831. 
 
Phenyl 2-O-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-3,4,6-tri-O-benzyl-1-thio-
-D-galactopyranoside (17) 
A solution of NaOMe in MeOH (0.50 M, 3.5 mL, 1.7 mmol) was added dropwise to a 
solution of phenyl-2-O-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-3,4,6-tri-O-acetyl-
1-thio--D-galactopyranoside (25) (0.51 g, 0.55 mmol) in MeOH (22 mL). After 2 h at rt, 
the reaction solution was neutralized with DOWEX resin. The mixture was filtered through 
celite, and the filtrate was concentrated under reduced pressure to yield an orange oil. 
The oil was dissolved in DMF (17 mL). NaH (60% in mineral oil, 0.14 g, 3.4 mmol) was 
added, followed by benzyl bromide (0.32 g, 1.9 mmol), and the suspension was stirred at 
rt overnight. The excess NaH was quenched with MeOH (3 mL), and the reaction mixture 
was poured onto crushed ice. The mixture was extracted with Et2O (3 x 50 mL), and the 
organic layers were combined, dried (MgSO4), and concentrated under reduced pressure. 
The crude material was purified via flash chromatography on silica gel (petroleum 
ether/EtOAc 80:20) to yield a white solid (0.4 g, 67% over two steps):43 1H NMR (400 
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MHz, CDCl3)   7.56 (m, 2H), 7.44–7.17 (m, 38H), 5.89 (d, J = 3.6 Hz, 1H), 4.95–4.86 (m, 
4H), 4.82 (d, J = 2.7 Hz, 1H), 4.79 (d, J = 2.8 Hz, 1H), 4.73 (d, J = 11.6 Hz, 1H), 4.69 (d, 
J = 11.8 Hz, 1H), 4.62–4.54 (m, 3H), 4.53 (d, J = 9.2 Hz, 1H), 4.47 (d, J = 11.4 Hz, 1H), 
4.42 (d, J = 9.4 Hz, 1H), 4.33 (d, J = 12.0 Hz, 1H), 4.27 (d, J = 12.0 Hz, 1H), 4.15 (dd, J 
= 10.2, 3.7 Hz, 1H), 4.04 (d, J = 2.4 Hz, 1H), 3.91 (dd, J = 10.2, 2.7 Hz, 1H), 3.83 (m, 1H), 
3.75 (dd, J = 9.4, 2.5 Hz, 1H), 3.71 (m, 3H), 3.50-3.41 (m, 2H). 
 
 
(2S,3S,4R)-2-Amino-3,4-(di-O-benzoyl)-N-(11-(4-fluorophenyl)undecanoyl)octa-
decan-1,3,4-triol (19) 
(2S,3S,4R)-2-Amino-3,4-(di-O-benzoyl)-N-(11-(4-fluorophenyl)undecanoyl)-1-(O-trityl)- 
octadecan-1,3,4-triol (31) (0.387 g, 0.376 mmol) was dissolved in DCM:MeOH (v/v 2:1, 
11 mL). p-Toluenesulfonic acid monohydrate (0.036 g, 0.19 mmol) was added, and the 
reaction was stirred at rt for 7 h and was then diluted with EtOAc (20 mL). The mixture 
was then washed with 5% aqueous NaHCO3 (20 mL) and brine (20 mL). The organic 
phase was dried (MgSO4) and concentrated under reduced pressure. The crude product 
was purified via flash chromatography on silica gel (petroleum ether/EtOAc 70:30) to yield 
19 as a colorless oil (0.215 g, 73%): []21D +29.7 (c 1.2, DCM); IR (neat) 2922, 2852, 
1719, 1509, 1450, 1263, 1095 cm-1; 1H NMR (400 MHz, CDCl3)  8.04 (m, 2H), 7.94 (m, 
2H), 7.62 (t, J = 7.4 Hz, 1H), 7.50 (m, 3H), 7.37 (t, J = 7.8 Hz, 2H), 7.10 (m, 2H), 6.94 (m, 
HO C13H27
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2H), 6.48 (d, J = 9.3 Hz, 1H), 5.45 (dd, J = 9.6, 2.4 Hz, 1H), 5.37 (m, 1H), 4.40 (dd, J = 
9.4, 9.4 Hz, 1H), 3.65 (m, 2H), 2.93 (dd, J = 8.4, 5.1 Hz, 1H), 2.55 (t, J = 7.5 Hz, 2H), 2.28 
(t, J = 7.5 Hz, 2H), 2.03 (m, 2H), 1.69 (m, 2H), 1.57 (m, 2H), 1.25 (m, 36H), 0.88 (t, J = 
6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3)  173.5, 167.2, 166.6, 161.3 (dC-F, J = 241.3 Hz), 
138.7 (dC-F, J = 2.9 Hz), 133.9, 133.3, 130.2, 129.9, 129.7, 129.4, 128.7 (dC-F, J = 7.3 Hz), 
115.1 (dC-F, J = 21.0 Hz), 74.2, 73.8, 61.7, 50.2, 37.0, 35.3, 32.1, 31.8, 29.9, 29.9, 29.8, 
29.8, 29.7, 29.6, 29.6, 29.5, 29.4, 28.6, 26.0, 25.9, 22.8, 14.3; HRMS (ESI) for 
C49H71FNO6 (M + H)+ m/z calcd: 788.5260. Found: 788.5240. 
Phenyl-2,3,4,6-tetra-O-acetyl-1--D-thiogalactopyranoside (22) 
Thiophenol (4.09 g, 37.1 mmol, 3.79 mL) was added to a solution of -D-galactose 
pentacetate (5.00 g, 12.8 mmol) in dry DCM (50 mL) at 0 °C. After 30 min, BF3
 
etherate 
(6.29 g, 44.3 mmol, 5.5 mL) was added dropwise, and the solution was left at rt for 3 days. 
The reaction mixture was diluted with DCM (50 mL), washed with saturated aqueous 
NaHCO3
 
(75 mL) and brine (30 mL), dried (Na2SO4) and concentrated. Purification by 
flash chromatography on silica gel (petroleum ether/EtOAc 80:20) afforded phenyl 
2,3,4,6-tetra-O-acetyl-1--D-thiogalacto-pyranoside (22) as a white solid (3.68 g, 83%):44 
1H NMR (400 MHz, CDCl3)  7.51–7.48 (m, 2H), 7.30–7.28 (m, 3H), 5.39 (d, J = 3.2 Hz, 
1H), 5.22 (dd, J = 10.0 Hz, 1H), 5.04 (dd, J = 9.9, 3.3 Hz, 1H), 4.71 (d, J = 10.0 Hz, 1H), 
4.16 (dd, J = 11.4, 7.1 Hz, 1H), 4.10 (dd, J = 11.3, 6.1 Hz, 1H), 3.93 (dd, J = 6.4, 6.4 Hz, 
1H), 2.09 (s, 3H), 2.07 (s, 3H), 2.02 (s, 3H), 1.95 (s, 3H).  
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Phenyl-2,3,4,6-tetra-O-benzyl-1--D-thiogalactopyranoside (23) 
NaOMe in MeOH (4.37 M, 24.6 mmol, 5.62 mL) was added to a solution of phenyl 2,3,4,6-
tetra-O-acetyl-1-thio--D-galactopyranoside (22) (2.70 g, 6.14 mmol) in THF (40 mL), and 
the solution was left at rt for 4 h. The reaction mixture was neutralized using Dowex (C-
211, H, 16-50 mesh) resin. The resin was filtered, and the filtrate was concentrated to 
afford phenyl 1-thio--D-galactopyranoside as a pale brown solid (1.64 g). The crude 
product was then dissolved in DMF (35 mL), and benzyl bromide (4.84 g, 28.3 mmol, 3.37 
mL) was added, followed by NaH (60% in mineral oil, 1.97 g, 49.4 mmol) at 0 °C. The 
resulting suspension was stirred at rt overnight. The reaction mixture was diluted with 
H2O (100 mL) at 0 °C and then extracted with diethyl ether (3 x 50 mL). The combined 
organic extracts were dried (Na2SO4) and concentrated. The residue was purified by flash 
chromatography on silica gel (petroleum ether/EtOAc 80:20) to afford phenyl 2,3,4,6-
tetra-O-benzyl-1--D-thiogalactopyranoside as a white solid (2.74 g, 72%):44 1H NMR 
(400 MHz, CDCl3)  7.62–7.60 (m, 2H), 7.43–7.29 (m, 20H), 7.23–7.22 (m, 3H), 5.01 (d, 
J = 11.5 Hz, 1H), 4.84 (d, J = 10.2 Hz, 1H), 4.78 (d, J = 9.7 Hz, 1H), 4.77–4.74 (m, 2H), 
4.69 (d, J = 9.6 Hz, 1H), 4.65 (d, J = 11.6 Hz, 1H), 4.52 (d, J = 11.7 Hz, 1H), 4.47 (d, J = 
11.7 Hz, 1H), 4.02 (d, J = 1.9 Hz, 1H), 3.98 (dd, J = 9.6, 9.6 Hz, 1H), 3.71–3.64 (m, 4H). 
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Tri-O-acetylgalactalepoxide  
Saturated NaHCO3 (150 mL) and acetone (10 mL) were added to a solution of 3,4,6-tri-
O-acetylgalactal (5.74 g, 21.1 mmol) in DCM (100 mL). After stirring for 10 min, Oxone 
(26.0 g, 42.2 mmol) was added slowly at 0 °C. The mixture was stirred at 0 °C for 30 min 
and at rt for 5 h. The reaction mixture was diluted with DCM (20 mL), and the layers were 
separated. The aqueous layer was extracted with DCM (3 x 50 mL). The combined 
organic extracts were dried (Na2SO4) and concentrated to give tri-O-
acetylgalactalepoxide as a viscous oil (5.39 g).
 
The product was azeotroped with toluene 
(2 x 40 mL) and used in the next reaction without further purification:45 1H NMR (300 MHz, 
CDCl3)  5.25 (d, J = 4.0 Hz, 1H), 5.19 (d, J = 4.1 Hz, 1H), 5.08 (d, J = 2.1 Hz, 1H), 4.16–
4.10 (m, 2H), 4.05 (dd, J = 13.0, 6.6 Hz, 1H), 3.02 (m, 1H), 2.15 (s, 3H), 2.09 (s, 6H).  
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Phenyl 3,4,6-tri-O-acetyl-1--D-thiogalactopyranoside (24)  
Thiophenol (8.24 g, 74.8 mmol) and triethylamine (15.2 g, 150 mmol, 21.0 mL) were 
added to a solution of tri-O-acetylgalactalepoxide (5.39 g, 18.7 mmol) in THF (60 mL). 
After stirring for 24 h, the resulting solution was concentrated, and the residue was purified 
by flash chromatography on silica gel (petroleum ether/EtOAc 90:10 to 70:30) to give 
phenyl 3,4,6-tri-O-acetyl-1--D-thiogalacto-pyranoside (24) as a pale yellow oil (2.76 g, 
63% over 2 steps):45 1H NMR (400 MHz, CDCl3)  7.62–.59 (m, 2H), 7.37–7.35 (m, 3H), 
5.43 (d, J = 3.1 Hz, 1H), 4.98 (dd, J = 9.7, 3.2 Hz, 1H), 4.64 (d, J = 9.7 Hz, 1H), 4.21 (dd, 
J = 11.3, 6.9 Hz, 1H), 4.14 (dd, J = 10.9, 6.2 Hz, 1H), 3.97 (dd, J = 6.5, 6.5 Hz, 1H), 3.84 
(ddd, J = 12.3, 9.7, 2.6 Hz, 1H), 2.44 (d, J = 2.6 Hz, 1H), 2.10 (s, 3H), 2.07 (s, 3H), 2.05 
(s, 3H). 
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Phenyl-2-O-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-3,4,6-tri-O-acetyl-1-thio-
-D-galactopyranoside (25) 
Phenyl 2,3,4,6-tetra-O-benzyl-1--D-thiogalactopyranoside (23) (1.80 g, 2.85 mmol) and 
phenyl 3,4,6-tri-O-acetyl-1--D-thiogalactopyranoside (24) (1.25 g, 3.14 mmol) were dried 
by azeotroping with toluene (3 x 40 mL). The mixture was dissolved in DCM (60 mL) 
under N2, and freshly ground activated 4 Å MS (2.0 g) were added. The mixture was 
cooled to –45 °C, and N-iodosuccinimide (0.802 g, 3.56 mmol) and silver triflate (0.217 g, 
0.840 mmol) were added. The mixture was stirred at –45 °C until the donor was consumed 
(based on TLC and and a color change to magenta). Et3N (20 mL) was added. The 
reaction mixture was diluted with DCM (100 mL) and filtered through a pad of celite. The 
celite was washed with DCM (50 mL). The filtrate was concentrated, and the residue was 
purified by flash chromatography on silica gel (petroleum ether/EtOAc 90:10 to 60:40) to 
afford phenyl 2-O-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-3,4,6-tri-O-acetyl-1-
thio--D-galactopyranoside (25) as a viscous oil (1.58 g, 60%):43 1H NMR (400 MHz, 
CDCl3)  7.54–7.52 (m, 2H), 7.41–7.26 (m, 23H), 5.71 (d, J = 3.6 Hz, 1H), 5.46 (d, J = 
2.9 Hz, 1H), 5.10 (dd, J = 9.5, 3.2 Hz, 1H), 5.01–4.75 (m, 6H), 4.59 (d, J = 11.3 Hz, 1H), 
4.49–4.40 (m, 2H), 4.22–3.91 (m, 8H), 3.64 (t, J = 8.5 Hz, 1H), 3.50 (dd, J = 8.5, 5.1 Hz, 
1H), 2.06 (s, 6H), 1.97 (s, 3H).  
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11-(4-Fluorophenyl)undecanoic acid (26) 
 
4-Fluoroiodobenzene (2.77 g, 12.5 mmol) and 10-undecynoic acid (3.11 g, 17.1 mmol) 
were dissolved in Et3N (28 mL). Bis(triphenyl phosphine) palladium (II) dichloride (0.700 
g, 0.998 mmol) was then added to the reaction flask. The mixture was stirred for 5 min, 
and copper (I) iodide (1.28 g, 6.74 mmol) was added. The reaction mixture was heated 
to 50 °C and stirred under N2 overnight. The mixture was allowed to cool to rt and passed 
through a pad of celite. The celite was rinsed with Et2O (500 mL). The filtrate was 
concentrated. The resulting crude material was a brown solid:47 1H NMR (400 MHz, 
CDCl3)  7.35 (m, 2H), 6.97 (m, 2H), 2.34 (m, 2H), 1.56 (m, 3H), 1.27 (m, 10H); 
The crude 11-(4-fluorophenyl)undec-10-ynoic acid was dissolved in MeOH (120 mL) 
under N2. Pd/C (3.00 g) and AcOH (6 mL) were added. The reaction vessel was purged 
with H2 for 10 min. The reaction was then stirred overnight at rt under a H2 balloon. The 
suspension was filtered through celite, and the celite was washed with CHCl3/MeOH (v/v 
1:1, 150 mL) and concentrated under reduced pressure. The crude product was purified 
via flash chromatography on silica gel (petroleum ether/EtOAc 80:20) to yield a white solid 
(2.81 g, 80% over 2 steps):47 1H NMR (400 MHz, CDCl3)  7.10 (m, 2H), 6.97 (m, 2H), 
3.67 (s, 1H), 2.57 (t, J = 7.7 Hz, 2H), 2.31 (t, J = 7.5 Hz, 2H), 1.59 (m, 4H), 1.30 (m, 12H). 
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4-Nitrophenyl-11-(4-fluorophenyl)undecanoate (27)  
 
11-(4-Fluorophenyl)undecanoic acid (26) (0.672 g, 2.40 mmol), 4-nitrophenol (0.303 g, 
2.18 mmol), and DMAP (0.0530 g, 0.436 mmol) were dissolved in dry DCM (100 mL), 
and the solution was stirred for 15 min at rt. DCC (0.468 g, 2.27 mmol) was dissolved in 
dry DCM (20 mL) then added to the reaction flask. The reaction mixture was stirred 
overnight and was then concentrated under reduced pressure. The crude material was 
purified via flash chromatography on silica gel (petroleum ether/EtOAc 95:5) to give 27 
as a white solid (0.89 g, 90%): mp 37.7–38.5 °C; IR (neat) 2922, 2851, 1758, 1527, 1343, 
1200, 1141 cm-1; 1H NMR (400 MHz, CDCl3)  8.25 (m, 2H), 7.28 (m, 2H), 7.12 (m, 2H), 
6.95 (m, 2H), 2.60 (t, J = 7.44 Hz, 2H) 2.58 (t, J = 7.56 Hz, 2H), 1.76 (quint, J = 7.36 Hz, 
2H), 1.58 (m, 2H), 1.31 (m, 12H); 13C NMR (100 MHz CDCl3)  171.1, 161.0 (dC-F J = 
241.5 Hz), 155.4, 145.0, 138.3 (dC-F J = 3.1 Hz), 129.5 (dC-F J = 7.8 Hz), 124.9, 122.3, 
114.7 (dC-F J = 21.1 Hz), 35.1, 34.3, 31.6, 29.6, 29.5, 29.5, 29.3, 29.2, 29.1, 24.7; HRMS 
(ESI) for C23H28FNNaO6 (M + Na)+ m/z calcd: 424.1885. Found: 424.1868. 
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(2S,3S,4R)-2-Amino-N-(11-(4-fluorophenyl)undecanoyl)octadecan-1,3,4-triol  
(28) 
 
4-Nitrophenyl-11-(4-fluorophenyl)undecanoate 27 (0.361 g, 0.900 mmol) and phyto-
sphingosine (20) (0.238 g, 0.750 mmol) were combined in THF (18 mL) and stirred at rt. 
Et3N (0.36 mL) was added, and the reaction was stirred for 2 d at 50 °C. The solution was 
concentrated under reduced pressure, and the resulting solid was purified via flash 
chromatography on silica gel (petroleum ether/EtOAc/MeOH 50:47:3) to give 27 as a 
white solid (0.435 g, 92%): mp 109.5–111.2 °C; []21D –116 (c 0.6, MeOH); IR (neat) 3371 
(br), 3327 (br), 2917, 2849, 1611, 1556, 1510, 1467, 1261, 1233, 1095 cm-1; 1H NMR 
(400 MHz, CDCl3)  7.11 (m, 2H), 6.94 (m, 2H), 6.32 (d, J = 7.4 Hz, 1H), 4.13 (m, 1H), 
3.91 (dd, J = 11.6, 2.2 Hz, 1H), 3.87 (d, J = 7.0 Hz, 1H), 3.73 (dd, J = 11.2, 5.3 Hz, 2H), 
3.58 (m, 3H), 2.56 (t, J = 7.6 Hz, 2H), 2.56 (br, 1H) 2.23 (t, J = 7.4 Hz, 2H), 1.77 (m, 1H), 
1.57 (m, 8H), 1.25 (m, 36H), 0.88 (t, J = 6.5 Hz, 3H); 13C NMR (100 MHz CDCl3/MeOD 
v/v 2:1)  174.6, 161.1 (dC-F J = 241.0 Hz), 138.4,129.5 (dC-F J = 7.5 Hz),114.7 (dC-F J = 
20.9 Hz), 75.5, 72.4, 61.0, 51.9, 36.4, 35.0, 32.9, 31.8, 31.5, 29.6, 29.5, 29.4, 29.3, 29.1, 
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25.8, 25.7, 22.6, 13.9; HRMS (ESI) for C35H63FNO4 (M + H)+ m/z calcd: 580.4741. Found: 
580.4717. 
 
 
(2S,3S,4R)-2-Amino-1,3,4-(tri-O-tert-butyldimethylsilyl)N-(11-(4-fluorophenyl) 
undecanoyl)octadecan-1,3,4-triol (29) 
 
(2S,3S,4R)-2-Amino-N-(11-(4-fluorophenyl)undecanoyl)octadecan-1,3,4-triol (28) 
(0.206 g, 0.355 mmol) was suspended in DCM (2.5 mL) at 0 °C. TBDMSOTf (0.845 g, 
3.20 mmol) dissolved in 2,6-lutidine (0.82 mL) was added, and the reaction mixture was 
stirred at rt overnight. The reaction mixture was diluted with H2O (8 mL) and extracted 
with DCM (2 x 16 mL). The organic layers were combined, dried (MgSO4), and 
concentrated under reduced pressure. The crude product was purified via flash 
chromatography on silica gel (petroleum ether/EtOAc 95:5) to give 29 as a colorless oil 
(0.226 g, 69%): []22D –0.69 (c 0.12, DCM); IR (neat) 2926, 2854, 833, 775 cm-1; 1H NMR 
(400 MHz, CDCl3)  7.11 (m, 2H), 6.94 (m, 2H), 5.81 (d, J = 8.5 Hz, 1H), 3.95 (m, 1H), 
3.86 (dd, J = 10.1, 4.3 Hz, 1H), 3.82 (dd, J = 7.3, 1.0 Hz, 1H), 3.68 (m, 1H), 3.63 (dd, J = 
10.1, 4.5 Hz, 1H), 2.56 (t, J = 7.6 Hz, 2H), 2.14 (t, J = 7.6 Hz, 2H), 1.58 (m, 6H), 1.27 (m, 
36H), 0.90 (m, 30H), 0.13 (s, 3H), 0.06 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); 13C NMR (100 
MHz, CDCl3)  172.4, 161.3 (dC-F, J = 244.5 Hz), 138.6 (dC-F, J = 2.9 Hz), 129.8 (dC-F, J = 
7.7 Hz), 115.1 (dC-F, J = 21.2 Hz), 75.7, 75.6, 61.6, 52.8, 37.3, 35.3, 32.4, 32.1, 31.8, 30.2, 
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29.9, 29.8, 29.7, 29.7, 29.6, 29.6, 29.4, 26.5, 26.3, 26.3, 26.2, 26.1, 26.0, 25.9, 25.8, 25.7, 
25.7, 22.9, 18.5, 18.4, 18.3, 18.3, 14.3, 1.4, 1.2, -2.8, -2.8, -3.3, -3.6, -3.9, -4.6, -4.9, -5.0, 
-5.4; HRMS (ESI) for C53H105FNO4Si3 (M + H)+ m/z calcd: 922.7335. Found: 922.7358. 
 
(2S,3S,4R)-2-Amino-3,4-(di-O-tert-butyldimethylsilyl)-N-(11-(4-fluorophenyl)un-
decanoyl)octadecan-1,3,4-triol (30)  
 
(2S,3S,4R)-2-Amino-1,3,4-(tri-O-tert-butyldimethyl-silyl)-N-(11-(4-fluorophenyl)un-
decanoyl)octadecan-1,3,4-triol (29) (0.165 g, 0.180 mmol) was dissolved in THF (2 mL) 
at 0 °C. A mixture of H2O/TFA (10:1/0.83 mL) was also cooled to 0 °C and added to the 
solution. The reaction was monitored by TLC until the starting material was consumed. 
The mixture was neutralized with saturated aqueous NaHCO3 (2 mL) and extracted with 
DCM (2 x 10 mL). The organic layers were combined and dried (MgSO4). The solution 
was concentrated under reduced pressure, and the crude product was purified via flash 
column chromatography on silica gel (petroleum ether/EtOAc 85:15) to yield 30 as a clear, 
colorless oil (0.125 g, 86%): []25D –8.2 (c 1.5, DCM); IR (neat) 2924, 2853, 1509, 1250, 
832, 774 cm-1; 1H NMR (400 MHz, CDCl3)  7.11 (m, 2H), 6.94 (m, 2H), 6.24 (d, J = 7.8 
Hz, 1H), 4.21 (d, J = 11.2 Hz, 1H), 4.06 (m, 1H), 3.91 (t, J = 2.8 Hz, 1H), 3.76 (ddd, J = 
6.4, 2.5 Hz, 1H), 3.58 (m, 1H), 3.15 (d, J = 6.4 Hz, 1H), 2.56 (t, J = 7.6 Hz, 2H), 2.18 (t, J 
= 7.6 Hz, 2H), 1.58 (m, 6H), 1.26 (m, 36 H), 0.93 (s, 9H), 0.91 (s, 9H), 0.88 (t, J = 6.5 Hz, 
3H), 0.11 (s, 6H), 0.09 (s, 3H), 0.08 (s, 3H); 13C NMR (100 MHz, CDCl3)  173.1, 161.3 
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(dC-F, J = 242.6 Hz) , 138.9 (dC-F, J = 2.9 Hz), 130.1 (dC-F, J = 7.91 Hz), 115.3 (dC-F, J = 
20.9 Hz), 77.9, 77.8, 64.1, 51.8, 37.4, 35.6, 34.9, 32.4, 32.1, 30.3, 30.2, 30.1, 30.0, 30.0, 
29.9, 29.8, 29.7, 26.5, 26.5, 26.3, 26.1, 23.2, 18.6, 18.6, 14.6, -3.3, -3.6, -4.0, -4.4; HRMS 
(ESI) for C47H91FNO4Si2 (M + H)+ m/z calcd: 808.7335. Found: 808.6487. 
 
(2S,3S,4R)-2-Amino-N-(11-(4-fluorophenyl)undecanoyl)-1-(O-trityl)octadecan-1,3,4-
triol  
 
(2S,3S,4R)-2-Amino-N-(11-(4-fluorophenyl)undecanoyl)-octadecan-1,3,4-triol (28) 
(0.280 g, 0.484 mmol) was dissolved in EtOAc (3.2 mL) and Et3N (0.66 mL). TrtCl (0.270 
g, 0.969 mmol) was added, and the reaction solution was stirred at 75 °C for 4 h. The 
reaction mixture was concentrated under reduced pressure and purified via flash 
chromatography on silica gel (petroleum ether/EtOAc/Et3N 70:25:5) to give (2S,3R,4R)-
2-amino-N-(11-(4-fluorophenyl)undecanoyl)-1-(O-trityl)octadecan-1,3,4-triol as a clear, 
yellow oil (0.365 g, 92%): []25D +4.4 (c 1.0, DCM); IR (neat) 2922, 2852, 1638, 1509, 
1448, 1220 cm-1; 1H NMR (400 MHz, CDCl3)  7.42 (m, 6H), 7.32 (m, 6H), 7.25 (m, 3H), 
7.10 (m, 2H), 6.95 (m, 2H), 6.00 (d, J = 8.3 Hz, 1H), 4.26 (m, 1H), 3.57 (m, 1H), 3.50 (dd, 
J = 9.8, 3.6 Hz, 1H), 3.39 (m, 1H), 3.35 (dd, J = 9.9, 4.7 Hz, 1H), 3.07 (d, J = 8.4, 1H), 
2.56 (t, J = 7.6 Hz, 2H), 2.15 (t, J = 7.5 Hz, 2H), 1.56 (m, 6H), 1.45 (m, 3H), 1.24 (m, 34H), 
0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz CDCl3) 173.2, 161.8 (dC-F, J = 244.8 Hz), 
143.2, 138.5 (dC-F, J = 3.0 Hz), 133.1, 129.7 (dC-F, J = 7.8 Hz),  128.5, 128.1, 127.6, 127.4, 
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115.4, 115.2, 114.9 (dC-F, J = 21.0 Hz), 87.6, 75.7, 72.9, 62.9, 60.5, 50.1, 36.5, 35.2, 33.3, 
32.0, 31.8, 30.0, 29.8, 29.7, 29.6, 29.5, 29.4, 29.3, 26.0, 25.8, 22.8, 21.2, 14.3; HRMS 
(ESI) for C54H77FNNaO6 (M + Na)+ m/z calcd: 844.5651. Found: 844.5672. 
 
(2S,3S,4R)-2-Amino-3,4-(di-O-benzoyl)-N-(11-(4-fluorophenyl)undecanoyl)-1-(O-
trityl)octadecane-1,3,4-triol (31)  
 
(2S,3S,4R)-2-Amino-N-(11-(4-fluorophenyl)undecanoyl)-1-(O-trityl)octadecan-1,3,4-triol 
(0.532 g, 0.647 mmol) was dissolved in pyridine (9.0 mL). DMAP (9.58 mg, 0.0784 mmol) 
was added to the solution; then BzCl (0.656 g, 0.54 mL, 4.67 mmol) was added drop wise 
and the reaction stirred overnight. The reaction was quenched with H2O (15 mL), and 
then the solution was extracted with CHCl3 (2 x 15mL). The combined organic extracts 
were combined, dried (MgSO4), and concentrated under reduced pressure. The crude 
material was purified via flash chromatography on silica gel (petroleum ether/EtOAc/Et3N 
90:5:5 then increased to petroleum ether/EtOAc 93:7) to give 31 as a clear, colorless oil 
(0.526 g, 79%): []25D –4.1 (c 0.15, DCM); IR (neat) 2925, 2853, 1723, 1509, 1449, 1275, 
1095, cm-1; 1H NMR (400 MHz, CDCl3)  7.95 (m, 2H), 7.88 (m, 2H), 7.56 (m, 2H), 7.40, 
(m, 4H), 7.29 (m, 6H), 7.12 (m, 11H), 6.95 (m, 2H), 5.97 (d, J = 9.3 Hz, 1H), 5.78 (dd, J = 
9.0, 2.6 Hz, 1H), 5.34 (ddd, J = 9.7, 2.8, 2.8 Hz, 1H), 4.58 (m, 1H), 3.33 (dd, J = 9.9, 3.8 
Hz, 1H), 3.28 (dd, J = 9.7, 3.0 Hz, 1H), 2.56 (t, J = 7.5 Hz, 2H), 2.16 (m, 2H), 1.85 (m, 
2H), 1.59 (m, 5H), 1.24 (m, 35H), 0.88 (m, 3H); 13C NMR (100 MHz CDCl3)  173.0, 166.7, 
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165.2, 161.4 (dC-F, J = 241.4 Hz), 143.5, 138.7 (dC-F J = 3.0 Hz), 133.3, 133.1, 130.4,  
130.0, 130.0, 129.9 (dC-F, J = 7.6 Hz), 129.8, 129.8, 128.8, 128.7, 128.6, 128.5, 127.3, 
127.2, 127.1, 115.2, 115.0 (dC-F J = 21.0 Hz), 87.1, 74.4, 73.9, 73.0, 72.8, 61.9, 53.6, 
49.6, 48.9, 37.1, 35.4, 34.7, 32.1, 31.9, 30.2, 29.9, 29.8, 29.8, 29.7, 29.7, 29.6, 29.4, 29.4, 
28.7, 28.3, 25.9, 25.9, 25.1, 22.9, 14.3; HRMS (ESI) for C68H85FNO6 (M + H)+ m/z calcd: 
1030.6361. Found: 1030.6390. 
 
 
(2S,3S,4R)-2-Amino-3,4-(di-O-benzoyl)-1-O-[2-O-(2,3,4,6-tetra-O-benzyl--D-
galactopyranosyl)-3,4,6-tri-O-benzyl--D-galactopyranosyl]-N-(11-(4-fluorophenyl) 
undecanoyl)octadecan-1,3,4-triol (32)  
Phenyl 2-O-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-3,4,6-tri-O-benzyl-1-thio--D-
galactopyranoside (17) (0.122 g, 0.116 mmol) and (2S,3S,4R)-2-amino-3,4-(di-O-
benzoyl)-N-(11-(4-fluorophenyl)undecanoyl)octadecan-1,3,4-triol 31 (0.126 g, 0.162 
mmol) were azeotroped with toluene. Silver triflate (0.010 g, 0.037 mmol) was separately 
azeotroped with toluene. The donor and acceptor were dissolved in DCM (7.7 mL) at -40 
°C under N2. Silver triflate and NIS (0.033 g, 0.145 mmol) were added, and the reaction 
mixture was stirred at –20 °C for 2.5 hr. The reaction was quenched with Et3N (1 mL). 
The crude mixture was filtered through celite and concentrated under reduced pressure. 
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The crude mixture was purified via flash column chromatography on silica gel (petroleum 
ether/EtOAc 90:10), which gave 32 as a clear, yellow oil (0.103 g, 60%): []25D –25.9 (c 
0.80, DCM); IR (neat) 2924, 2853, 1720, 1508,1453,1274, 1095, 697 cm-1; 1H NMR (400 
MHz, CDCl3)  7.90 (d, J = 7.7 Hz, 2H), 7.84 (d, J = 7.7 Hz, 2H), 7.44 (m, 2H), 7.31 (t, J 
= 7.5 Hz, 2H), 7.27–7.10 (m, 37H), 7.02 (m, 2H), 6.86 (m, 2H), 6.75 (d, J = 9.2 Hz, 1H), 
5.52 (d, J = 9.1 Hz, 1H), 5.33 (m, 1H), 4.89 (d, J = 2.9 Hz, 1H), 4.81 (d, J = 2.7 Hz, 1H), 
4.74 (t, J = 10.6 Hz, 2H), 4.62 (m, 2H), 4.57–4.35 (m, 9H), 4.21 (m, 2H), 4.12 (m, 2H), 
3.90 (m, 2H), 3.72 (m, 3H), 3.49 (m, 2H), 3.42 (m, 2H), 3.26 (m, 2H), 2.47 (t, J = 7.6 Hz, 
2H), 2.07 (m, 2H), 1.83 (m, 2H), 1.50 (m, 4H), 1.17 (m, 36H), 0.79 (t, J = 6.8 Hz, 3H); 13C 
NMR (100 MHz, CDCl3)   173.6, 166.2, 165.5, 161.3 (dC-F, J = 243.9 Hz), 139.2, 138.9, 
138.9, 138.8, 138.6, 138.5, 138.4, 138.0, 137.9, 133.3, 132.9, 130.4, 130.2, 129.9, 129.8 
(dC-F, J = 7.7 Hz), 129.7, 129.2, 128.7, 128.6, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 
128.1, 128.0, 127.8, 127.7, 127.6, 127.6, 127.5, 127.4, 115.0 (dC-F, J = 21.0 Hz), 99.8, 
96.5, 79.2, 76.5, 75.9, 74.9, 74.8, 74.7, 74.6, 73.9, 73.6, 73.4, 73.3, 73.2, 73.1, 72.9, 72.7, 
72.3, 71.7, 70.6, 69.4, 69.2, 68.8, 68.5, 68.1, 67.2, 48.9, 48.4, 36.8, 36.6, 35.3, 32.1, 31.8, 
29.8, 29.7, 29.6, 29.6, 29.5, 29.4, 28.7, 25.9, 25.8, 22.8, 14.3; HRMS (ESI) for 
C110H133FNO16 (M + H)+ m/z calcd: 1742.9608. Found: 1742.9610. 
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(2S,3S,4R)-2-Amino-1-O-[2-O-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-3,4,6-
tri-O-benzyl--D-galactopyranosyl]-N-(11-(4-fluorophenyl)undecanoyl)octadecan-
1,3,4-triol  
(2S,3R,4R)-2-Amino-3,4-(di-O-benzoyl)-1-O-[2-O-(2,3,4,6-tetra-O-benzyl--D-
galactopyranosyl)-3,4,6-tri-O-benzyl--D-galactopyranosyl]-N-(11-(4-fluorophenyl)-
undecanoyl)octadecan-1,3,4-triol (32) (0.100 g, 0.067 mmol) was dissolved in 
MeOH/THF (v/v 1:1, 6.5 mL). NaOMe (0.5 M, 0.39 mmol, 0.78 mL) was added, and the 
reaction was stirred under N2 for 2.5 hr. The reaction was neutralized with DOWEX resin, 
filtered through celite and concentrated under reduced pressure. The crude product was 
purified via flash column chromatography on silica gel (petroleum ether/EtOAc 70:30) to 
give (2S,3S,4R)-2-amino-1-O-[2-O-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-3,4,6-
tri-O-benzyl--D-galactopyranosyl]-N-(11-(4-fluorophenyl)undecanoyl)octadecan-1,3,4-
triol as a colorless oil (0.038 g, 88%): 1H NMR (400 MHz, CDCl3)  7.38–7.24 (m, 31H), 
7.13 (m, 3H), 6.95 (m, 2H), 6.41 (d, J = 8.3 Hz, 1H), 5.01 (d, J = 3.4 Hz, 1H), 4.85–4.74 
(m, 5H), 4.68–4.49 (m, 6H), 4.39 (m, 1H), 4.28 (m, 1H), 4.23–4.19 (m, 3H), 4.14–4.08 (m, 
3H), 4.01 (dd, J = 10.1, 3.6 Hz, 1H), 3.94 (m, 2H), 3.87–3.83 (m, 3H), 3.57 (m, 1H),  3.51–
3.47 (m, 4H), 3.31 (dd, J = 8.8, 5.1 Hz, 1H), 2.55 (m, 2H), 2.32 (t, J = 7.5 Hz, 1H), 2.14 
(t, J = 7.3 Hz, 2H), 1.58 (m, 6H), 1.26 (m, 38H), 0.89 (t, J = 6.6 Hz, 3H); 13C NMR (125 
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MHz, CDCl3)  173.3, 161.3 (dC-F, J = 240.8 Hz), 138.9, 138.8, 138.7, 138.6 (dC-F, J = 3.0 
Hz), 138.5, 138.3, 138.0, 137.8, 129.8 (dC-F, J = 7.6 Hz), 128.7, 128.6, 128.6, 128.4, 
128.3, 128.2, 128.2, 128.2, 128.1, 128.0, 127.8, 127.7, 127.7, 127.6, 127.4, 115.0 (dC-F, 
J = 21.0 Hz), 98.9, 98.0, 79.4, 77.9, 76.4, 75.7, 75.1, 75.0, 74.9, 74.8, 74.4, 74.3, 73.8, 
73.4, 73.4, 72.6, 72.4, 70.1, 70.0, 69.3, 69.1, 68.3, 49.5, 36.8, 35.3, 34.0, 32.7, 32.1, 31.8, 
29.9, 29.8, 29.7, 29.6, 29.4, 29.4, 29.3, 29.3, 26.6, 25.9, 24.9, 22.9, 14.3; HRMS (ESI) for 
C96H125FNO14 (M + H)+ m/z calcd: 1534.9084. Found: 1534.9054. 
 
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-3-benzyloxyoctadecan-1-ol  (34) 
TBAF (1.0 M in THF, 3.3 mL, 3.3 mmol) was added to a solution of (2S,3R)-2-(N-tert-
butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxy-3-benzyloxyoctadecane (39) (1.20 
g, 1.64 mmol) in THF (7.8 mL) under N2
 
at 0 °C. The cooling bath was removed, and the 
mixture was stirred for 4 h at rt. The reaction mixture was concentrated, and the residue 
was dissolved in CHCl3 (20 mL), washed with brine (10 mL), dried (MgSO4) and 
concentrated. Purification by flash chromatography on silica gel (petroleum ether/EtOAc 
95:5 to 85:15) afforded 33 as a white solid (0.735 g, 91%):28 1H NMR (400 MHz, CDCl3) 
 7.32 (m, 5H), 5.27 (d, J = 7.4 Hz, 1H), 4.63 (d, J = 11.4 Hz, 1H), 4.48 (d, J = 11.4 Hz, 
1H), 3.95 (m, 1H), 3.65 (m, 3H), 2.95 (s, 1H), 1.67 (m, 1H), 1.44 (s, 9H), 1.26 (br s, 27H), 
0.88 (t, J = 6.8 Hz, 3H).  
  
HO
C14H29
NHBoc
OBn
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[2-Hydroxy-1-(methoxymethylcarbamoyl)ethyl]-carbamic acid tert-Butyl Ester (37) 
Boc-L-serine (8.00 g, 39.0 mmol) was dissolved in dry DCM (153 mL) and the solution 
cooled to –15 °C under N2. N,O-Dimethylhydroxylamine hydrochloride (3.92 g, 40.0 
mmol) was added, followed by N-methylmorpholine (4.42 mL, 40.2 mmol). After 5 min 
1-(3-methylaminopropyl-3-ethylcarbodiiimide hyrdrochloride (7.70 g, 40.2 mmol) was 
added in five portions over 30 min. After being stirred for 1 h at –15 °C, the reaction was 
quenched with HCl (1 M, 25 mL), and the layers were separated. The aqueous layer 
was extracted with DCM (3 × 50 mL). The organic extracts were combined, washed with 
saturated aqueous NaHCO3 (23 mL) and H2O (23 mL), dried (MgSO4), and 
concentrated to provide 37 as a white solid (8.52 g, 88%):28 1H NMR (400 MHz, CDCl3) 
 5.71 (br s, 1H), 4.95 (br s, 1H), 3.82–3.78 (m, 5H), 3.23 (s, 3H), 2.90 (br s, 1H), 1.43 
(s, 9H).  
 
(2S)-2-(N-tert-Butoxycarbonylamino)-1-hydroxyoctadecan-3-one (38) 
 
s-BuMgCl (2.0 M in THF, 19.5 mL, 38.9 mmol) was added dropwise to a solution of (2S)-
methyl-[2-hydroxyl-(methoxymethylcarbomoyl)ethyl]carbamic acid tert-butyl ester 37
 
(4.60 g, 18.5 mmol) in THF (60 mL) at –15 °C. After stirring for 5 min, 
pentadecylmagnesium bromide (0.6 M in THF, 36.5 mL, 22.2 mmol) was added at –15 
°C; the resulting solution was warmed to rt and stirred overnight. The reaction mixture 
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was cooled to –15 °C. Aqueous HCl (1M, 40 mL) was added, followed by EtOAc (40 mL), 
and the two layers were separated. The aqueous layer was extracted with DCM (3 x 50 
mL), and the combined organic extracts were washed with H2O (50 mL), dried (Na2SO4) 
and concentrated. Purification by flash chromatography on silica gel yielded 36 as a white 
solid (5.54 g, 74%):28 1H NMR (400 MHz, CDCl3)  5.48 (br s, 1H), 4.26 (m, 1H), 3.94 (m, 
2H), 2.63 (br s, 1H), 2.55 (m, 2H), 1.57 (m, 2H), 1.45 (s, 9H), 1.20 (s, 24H), 0.80 (t, J = 
6.8 Hz, 3H).  
(2S)-2-(N-tert-Butoxycarbonylamino)-1-(tert-butyldiphenylsilyloxy)octadecan-3-
one (39) 
4-DMAP (0.264 g, 2.16 mmol), imidazole (2.20 g, 32.4 mmol) and TBDPSCl (3.55 g, 12.9 
mmol, 3.40 mL) were added to a solution of (2S)-2-(N-tert-butoxycarbonylamino)-1-
hydroxyoctadecan-3-one (36) (4.30 g, 10.8 mmol) in DMF (30 mL). After stirring at rt 
overnight, the reaction mixture was diluted with Et2O (150 mL). The resulting solution was 
then washed with H2O (3 x 50 mL), dried (Na2SO4) and concentrated. Purification by flash 
chromatography on silica gel (petroleum ether/EtOAc, 90:10) yielded 37 as a colorless oil 
(6.55 g, 95%):28 1H NMR (400 MHz, CDCl3)  7.35–7.60 (m, 10H), 5.53 (d, J = 1.1 Hz, 
1H), 4.33 (d, J = 1.9 Hz, 1H), 4.04 (dd, J = 10.6, 3.1 Hz, 1H), 3.90 (dd, J = 10.9, 3.8 Hz, 
1H), 2.51 (m, 2H), 1.58 (m, 2H), 1.44 (s, 9H), 1.26 (m, 24H), 1.03 (s, 9H), 0.89 (t, J = 7.0 
Hz, 3H).  
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(2S,3R)-2-(N-tert-Butoxycarbonylamino)-1-(tert-butyldiphenylsilyloxy)octadecan-
3-ol (40) 
LiAl(Ot-Bu)3H (8.03 g, 31.6 mmol) was added to dry EtOH (40 mL) at –78 °C. After stirring 
for 20 min, a solution of (2S)-2-N-tert-butoxycarbonylamino)-1-(tert-butyldiphenyl-
silyloxy)octadecan-3-one (37) (3.36 g, 5.26 mmol) in dry EtOH (40 mL) was added slowly, 
and stirring at –78 °C was continued for 6 h. The reaction mixture was diluted with 
aqueous citric acid (10%, 100 mL) and allowed to warm to rt over 1.5 h, and the resulting 
suspension was extracted with DCM (3 x 100 mL). The combined organic extracts were 
washed with H2O (50 mL) and brine (50 mL), dried (Na2SO4) and concentrated. The 
residue was purified via flash chromatography on silica gel (petroleum ether/EtOAc, 95:5 
to 90:10) to yield 38 as a colorless oil (3.27 g, 97%):28 1H NMR (300 MHz, CDCl3)  7.40– 
7.65 (m, 10H), 5.30 (d, J = 8.1 Hz, 1H), 3.93 (m, 1H), 3.90 (d, J = 10.4 Hz, 1H), 3.67 (m, 
1H), 3.57 (s, 1H), 2.88 (d, J = 8.1 Hz, 2H), 1.57 (m, 2H), 1.45 (s, 9H), 1.27 (m, 25H), 1.1 
(s, 9H), 0.87 (t, J = 6.6 Hz, 3H).  
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(2S,3R)-3-(Benzyloxy)-2-(N-tert-butoxycarbonylamino)-1-(tert-butylphenyl- 
silyloxy)octadecane (41) 
Tetrabutylammonium iodide (1.40 g, 4.33 mmol) and benzyl bromide (0.809 g, 4.73 mmol, 
0.56 mL) were added to a solution of (2S,3R)-2-(N-tert-butoxycarbonyl-amino)-1-(tert-
butyldiphenylsilyloxy)octadecan-3-ol (38) (2.52 g, 3.94 mmol) in DMF (20 mL) at 0 °C. 
After stirring for 10 min, NaH (60% in mineral oil, 0.189 g, 4.73 mmol) was added at 0 °C, 
and stirring at 0 °C was continued for 20 min. The mixture was allowed to warm to at rt 
and stirred overnight. The resulting solution was diluted with saturated aqueous NH4Cl 
(100 mL) and extracted with Et2O (3 x 50 mL). The combined organic extracts were 
washed with H2O (2 x 100 mL) and brine (100 mL), dried (Na2SO4) and concentrated. 
Purification by flash chromatography on silica gel (petroleum ether/EtOAc, 100:0 to 95:5) 
provided 39 as a pale yellow oil (2.24 g, 78%):28 1H NMR (400 MHz, CDCl3)  7.32–7.65 
(m, 15H), 4.71 (d, J = 8.0 Hz, 1H), 4.54 (d, J = 11.3 Hz, 1H), 4.49 (dd, J = 10.0, 4.9 Hz, 
2H), 3.86 (dd, J = 9.0, 4.1 Hz, IH), 3.72 (s, 1H), 3.58 (m, 1H), 1.55 (m, 2H), 1.42 (s, 9H), 
1.28 (m, 26H), 1.05 (s, 9H), 0.88 (t, J = 7.0 Hz, 3H).  
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(2S,3R)-1-(2,3-di-O-Benzyl-4,6-O-benzylidene--D-galactopyranosyl)2-(N-tert-
butoxycarbonylamino)-3-(O-benzyl)-octadecan-1,3-diol (42) 
Phenyl 4,6-O-benzylidene-1-thio--D-galactopyranoside (43) (0.330 g, 0.611 mmol) and 
(2S,3R)-2-(N-tert-butoxycarbonyl)amino-3-benzyloxy-octadecan-1,3-diol  (33) (0.200 g, 
0.407 mmol) were azeotroped in toluene. Silver triflate (0.021 g, 0.081 mmol) was 
separately azeotroped with toluene. The donor and acceptor were dissolved in DCM (8.6 
mL) at –40 °C under N2 with 4 Å molecular sieves. Silver triflate and NIS (0.137 g, 0.611 
mmol) were added, and the reaction mixture was stirred at –20 °C for 5 d. The reaction 
was quenched with Et3N (2 mL). The crude mixture was filtered through a celite pad. The 
celite pad was rinsed with DCM (20 mL), and the filtrate was concentrated under reduced 
pressure. The crude mixture was purified via flash column chromatography on silica gel 
(petroleum ether/EtOAc 85:15), which resulted in 44 as a yellow oil (0.113 g, 30%): []22D 
–68.4 (c 1.61, DCM);  IR (neat) 2923, 2853, 1741, 1099, 1050f cm-1; 1H NMR (400 MHz, 
CDCl3)  7.52 (m, 3H), 7.42–7.26 (m, 17H), 5.47 (s, 1H), 4.95 (d, J = 3.2 Hz, 1H), 4.85 
(m, 2H), 4.65 (d, J = 11.9 Hz, 1H), 4.49 (m, 2H), 4.20 (m, 2H), 4.08 (dd, J = 10.0, 3.3 Hz, 
1H), 3.98 (m, 2H), 3.90 (m, 2H), 3.75 (m, 2H), 3.65 (m, 1H), 3.56 (m, 1H), 1.44 (s, 9H), 
1.27 (m, 27H), 0.89 (t, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3)   171.3, 155.7, 139.0, 
138.9, 138.7, 138.0, 129.6, 129.0, 128.5, 128.5, 128.3, 128.0, 127.9, 127.8, 127.7, 126.5, 
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101.2, 99.7, 79.3, 76.8, 75.8, 74.8, 73.8, 72.3, 72.1, 69.6, 68.2, 63.1, 60.5, 53.1, 32.1, 
31.0, 30.1, 29.9, 29.5, 28.6, 25.5, 22.9, 21.2, 14.4, 14.3; HRMS (ESI) for C57H80NO9 (M+ 
+ H) m/z calcd: 922.5835. Found: 922.5873. 
 
(2S,3R)-2-Amino-1-(2,3,4-tri-O-benzyl--D-galactopyranosyl)-3-(O-
benzyl)octadecan-1,3-diol (43) 
 
(2S,3R)-1-(2,3-di-O-Benzyl-4,6-O-benzylidene--D-galactopyranosyl)-2-(N-tert-
butoxycarbonylamino)-3-(O-benzyl)octadecan-1,3-diol (42) (0.050 g, 0.054 mmol) was 
vigorously stirred in DCM (0.5 mL). BH3.THF (0.270 mmol, 0.300 mL) was added at rt, 
stirring was continued for 45 min. Sc(OTf)3 (0.005 g, 0.011 mmol) was then added and 
the reaction mixture stirred for 5 h. The reaction was quenched with MeOH (1 mL) and 
Et3N (1 mL), and the mixture was concentrated in vacuo. The crude mixture was purified 
via flash column chromatography on silica gel (DCM/MeOH 95:5), which resulted in 
yellow oil 43 (0.115 g, 64%: []23D +40 (c 0.08, DCM);  IR (neat) 3374 (br), 2922, 2853, 
1454, 1029 cm-1; 1H NMR (400 MHz, CDCl3)  7.36–7.22 (m, 20H), 4.90 (d, J =  3.3 Hz, 
1H), 4.77 (m, 1H), 4.71–4.55 (m, 5H), 4.45 (d, J = 11.0 Hz, 1H), 3.95 (m, 3H), 3.89 (m, 
1H), 3.78 (m, 2H), 3.72 (m, 2H), 3.61 (m, 1H), 3.49 (m, 1H), 3.39 (m, 1H), 2.43 (br s, 2H), 
1.61 (m, 4H), 1.23 (m, 25H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)   138.4, 
138.3, 138.1, 128.6, 128.6, 128.6, 128.2, 129.0, 129.0, 98.8, 76.2, 73.8, 72.7, 72.5, 70.9, 
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67.8, 66.0, 62.2, 53.3, 46.3, 37.7, 34.3, 32.1, 30.6, 29.9, 29.6, 25.4, 22.9, 22.5, 14.2; 
HRMS (ESI) for C54H74FNO7 (M+ + H) m/z calcd: 824.5467. Found: 824.5462. 
 
 
(2S,3R)-2-Amino-1-(2,3,4-tri-O-benzyl--D-galactopyranosyl)-3-(O-benzyl)-N-(11-(4-
fluorophenyl)undecanoyl)octadecan-1,3-diol (44) 
 
(2S,3R)-2-Amino-1-(2,3,4-tri-O-benzyl--D-galactopyranosyl)-3-(O-benzyl)-octadecan-
1,3-diol (43) (0.100 g, 0.121 mmol) was dissolved in pyridine (2.4 mL). PNP ester (0.140 
g, 0.242 mmol) was added and the reaction stirred at rt overnight. The crude material 
was concentrated under reduced pressure and purified via flash column chromato-
graphy on silica gel (petroleum ether/EtOAc 60:40), which resulted in a white solid 44 
(0.100 g, 73%): []22D –398 (c 0.26, DCM);  IR (neat) 3317 (br), 2923, 2853, 1027 cm-1; 
1H NMR (400 MHz, CDCl3)  7.32 (m, 20H), 7.11 (m, 2H), 6.95 (m, 2H), 5.76 (d, J = 9.1 
Hz, 1H), 4.95 (d, J = 11.5 Hz, 1H), 4.87 (d, J = 3.8 Hz, 1H), 4,81 (dd, J = 11.7, 8.7 Hz, 
2H), 4.73 (d, J = 11.7 Hz, 1H), 4.64 (dd, J = 11.8, 9.7 Hz, 2H), 4.59 (d, J = 11.7 Hz, 1H) 
4.65 (d, J = 9.7 Hz, 1H), 4.63 (d, J = 9.5 Hz, 1H), 4.59 (d, J = 11.7 Hz, 1H), 4.39 (d, J = 
11.6 Hz, 1H), 4.32 (m, 1H), 4.04 (dd, J = 9.9, 3.8 Hz, 1H), 3.87 (m, 2H), 3.85 (dd, J = 
9.9, 2.7 Hz, 1H), 3.71 (m, 2H), 3.68 (m, 1H), 3.51 (m, 2H), 2.56 (t, J = 7.6 Hz, 2H), 2.45 
(m, 1H), 1.97 (m, 2H), 1.53 (m, 6H), 1.25 (m, 38H), 0.89 (t, J = 6.6 Hz, 3H); 13C NMR 
(100 MHz, CDCl3)   173.3, 161.3 (dC-F, J = 240.9 Hz), 138.8, 138.6 (dC-F, J = 2.9 Hz), 
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138.4, 129.8 (dC-F, J = 7.5 Hz), 128.7, 128.6, 128.2, 128.0, 127.9, 127.8, 127.6, 115.1 
(dC-F, J = 20.9 Hz), 100.3, 80.0, 79.4, 76.9, 75.1, 74.7, 73.7, 73.5, 72.4, 71.4, 69.0, 62.7, 
51.8, 37.1, 35.3, 32.1, 31.8, 31.1, 30.0, 29.9, 29.8, 29.7, 29.7, 29.6, 29.5, 29.4, 25.9, 
25.6, 22.9, 14.3; HRMS (ESI) for C69H97FNO8 (M+ + H) m/z calcd: 1086.7198. Found: 
1086.7168. 
 
(2S,3R)-2-Amino-1-(2,3,4-tri-O-benzyl-6-phenylacetoyl--D-galactopyranosyl)-3-(O-
benzyl)-N-(11-(4-fluorophenyl)undecanoyl)octadecan-1,3,-diol (45a) 
 
(2S,3R)-2-Amino-N-(11-(4-fluorophenyl)undecanoyl)-1-(2,3,4-tri-O-benzyl--D-galacto-
pyranosyl)octadecan-3-(O-benzyl)-1,3-diol (44) (0.030 g, 0.028 mmol) was dissolved in 
DCM (2.8 mL). Phenylacetic acid (0.005 g, 0.034 mmol) and DMAP (0.001 g, 0.006 mmol) 
were added and the reaction stirred at rt for 5 min. DCC (0.006 g, 0.030 mmol) dissolved 
in DCM (0.5 mL) was added to the reaction and the mixture stirred at rt overnight. The 
crude mixture was concentrated in vacuo and purified via flash column chromatography 
on silica gel (petroleum ether/EtOAc 70:30), which resulted in a clear, colorless oil 45a 
(0.027 g, 79%): []22D +7.6 (c 0.10, DCM);  IR 2923, 2853, 1455, 1096 cm-1; 1H NMR (400 
MHz, CDCl3)  7.37–7.22 (m, 25H), 7.10 (m, 2H), 6.95 (m, 2H), 5.75 (d, J = 8.6 Hz, 1H), 
4.87 (m, 2H), 4.79 (d, J = 8.9 Hz, 1H), 4.77 (d, J = 8.8 Hz, 1H), 4.71 (d, J = 11.7 Hz, 1H), 
4.62 (d, J = 11.7 Hz, 1H), 4.54 (d, J = 11.6 Hz, 1H), 4.44 (dd, J = 11.2, 3.8 Hz, 1H), 4.21 
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(m, 1H), 4.18 (m, 1H), 4.07–4.00 (m, 2H), 3.89 (m, 1H), 3.84 (dd, J = 10.4, 2.6 Hz, 1H), 
3.75 (m, 1H), 3.68 (m, 2H), 3.57 (m, 3H), 2.55 (t, J = 7.6 Hz, 2H), 2.00 (m, 4H), 1.53 (m, 
6H), 1.24 (m, 35H), 0.88 (t, J = 6.0 Hz, 3H); 13C NMR (100 MHz, CDCl3)   172.9, 171.2, 
138.8, 138.7, 138.6, 138.4, 134.0, 129.8 (dC-F, J = 7.7 Hz), 129.5, 128.8, 128.6, 128.5, 
128.5, 128.0, 127.9, 127.8, 127.6, 127.4, 115.0 (dC-F, J = 20.9 Hz), 100.0, 79.0, 78.9, 
76.7, 74.8, 73.7, 73.3, 72.3, 68.9, 67.6, 63.8, 51.4, 45.6, 45.4, 41.6, 41.4, 37.7, 37.3, 37.0, 
35.3, 34.3, 33.0, 32.1, 31.8, 31.0, 30.6, 30.2, 30.1, 29.9, 29.8, 29.7, 29.7, 29.6, 29.6, 29.4, 
27.8, 27.6, 27.3, 25.9, 25.5, 24.7, 22.9, 22.8, 22.5, 21.6, 20.7, 19.9, 19.8, 14.3; HRMS 
(ESI) for C77H103FNO9 (M+ + H) m/z calcd: 1204.7617. Found: 1204.7574. 
 
 
(2S,3R)-2-Amino-(2,3,4-tri-O-benzyl-6-hydrocinnamoyl--D-galactopyranosyl)-3-
(O-benzyl)-N-(11-(4-fluorophenyl)undecanoyl)octadecan-1,3,-diol (45b) 
 
(2S,3R)-2-Amino-1-(2,3,4-tri-O-benzyl--D-galactopyranosyl)-3-(O-benzyl)-N-(11-(4-
fluorophenyl)undecanoyl)octadecan-1,3-diol (44) (0.030 g, 0.028 mmol) was dissolved in 
DCM (2.8 mL). Hydrocinnamic acid (0.005 g, 0.03 mmol) and DMAP (0.001 g, 0.006 
mmol)) were added and the reaction stirred at rt for 5 min. DCC (0.006 g, 0.03 mmol) 
dissolved in DCM (0.5 mL) was added to the reaction and the mixture stirred at rt 
overnight. The crude mixture was concentrated in vacuo and purified via flash column 
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chromatography on silica gel (petroleum ether/EtOAc 70:30), which resulted in a clear, 
colorless oil 45b (0.032 g, 94%): []25D +10 (c 0.08, DCM);  IR (neat) 2924, 2854, 1733, 
1455, 1099 cm-1; 1H NMR (400 MHz, CDCl3)  7.40–7.15 (m, 25H), 7.10 (m, 2H), 6.96 (m, 
2H), 5.81 (d, J = 8.7 Hz, 1H), 4.93 (d, J = 11.4 Hz, 1H), 4.85 (m, 1H), 4.80 (d, J = 9.4 Hz, 
1H), 4.76 (d, J = 4.6 Hz, 1H), 4.72 (m, 1H), 4.64 (d, J = 11.8 Hz, 1H), 4.57 (d, J = 6.6 Hz, 
1H), 4.54 (d, J = 6.8 Hz, 1H), 4.43 (d, J = 1.6 Hz, 1H), 4.22 (m, 1H), 4.15 (dd, J = 11.2, 
7.0 Hz, 1H), 4.06–-4.02 (m, 2H), 3.89–3.84 (m, 2H), 3.79 (m, 1H), 3.72 (m, 2H), 3.58 (m, 
1H), 2.97 (m, 3H), 2.89 (t, J = 7.7 Hz, 2H), 2.69 (m, 3H), 2.55 (m, 4H), 2.00 (m, 2H), 1.56 
(m, 6H), 1.24 (m, 32H), 0.89 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)   177.8, 
173.1, 172.6, 161.2 (dC-F, J = 254.9 Hz), 140.5, 140.4, 138.8, 138.6 (dC-F, J = 4.1 Hz), 
138.3, 129.8 (dC-F, J = 7.7 Hz), 128.7, 128.7, 128.6, 128.5, 128.4, 128.4, 128.0, 128.0, 
127.9, 127.8, 127.6, 126.5, 126.5, 115.0 (dC-F, J = 20.8 Hz), 99.0, 79.0, 78.9, 76.8, 74.8, 
73.6, 73.4, 72.3, 69.0, 67.8, 63.6, 51.5, 37.0, 35.7, 35.6, 35.3, 34.1, 34.0, 32.8, 32.1, 31.8, 
31.0, 30.9 30.8, 30.1, 29.9, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 26.4, 25.9, 25.7, 25.5, 24.9, 
22.9, 14.3; HRMS (ESI) for C78H105FNO9 (M+ + H) m/z calcd: 1218.7773. Found: 
1218.7717. 
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(2S,3R)-1-(2,3,4,6-tetra-O-Benzyl--D-galactopyranosyl)-3-(O-benzyl)-2-(N-tert-
butoxycarbonylamino)octadecan-1,3-diol (46) 
Phenyl 2-O-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-3,4,6-tri-O-benzyl-1-thio--D-
galactopyranoside 17 (0.203 g, 0.321 mmol) and (2S,3R)-2-(N-tert-butoxycarbonyl) 
amino-3-(O-benzyl)-octadecan-1,3-diol 33 (0.105 g, 0.234 mmol) were azeotroped with 
toluene. Silver triflate (0.012 g, 0.047 mmol) was separately azeotroped with toluene. The 
donor and acceptor were dissolved in DCM (11.7 mL) at -40 °C under N2. Silver triflate 
and NIS (0.072 g, 0.321 mmol) were added and the reaction mixture was stirred at -20 
°C for 3 d. The reaction was quenched with Et3N (1 mL). The crude mixture was filtered 
through a celite pad and concentrated under reduced pressure. The crude mixture was 
purified via flash column chromatography on silica gel (petroleum ether/EtOAc 85:15), 
which resulted in 46 as a clear, colorless oil (0.083 g, 35%): []20D +194 (c 0.7, DCM); IR 
(neat) 2942, 2853, 1715, 1101 cm-1; 1H NMR (400 MHz, CDCl3)  7.39–7.23 (m, 25H), 
5.03 (d, J = 8.8 Hz, 1H), 4.93 (d, J = 11.4 Hz, 1H), 4.86 (d, J = 3.6 Hz, 1H), 4.82 (m, 1H), 
4.75 (m, 2H), 4.65 (d, J = 11.9 Hz, 1H), 4.50 (m, 3H), 4.39 (d, J = 12.0 Hz, 1H), 4.04 (dd, 
J = 9.9, 3.6 Hz, 1H), 3.94 (m, 2H), 3.91 (m, 2H), 3.80 (dd, J = 11.9, 4.8 Hz, 1H),  3.71 (dd, 
J – 10.5, 3.8 Hz, 1H), 3.58 (m, 1H), 3.50 (m, 2H), 1.43 (s, 9H), 1.26 (m, 28 H), 0.88 (t, J 
= 6.4 Hz, 3H); 13C NMR (100 MHz CDCl3)  138.8, 128.5, 128.4, 128.0, 128.0, 128.0, 
 79 
127.7, 127.7, 99.2, 79.1, 78.7, 77.4, 75.2, 74.9, 73.7, 73.5, 73.2, 73.0, 72.2, 70.8, 70.4, 
69.9, 69.2, 32.1, 30.8, 30.1, 29.9, 29.6, 28.6, 28.0, 26.7, 25.9, 22.9, 14.3; HRMS (ESI) for 
C64H88NO9 (M + H)+ m/z calcd: 1014.6461. Found:1014.6448. 
 
(2S,3R)-2-Amino-1-(2,3,4,6-tetra-O-benzyl--D-galactopyranosyl)-3-(O-benzyl)-N-
(11-(4-fluorophenyl)undecanoyl)octadecan-1,3-diol (47) 
(2S,3R)-1-(2,3,4,6-tetra-O-Benzyl--D-galactopyranosyl)-3-(O-benzyl)-2-(N-tert-
butoxycarbonylamino)octadecan-1,3-diol 46 (0.029 g, 0.029 mmol) was dissolved in DCM 
(0.2 mL) at rt. TFA (0.992 mmol, 0.70 mL) was added dropwise. After 30 min, the reaction 
was concentrated under reduced pressure. The crude material was dissolved in DCM (5 
mL), and washed with NaHCO3(aq) (5 mL). The organic phase was dried over MgSO4, 
concentrated in vacuo, and was used directly in the next step. 
The glycolipid (0.020 g, 0.02 mmol) and 27 (0.015 g, 0.026 mmol) were combined in 
pyridine (0.5 mL) and allowed to stir at rt overnight. The solution was concentrated under 
reduced pressure and the resulting crude material was purified via flash chromatography 
on silica gel (petroleum ether/EtOAc 85:15) to give 47 as a waxy solid (0.011 g, 35%): 
[]20D +24 (c 0.18, DCM); IR (neat) 2922, 2852, 1508, 1043, 695 cm-1; 1H NMR (400 MHz, 
CDCl3)  7.38–7.23 (m, 25H), 7.10 (m, 2H) 6.94 (m, 2H), 6.05 (d, J = 8.8 Hz, 1H), 4.92 
(d, J = 11.5 Hz, 1H), 4.82 (d, J = 3.2 Hz, 1H), 4.79 (m, 1H), 4.74 (t, J = 11.4 Hz, 2H), 4.64 
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(d, J = 11.8 Hz, 1H), 4.55 (t, J = 11.3 Hz, 2H), 4.46 (dd, J = 11.8, 9.8 Hz, 2H), 4.37 (d, J 
= 11.8 Hz, 1H), 4.16 (m, 1H), 4.02 (dd, J = 9.8, 3.1 Hz, 1H), 3.95 (dd, J = 11.0, 5.1 Hz, 
1H), 3.88 (m, 3H), 3.67 (dd, J = 11.0, 3.8 Hz, 1H), 3.56 (m, 1H), 3.51 (dd, J = 9.3, 6.6 Hz, 
1H), 3.38 (dd, J = 9.3, 5.8 Hz, 1H), 2.55 (t, J = 7.6 Hz, 2H), 1.98 (m, 2H), 1.54 (m, 6H), 
1.23 (m, 38H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz CDCl3)  173.1, 161.3 (dC-F, J 
= 241.3 Hz), 138.8 (dC-F, J = 2.4 Hz), 138.7, 138.7, 137.9, 129.8 (dC-F, J = 7.9 Hz), 128.6, 
128.5, 128.5, 128.1, 128.1, 127.9, 127.8, 127.7, 126.3, 115.8, 115.1 (dC-F, J = 20.9 Hz), 
99.8, 79.0, 78.4, 77.4, 75.1, 74.9, 73.7, 73.6, 73.2, 72.8, 72.4, 72.2, 70.2, 70.0, 69.6, 69.3, 
51.7, 36.9, 35.3, 32.1, 31.8, 30.9, 30.2, 29.9, 29.8, 29.7, 29.7, 29.6, 29.6, 29.4, 25.8, 
25.35 25.2, 22.9, 14.3; HRMS (ESI) for C76H103FNO8 (M + H)+ m/z calcd: 1176.7670. 
Found:1176.7661. 
 
(2S,3S,4R)-2-Amino-(N-tert-butoxycarbonyl)-octadecan-3,4-(O-dibenzoyl)-1,3,4-
triol (48b) 
 
(2S,3S,4R)-2-(N-tert-Butoxycarbonylamino)-3,4-(O-dibenzoyl)-1-(O-tert-butylphenyl- 
silyl)octadecan-1,3,4-triol (52) (0.700 g, 0.810 mmol) was dissolved in dry MeOH (7.4 mL) 
at 0 °C. TFA (14.7 mL) was added dropwise and the reaction stirred for 2 h. The solution 
was evaporated to dryness and co-evaporated with toluene 3 times. The residue was 
dissolved in dioxane (22 mL) and saturated NaHCO3 (aq) (22 mL). Na2CO3
 
(0.232 g, 2.187 
mmol) and Boc2O (0.495, 2.27 mmol) were added and stirred overnight. This solution was 
extracted with EtOAc (50 mL). The organic phased was washed brine (50 mL), dried with 
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MgSO4,
 
and concentrated under reduced pressure. The crude residue was purified via 
flash column chromatography on silica gel (Hexanes/EtOAc 80:20) to give 48b (0.203 g, 
40% over 2 steps) as a colorless oil.54 1H NMR (400MHz, CDCl3)  8.05 (d, J = 7.2 Hz, 
2H), 7.95 (d, J = 7.1 Hz, 2H), 7.63 (t, J = 7.5 Hz, 1H), 7.54 (m ,3H), 7.38 (t, J = 7.5 Hz, 
2H), 5.50 (d, J = 9.6 Hz, 1H), 5.40 (dd, J = 9.2 Hz, 2.4 Hz, 1H), 5.33 (d, J = 9.5Hz, 1H), 
4.05 (m, 1H), 3.64 (m, 2H), 2.60 (m, 1H), 1.99 (m, 2H), 1.48 (s, 9H), 1.27 (m, 24H), 0.88 
(t, J = 7.0 Hz, 3H).  
 
 
tert-Butyl [(2R,3S,4S)-1,3,4-trihydroxyoctadecan-2-yl)]carbamate (49) 
 
Phytosphingsine (20) (3.00 g, 9.45 mmol) was added to THF (95 mL). Et3N (3.8 mL) was 
added followed by Boc2O (2.47 g, 11.3 mmol). The reaction mixture was stirred at rt 
overnight and was concentrated under reduced pressure. The crude material of 49 was 
carried over to the next step:55 ‘H NMR (400 MHz, CDCl3)  5.30 (m, 1H), 3.92 (m, 1H), 
3.85 (m, 1H), 3.77 (m, 1H), 3.68 (m, 1H), 3.62 (m, 1H), 3.29 (d, J = 6.9 Hz, 1H), 2.98 (m, 
1H), 2.42 (d, J = 4.0 Hz, 1H), 1.52 (m, 2H), 1.45 (s, 9H), 1.29 (m, 24H), 0.88 (t, J = 6.9 
Hz, 3H). 
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 (2S,3S,4R)-1-(tert-Butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl) 
amino]octadecan-3,4-diol (51) 
tert-Butyl[(2R,3S,4S)-1,3,4-trihydroxyoctadecan-2-yl)]carbamate was dissolved in 1:1 
DCM/DMF (1:1 v/v, 20 mL). Et3N (1.8 mL), DMAP (0.090 g, 0.080 mmol), and TBDPSCl 
(11.7 mmol, 3.0 mL) were added at 0 C, and the solution was stirred at rt overnight. It 
was then diluted with EtOAc (50 mL), and the solution was washed with brine (5 x 40 mL). 
The organic phase was dried over MgSO4 and concentrated in vacuo. Purification of the 
crude product by flash column chromatography on silica gel (hexanes/EtOAc, 10:1) 
afforded (2S,3S,4R)-1-(tert-Butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]-
octadecan-3,4-diol (51) (4.75 g, 77% over 2 steps) as a colorless oil:56 1H NMR (CDCl3, 
400 MHz)  7.65 (m, 4H), 7.42 (m, 6H), 5.17 (d, J = 8.4 Hz, 1H), 3.98 (m, 1H), 3.82 (m, 
2H), 3.62 (m, 2H), 3.11 (d, J = 6.9 Hz, 1H), 2.62 (br s, 1H), 1.69 (m, 1H), 1.51 (m, 2H), 
1.41 (s, 9H), 1.25 (s, 23H), 1.06 (s, 9H), 0.87 (t, J = 6.6 Hz, 3H). 
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(2S,3S,4R)-1-(tert-Butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl) 
amino]octadecan-3,4-dibenzoate (52) 
(2S,3S,4R)-1-(tert-Butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl)amino]octadecan-
3,4-diol (51) (0.481 g, 0.733 mmol) was dissolved in pyridine (7.8 mL). DMAP (0.010 g, 
0.084 mmol) was added and the solution stirred at rt. BzCl (5.1 mmol, 0.60 mL) was 
added dropwise, and the solution was stirred overnight. The excess BzCl was slowly 
quenched with cold water, and the solution was then extracted with DCM (3 x 15 mL). 
The organic extracts were combined and dried (MgSO4). The solution was concentrated 
under reduced pressure, and the crude product was purified via flash column 
chromatography on silica gel (hexanes/EtOAc, 95:5) to yield (2S,3S,4R)-1-(tert-
butyldiphenylsilyloxy)-2-[N-(tert-butyloxycarbonyl) amino]octadecan-3,4-dibenzoate (52) 
as a colorless oil (0.531 g, 84% yield).54 1H NMR (CDCl3, 300 MHz)  7.96 (d, J = 8.0 Hz, 
4H), 7.59 (m, 3H), 7.51 (m, 4H), 7.41 (m, 4H), 7.31 (m, 3H), 7.13 (m, 2H), 5.69 (dd, J = 
9.6, 2.8 Hz, 1H), 5.49 (m, 1H), 5.06 (d, J = 10.0 Hz, 1H), 4.19 (m, 1H), 3.71 (m, 2H), 1.87 
(m, 2H), 1.48 (s, 9H), 1.23 (m. 24 H), 1.00 (s, 9H), 0.88 (t, J = 6.6 Hz, 3H). 
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(2S,3S,4R)-2-Amino-3,4-(di-O-benzoyl)-1-(2,3-di-O-benzyl-4,6-O-benzylidene--D-
galactopyranosyl)(N-tert-butoxycarbonyl)octadecan-1,3,4-triol (53) 
Benzyl-4,6-O-benzylidene-1-thio--D-galactopyranoside (42) (0.338 g, 0.624 mmol) and 
(2S,3S,4R)-2-amino-3,4-(di-O-benzoyl)(N-tert-butoxycarbonyl)octadecan-1,3,4-triol    
(48b) (0.261 g, 0.416 mmol) were azeotroped with toluene (3 x 5 mL) and left under 
vacuum overnight. Silver triflate (0.021 g, 0.083 mmol) was also azeotroped with toluene 
(1 mL) and left under vacuum overnight. Compounds 42 and 48b were then combined in 
DCM (8.9 mL) with activated molecular sieves and cooled to –20 C. Silver triflate and 
NIS (0.140 g, 0.624 mmol) were added and the reaction mixture stirred at –20 C for 3 d. 
Et3N (2 mL) was added, and the reaction mixture was filtered through celite. The celite 
pad was rinsed with DCM (3 x 10 mL). The crude mixture was concentrated under 
reduced pressure and purified via flash column chromatography on silica 
(hexanes/EtOAc, 5:1) to yield 53 as a light yellow oil (0.201 g, 45% yield). []22D +55.0 (c 
1.50, DCM);  IR (neat) 2924, 2853, 1716, 1261, 1097 cm-1; 1H NMR (400 MHz, CDCl3)  
8.07–7.95 (m, 5H), 7.59–7.29 (m, 17H), 7.18 (m, 3H), 5.61 (dd, J = 9.6, 3.8 Hz, 1H), 5.46 
(s, 1H), 5.40 (m, 2H), 4.87 (d, J = 3.4 Hz, 1H), 4.74–4.61 (m, 4H), 4.25 (m, 2H), 4.17 (d, 
J = 3.0 Hz, 1H), 4.03 (dd, J = 10.2, 3.4 Hz, 1H), 3.99 (m, 1H), 3.91 (dd, J = 10.2, 3.3 Hz, 
1H), 3.82 (dd, J = 10.8, 4.5 Hz, 1H), 3.75 (m, 2H), 1.87 (m, 2H), 1.47 (s, 9H), 1.27 (m, 
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24H), 0.89 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)   171.1, 165.2, 165.4, 155.5, 
138.9, 138.6, 137.9, 133.3, 133.0, 130.2, 130.1, 129.9, 129.8, 129.8, 129.7, 128.8, 128.6, 
128.4, 128.3, 128.2, 128.1, 128.0, 127.7, 127.6, 127.5, 126.3, 100.9, 100.2, 79.9, 75.9, 
75.7, 74.7, 73.9, 73.5, 73.1, 72.1, 69.5, 63.4, 60.4, 50.7, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 
28.7, 28.4, 25.6, 22.9, 14.3; HRMS (ESI) for C64H81NNaO12 (M + Na)+ m/z calcd: 
1078.5656. Found: 1078.5389. 
 
(2S,3S,4R)-2-Amino-3,4-(di-O-benzoyl)-1-(2,3,4-tri-O-benzyl--D-galactopyranosyl) 
octadecan-1,3,4-triol (54) 
(2S,3S,4R)-2-Amino-3,4-(di-O-benzoyl)-1-(2,3-di-O-benzyl-4,6-O-benzylidene--D-
galactopyranosyl)(N-tert-butoxycarbonyl)octadecan-1,3,4-triol (53) (0.090 g, 0.085 mmol) 
was stirred vigorously in DCM (0.8 mL). Borane tetrahydrofuran complex (0.425 mmol, 
0.4 mL) was added, and the solution was stirred at rt for 45 min. Scandium triflate (0.006 
g, 0.013 mmol) was added, and stirring was continued at rt until the starting material was 
consumed (monitored by TLC). The crude mixture was concentrated under reduced 
pressure, and the residue was purified via flash column chromatography on silica gel 
(hexanes/EtOAc 1:1) to yield (2S,3S,4R)-2-amino-3,4-(di-O-benzoyl)-1-(2,3,4-tri-O-
benzyl--D-galactopyranosyl) octadecan-1,3,4-triol (54) as a colorless oil (0.060 g, 73% 
yield). []22D –52.8 (c 1.20, DCM);  IR (neat) 3305 (br), 2923, 2853, 1720, 1263, 1050  
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cm-1; 1H NMR (400 MHz, CDCl3)  8.02 (d, J = 7.6 Hz, 2H), 7.96 (d, J = 7.7 Hz, 2H), 7.57 
(m, 2H), 7.45–7.20 (m, 19H), 5.58 (ddd, J = 8.9, 4.6, 4.6 Hz, 1H), 5.48 (dd, J = 5.9, 5.9 
Hz, 1H), 4.95 (d, J = 11.6 Hz, 1H), 4.84 (m, 1H), 4.75–4.69 (m, 2H), 4.62 (dd, J = 11.8, 
4.7 Hz, 2H), 4.03 (dd, J = 11.0, 4.2 Hz, 1H), 3.89 (m, 3H), 3.77 (dd, J = 6.0, 6.0, 1H), 3.70 
(dd, J = 11.3, 6.6 Hz, 1H), 3.51 (dd, J = 11.3, 5.0 Hz, 1H), 3.44 (m, 2H), 3.33 (m, 1H), 
1.85 (m, 4H), 1.27 (m, 25H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3)   166.3, 
165.8, 138.9, 138.7, 138.4, 133.4, 133.3, 130.1, 130.0, 129.9, 129.9, 129.8, 128.7, 128.6, 
128.6, 128.5, 128.5, 128.1, 128.0, 99.3, 79.2, 76.7, 75.2, 74.7, 73.7, 73.5, 71.4, 71.0, 
70.8, 64.2, 62.5, 52.2, 32.1, 29.8, 29.7, 29.6, 29.5, 28.6, 26.7, 25.5, 22.8, 14.3; HRMS 
(ESI) for C59H76FNNaO10 (M + Na)+ m/z calcd: 980.5288. Found: 980.5048. 
 
(2S,3S,4R)-2-Amino-3,4-(di-O-benzoyl)-1-(2,3,4-tri-O-benzyl--D-galactopyranosyl)-
N-(11-(4-fluorophenyl)undecanoyl)-octadecan-1,3,4-triol (55) 
(2S,3S,4R)-2-Amino-3,4-(di-O-benzoyl)-1-(2,3,4-tri-O-benzyl--D-galactopyranosyl)-
octadecan-1,3,4-triol (54) (0.181 g, 0.189 mmol) was dissolved in pyridine (3.8 mL). 4-
Nitrophenyl 11-(4-fluorophenyl)undecanoate 27 (0.219 g, 0.378 mmol) was added and 
the reaction stirred at rt overnight. The crude mixture was concentrated under reduced 
pressure and dissolved in DCM (10 mL). The organic phase was washed with 1M NaOH 
(3 x 15 mL) to removed excess PNP impurity and carried forward to the next step.  
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(2S,3S,4R)-2-Amino-N-(11-(4-fluorophenyl)undecanoyl)-1-(2,3,4-tri-O-benzyl--D-
galactopyranosyl)octadecan-1,3,4-triol (56) 
The crude material (2S,3S,4R)-2-amino-3,4-(di-O-benzoyl)-1-(2,3,4-tri-O-benzyl--D-
galactopyranosyl)-N-(11-(4-fluorophenyl)undecanoyl)octadecan-1,3,4-triol (55) (0.047 g, 
0.039 mmol) was dissolved in THF/MeOH (1:1 v/v. 3.8 mL). NaOMe (1M, 0.5 mL) was 
added dropwise and the reaction stirred at rt until starting material was completely 
consumed via TLC. The crude mixture was neutralized using DOWEX (C-211, H+, 16-50 
mesh) resin. The resin was filtered and the filtrate was concentrated under reduced 
pressure to yield (2S,3S,4R)-2-amino-1-(2,3,4-tri-O-benzyl--D-galactopyranosyl)-N-(11-
(4-fluorophenyl)undecanoyl)-octadecan-1,3,4-triol (56) as a yellow oil (0.036 g, 69% over 
2 steps). []21D +53 (c 0.36, DCM);  IR (neat) 3318 (br), 2922, 2853, 1222, 1046 cm-1; 1H 
NMR (400 MHz, CDCl3)  7.38–7.31 (m, 15H), 7.11 (m, 2H), 6.94 (m, 2H), 6.34 (m, 1H), 
4.94 (d, J = 11.6 Hz, 1H), 4.89 (m, 1H), 4.82 (d, J = 11.7 Hz, 1H), 4.76 (d, J = 11.7 Hz, 
1H), 4.69 (d, J = 11.6 Hz, 1H), 4.62 (d, J = 11.6 Hz, 1H), 4.26 (m, 1H), 4.06 (dd, J = 9.8 
Hz, 3.6 Hz, 1H), 3.87 (m, 2H), 3.82 (m, 2H), 3.67 (m, 4H), 3.45 (m, 4H), 2.56 (t, J = 7.5 
Hz, 3H), 2.14 (t, J = 7.5 Hz, 2H), 1.60 (m, 6H), 1.25 (m, 36H), 0.88 (t, J = 6.6 Hz, 3H); 13C 
NMR (100 MHz, CDCl3)   173.3, 161.3 (dC-F, J = 241.3 Hz), 138.6 (dC-F, J = 2.7 Hz), 
138.4, 138.2, 138.0, 129.8 (dC-F, J = 7.7 Hz), 128.7, 128.5, 128.3, 128.2, 128.0, 127.9, 
127.7, 115.0 (dC-F, J = 20.9 Hz), 99.2, 79.6, 76.4, 76.3, 74.7, 74.5, 74.4, 73.4, 73.3, 71.5, 
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70.8, 69.7, 62.3, 51.6, 49.6, 37.0, 35.3, 34.3, 33.6, 32.1, 31.8, 29.9, 29.7, 29.7, 29.6, 29.5, 
29.4, 29.3, 26.7, 26.1, 25.9, 25.1, 22.9, 14.3; HRMS (ESI) for C62H91FNNaO9 (M + Na)+ 
m/z calcd: 1034.6486. Found: 1034.6314. 
 
(2S,3S,4R)-2-Amino-1-(2,3,4-tri-O-benzyl-6-phenylacetoyl--D-galactopyranosyl)-
N-(11-(4-fluorophenyl)undecanoyl)-octadecan-1,3,4-triol (57a) 
(2S,3S,4R)-2-Amino-1-(2,3,4-tri-O-benzyl--D-galactopyranosyl)-N-(11-(4-fluorophenyl)-
undecanoyl)-octadecan-1,3,4-triol (56) (0.018 mg, 0.018 mmol) was dissolved in dry DCM 
(1.8 mL). DMAP (1 mg, 0.008 mmol) and phenylacetic acid (0.003 mg, 0.022 mmol) were 
added and the reaction stirred at rt for 5 min. DCC (0.004 mg, 0.019 mmol) was dissolved 
in dry DCM (0.5 mL) and added to the reaction flask, and the reaction stirred overnight. 
The crude mixture was concentrated under reduced pressure and purified via flash 
chromatography on silica gel (hexanes/EtOAc 70:30). (2S,3S,4R)-2-Amino-1-(2,3,4-tri-O-
benzyl-6-phenylacetoyl--D-galactopyranosyl)-N-(11-(4-fluorophenyl)undecanoyl)octa-
decan-1,3,4-triol (57a) was isolated as a white film (0.007 g, 20% yield).  []21D –56 (c 
0.14, DCM);  IR (neat) 3326 (br), 2925, 2853, 1626 cm-1; 1H NMR (400 MHz, CDCl3) 
 7.37–7.24 (m, 20H), 7.10 (m, 2H), 6.94 (m, 2H), 6.19 (d, J = 8.3 Hz, 1H), 4.86 (m, 2H), 
4.76 (d, J = 11.7 Hz, 1H), 4.72 (d, J = 11.7 Hz, 1H), 4.67 (d, J = 11.6 Hz, 1H), 4.45 (d, J 
= 11.4 Hz, 1H), 4.22 (m, 1H), 4.16 (m, 1H), 4.13 (d, J = 2.9 Hz, 1H), 4.09 (m, 2H), 4.03 
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(m, 1H), 3.79 (m, 2H), 3.74 (m, 2H), 3.57 (s, 2H), 3.46 (m, 4H), 2.56 (t, J = 7.6 Hz, 2H), 
2.14 (m, 2H), 1.93 (m, 4H), 1.70 (m, 4H), 1.25 (m, 28H),  0.86 (t, J = 13.8 Hz, 3H); 13C 
NMR (125 MHz, CDCl3)   173.2, 171.3, 162.2, 157.2, 138.6, 138.4, 138.3, 137.9, 129.8 
(dC-F, J = 7.0 Hz), 129.5, 128.7, 128.6, 128.6, 128.4, 128.3, 128.0, 127.7, 127.4, 115.1 
(dC-F, J = 22.9 Hz), 98.9, 79.4, 76.5, 76.0, 74.8, 74.4, 74.3, 73.1, 68.9, 63.8, 49.5, 45.7, 
41.5, 36.9, 35.3, 34.1, 33.6, 32.1, 31.8, 29.9, 29.7, 28.0, 27.5, 25.8, 25.1, 22.9, 14.3; 
HRMS (ESI) for C70H96FNNaO10 (M + Na)+ m/z calcd: 1152.6905. Found: 1152.6727. 
 
(2S,3S,4R)-2-Amino-1-(2,3,4-tri-O-benzyl-6-hydrocinnamoyl--D-galacto-
pyranosyl)-N-(11-(4-fluorophenyl)undecanoyl)octadecan-1,3,4-triol (57b) 
(2S,3S,4R)-2-Amino-1-(2,3,4-tri-O-benzyl--D-galactopyranosyl)-N-(11-(4-fluorophenyl) 
undecanoyl)-octadecan-1,3,4-triol (56) (0.018 mg, 0.018 mmol) was dissolved in dry DCM 
(1.8 mL). DMAP (0.001 mg, 0.008 mmol) and hydrocinnamic acid (0.003 mg, 0.022 mmol) 
were added and the reaction stirred at rt for 5 min. DCC (4 mg, 0.019 mmol) was dissolved 
in dry DCM (0.5 mL) and added to the reaction flask, and the reaction stirred overnight. 
The crude mixture was concentrated under reduced pressure and purified via flash 
chromatography on silica gel (hexanes/EtOAc 70:30). (2S,3S,4R)-2-Amino-1-(2,3,4-tri-O-
benzyl-6-hydrocinnamoyl--D-galacto-pyranosyl)-N-(11-(4-fluorophenyl)undecan-
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oyl)octadecan-1,3,4-triol (57b) was isolated as a white film (0.008 mg, 20% yield).  []21D 
–31 (c 0.18, DCM); IR (neat) 3348 (br), 2925, 2853, 1556, 1094 cm-1; 1H NMR (400 MHz, 
CDCl3)  7.38–7.25 (m, 15H), 7.10 (m, 2H), 6.95 (m, 2H), 6.21 (d, J = 8.3 Hz, 1H), 4.92 
(d, J = 11.4 Hz, 1H), 4.87 (m, 2H), 4.80 (d, J = 11.8 Hz, 1H), 4.75 (d, J = 11.6 Hz, 1H), 
4.68 (d, J = 11.6 Hz, 1H), 4.54 (m, 1H), 4.24 (m, 1H), 4.12 (m, 1H), 4.06 (m, 1H), 4.04 
(m, 2H), 3.80 (m, 4H), 3.55 (d, J = 9.0 Hz, 1H), 3.48 (m, 4H), 2.89 (t, J = 7.8 Hz, 2H), 2.56 
(m, 4H), 2.14 (m, 3H), 1.93 (m, 2H), 1.71 (m, 2H), 1.25 (m, 36H), 0.88 (t, J = 6.4 Hz, 3H); 
13C NMR (100 MHz, CDCl3)   173.0, 172.7, 161.3 (dC-F, J = 239.5 Hz), 156.9, 140.6, 
138.6 (dC-F, J = 2.7 Hz), 138.4, 138.2, 137.9, 129.8 (dC-F, J = 7.8 Hz), 128.7, 128.6, 128.5, 
128.5, 128.2, 128.1, 128.0, 127.6, 126.5, 115.1 (dC-F, J = 20.9 Hz), 98.9, 79.5, 77.4, 76.4, 
76.1, 74.8, 74.4, 74.3, 73.5, 73.3, 70.8, 69.7, 69.1, 63.5, 49.4, 36.9, 35.7, 35.3, 34.1, 33.6, 
32.1, 31.8, 30.9, 30.4, 29.9, 29.7, 29.7, 29.6, 29.5, 29.4, 27.9, 27.5, 26.7, 26.1, 25.9, 25.8, 
25.1, 22.9, 21.7, 14.3; HRMS (ESI) for C71H98FNNaO10 (M + Na)+ m/z calcd: 1166.7061. 
Found: 1166.6683. 
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CHAPTER 2 
Novel Reactions with Ketiminium Salts 
 
2.1 INTRODUCTION 
2.1.1 N-Sulfinyl Imines 
 
Chiral amines are prevalent in many of the top-selling small, organic molecule drugs on 
the market. They can be found in blockbuster drugs such as Harvoni (Gilead), Januvia 
(Merck), and Cialis (Lilly) (Fig. 2.1). Therefore, a significant challenge was presented in 
developing an efficient asymmetric synthesis of such amines without the use of expensive 
chiral and precious metal 
catalysts. The development of 
chiral N-sulfinyl imines seemed to 
solve this problem (Fig. 2.2). The 
work was pioneered by Franklin 
Davis who reported on the 
synthesis and utility of p-
toluenesulfinyl imines.1 This chiral 
auxiliary sulfinyl group is an ideal 
substituent because it activates the imine for nucleophilic addition while acting as a 
directing group for good to excellent facial selectivity. The sulfinyl group can also be easily 
removed after addition leaving a primary amine for further functionalization.  
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Figure 2.1. Blockbuster drugs containing chiral amines
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2.1.1.1 History of N-Sulfinyl Imine Development 
The first racemic N-sulfinyl imines were reported by Davis, Friedman, and Kluger in 1974. 
This chemical species was achieved by oxidizing N-sulfenyl imines with mCPBA (Fig. 
2.3a). Cinquini and Cozzi later reported the first enantio-pure synthesis of p-tolyl-N-
sulfinyl imine via a Grignard reaction with a nitrile followed by reaction with a chiral 
sulfinate ester (Fig. 2.3b).2 A major milestone in the field of N-sulfinyl imine chemistry 
came in 1997 when Ellman and co workers reported the first asymmetric synthesis of tert-
butane sulfinamide (TBSA).3 Soon after, the Ellman group published a new method of 
enantioselectively generating N-sulfinyl aldimines and ketimines through a Lewis acid-
mediated condensation reaction between a ketone or aldehyde and TBSA (Fig. 2.3c).4 
The sulfinamide reagents are often referred to as the chemist who pioneered the work 
with them: p-toluene sulfinamide will be referred to as the Davis sulfinamide, and TBSA, 
the Ellman sulfinamide. Therefore, products of reactions with the sulfinamides will be 
referred to as Davis and Ellman, respectively.  
H/R
N
Ph
S
O
Nu-
H/R
HN
Ph
S
O
Nu
HCl
H/R
NH2
Ph
Nu
.HCl
N-Sulfinyl Imine
Figure 2.2. Chiral amine synthesis through N-sulfinyl imines
MeOH, H2O
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Currently, the Ti(OEt)4 method is the most widely used for making both the Ellman and 
Davis sulfinyl-imine. One major drawback of the Ellman method is the use of 
stoichiometric amounts of Ti(OEt)4. Upon aqueous work up, the excess titanium reagent 
is converted to insoluble titanium oxide (TiO2). Filtration of TiO2 can be extremely slow 
and cumbersome specifically on the large scale required for industrial-sized drug 
synthesis. Recently, Reeves and co workers at Boehringer Ingelheim (BI) developed a 
new method of generating N-sulfinyl aldimines using borate reagents (Fig. 2.4).5,6 This 
method is useful for process scale synthesis of 
aldimines. Not only does it bypass the transition 
metal requirement, the reaction is run neat, and 
both the borate and sulfinamide reagent are 
R H
N
S
O
R H
O
(R)-TBSA
B(OiPr)3 or 
B(OCF2CF3)3
60 oC
Figure 2.4. Reeves method for N-
sulfinyl aldimine synthesis
a. Davis, 1974
b. Cinquini, 1977
R
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+
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Davis sulfinyl-imine
c. Ellman, 1999
H/R
O H2N
S
O
Ti(OEt)4
or CuSO4
H/R
N
S
O
Ellman sulfinyl-imine
Figure 2.3. Methods of generating N-sulfinyl imines. a. first synthesis 
reported by Davis. b. first asymmetric synthesis reported by Cinquini. c. first 
asymmetric synthesis using TBSA reported by Ellman
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removed upon workup resulting in minimal purification. The only drawback with this 
process is that it is limited to N-sulfinyl aldimines; N-sulfinyl ketimines still require Ti(OEt)4. 
Interestingly, Reeves could employ the same borate reagents and condensation 
conditions to generate N-phosphinyl aldimines and N-tosyl aldimines. Once again, these 
reactions did not tolerate ketones. Therefore, the significant challenge of overcoming the 
titanium requirement for ketone condensation still persists.  
 
2.1.2 N-Phosphinyl Imines 
N-Phosphinyl imines are another set of synthetically useful imines. These compounds are 
of interest because they provide another method of generating chiral amines. These 
phosphinyl species are easy to use- because they are highly crystalline which makes 
purification simple. The phosphinyl group is similar to the sulfinyl in that it is also easily 
removed by forming the HCl salt while maintaining stereochemistry. The synthesis of 
these compounds however, is not trivial. The first process of generating N-phosphinyl 
ketimines was reported by Krzyznowska and Stec in 1978.7 It begins with a condensation 
between a ketone and hydroxylamine to form an oxime.  Upon treatment with 
chlorodiphenylphosphine, an unstable O-phosphinyl oxime forms which undergoes a 
rearrangement to give the desired N-phosphinyl ketimine (Fig. 2.5a). Because oximes are 
high energy, and the reactive intermediate is not especially stable, this reaction process 
is not particularly popular in industrial settings. Following the Ellman method, N-
phosphinyl ketimines can also be generated using Ti(OEt)4 (Fig. 2.5b).8 Like the sulfinyl 
imines, one must overcome the necessity of a titanium reagent to produce N-phosphinyl  
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ketimines efficiently on large scales. One method for generating N-phosphinyl aldimines 
is a two-step process where condensation between an aldehyde and the phosphinamide 
occurs first with the addition of a tosyl group. The tosyl group is removed under basic 
conditions to establish the N-phosphinyl imine (Fig. 2.5c).9 The Reeves borate method 
overcomes the burden of the two step synthesis but is limited to aldehyde substrates (Fig 
2.5d). Unlike the sulfinyl imines, the phosphinyl imines are not chiral. The asymmetry is 
induced through nucleophilic addition in the presence of a chiral catalyst, usually with a 
PHOS-type ligand (Fig. 2.5e).10  
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Figure 2.5. Reactions involving N-phosphinyl imines. a-b. Methods for 
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2.1.3 N-Toluenesulfonyl Imines 
N-Toluenesulfonyl (tosyl) imines are synthetically useful intermediates that have been 
gaining more popularity.11 Unlike N-acyl imines which have a tendency to polymerize, N-
tosyl imines are much more stable and can be isolated and stored quite easily. The 
electron-withdrawing sulfonyl group activates the imines for nucleophilic addition similar 
to N-acyl imines. The Davis group has also pioneered additional reactions with N-tosyl 
imines by converting them to 2-sulfonyloxaziridines using peroxy acids in basic media. 
These species are useful neutral oxidants that can be used in a wide array of oxidation 
reactions.12 Therefore, N-tosyl imines are an essential intermediate for these reactions. 
The first synthesis of N-tosyl imines was reported in 1955 by Lichtenberger and co 
workers.13 The one-step process involves a Lewis acid-mediated condensation between 
an aromatic aldehyde and p-toluene sulfonamide (Fig. 2.6a). This process is limited to 
aromatic aldehydes and therefore is not practical for many substrates. Decades later, 
Jennings and Lovely reported a titanium-mediated method of generating N-tosyl imines 
that is limited to aromatic and aliphatic aldehydes (Fig.  2.6b).14 Although they attempted 
such a reaction on ketones, they observed no imine product and instead isolated the aldol 
adduct. Another method of generating N-tosyl imines utilizes the Ellman protocol for N-
sulfinyl imines using Ti(OEt)4 and then oxidizing the sulfinyl group to a sulfone using m-
CPBA (Fig. 2.6c).15 Although this protocol is much more useful as it applies to aldehydes 
and ketones, it hasn’t overcome the burden of removing titanium oxide in work up. 
Another proposed method involves reacting an oxime with p-toluenesulfinyl chloride. 
Similar to the reaction in Figure 2.5a, the reactive intermediate then undergoes a 
rearrangement to produce the N-tosyl imine (Fig. 2.6d).16 As with the N-phosphinyl 
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imines, these reactions are not preferred in large-scale reactors. As mentioned, the 
Reeves borate method can also generate N-tosyl imines but is limited to aldehyde 
substrates (Fig. 2.6e). Although there is a wealth of options for generating N-tosyl imines, 
each method is problematic in its own way.  
 
2.1.4 N-Carbamoyl Imines 
N-Carbamoyl imines (CBz-, Boc-protected imines) are another set of synthetically useful 
imine derivatives.17 Like the previously mentioned substituted imines, N-carbamoyl 
imines are activated for nucleophilic addition, and the carbamoyl protecting group can 
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easily be cleaved after addition. Cleavage of the carbamoyl group is arguably easier than 
the aforementioned imines in that the cation stabilization is stronger due to the greater 
availability of the nitrogen lone pair in the carbamate. Because they can be so reactive, 
one drawback of these compounds is that they are not stable for long-term storage and 
tend to be hygroscopic. N-carbamoyl imine synthesis is not trivial either. The first 
synthesis by Stravrovskaya in 1970 involved a reaction between diethylacetals and 
methyl carbamate (Fig. 2.7a).18 This method results in a mixture of the desired product 
and byproducts and was later improved upon by using silyl imines as the starting 
material.19 The synthesis, however, focused on methyl carbamates which are generally 
not used due to difficulties in later de-protection (Fig. 2.7b). This synthetic limitation was 
overcome by Collet and co workers in 1993 with the first reported synthesis of Boc-
protected imines (Fig. 2.7c).20 Although it was an impressive feat, the reaction is very low 
yielding. Today, the most popular method of generating N-carbamoyl imines is similar to 
an old method of generating N-phosphinyl imines (see Fig. 2.5b). Aromatic aldehydes 
react with benzenesulfinate and tert-butylcarbamate to form a highly stable intermediate 
N-(tertbutoxycarbonyl)--phenylsulfonylbenzylamine. In the presence of heat and base, 
the benzenesulfinate is eliminated to form the N-carbamoyl aldimine (Fig. 2.7d).21 
Although this method is the most promising in terms of yield and scale up, this two-step 
synthesis is inefficient (stoichiometric amounts of benzenesulfinate required) and is 
limited to aldehydes.  
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2.1.5 Goal: Develop a Process-Friendly Method of Generating 
Substituted Ketimines via Transimination 
2.1.5.1 Parameters for Process Chemistry 
Many of the disadvantages of the reactions mentioned involve low yield, scalability, and 
atom economy. In the timeline of drug development, an active pharmaceutical ingredient 
(API) is developed in a medicinal chemistry lab. The next step is to test the compound in 
toxicology studies, develop a viable formulation for administering the API, and 
subsequently testing the bioavailability, metabolism, safety and efficacy of the API in 
humans in clinical trials. The process chemistry lab takes over for large-scale synthesis 
of the API to support all of these activities (Fig. 2.8).22 Typically, medicinal chemistry 
synthetic routes cannot be scaled up in the process lab because the goal of medicinal 
OEt
R
OEt
a. Starvrovskaya, 1970
MeO NH2
O
+ H
+
R N
H
OEt
OMe
O
150-200 oC
R N OMe
O
+ byproducts
Ph
NTMS
Cl
O
OMe
Ph
N OMe
O
50-80%
b. Kupfer, 1984
Ph
NTMS
Ph
NBoc
<20%
c. Collet, 1993
Boc2O
d. Kanazawa, 1994
Ph
O
H
+ +
SO2Na
H2N OtBu
O
Ph SO2Ph
HN OtBu
O
K2CO3
THF, reflux Ph
NBoc
H
Figure 2.7. Various methods of accessing N-carbamoyl imines
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chemists is to make the API quickly on a small scale. A process chemist’s goal is to make 
the API as efficiently as possible on a large scale. Although speed remains a priority 
throughout the pharmaceutical process, safety, quality control, and economics are also 
important parameters that must be considered.  
 
Material cost is obviously a major factor in chemical development. Cheap starting 
materials such as commodity chemicals are ideal. Precious metal catalysts such as 
palladium reagents are avoided not just for cost considerations, but also safety 
regulations. When palladium is used in a reaction, proper precautions must be taken to 
ensure that no palladium contaminate persists in the product. Palladium removal methods 
have been developed to counter this issue, which unfortunately adds another step to the 
reaction sequence.23,24 Reaction time and temperature can also be costly factors. If a 
reaction must run overnight at 100 C, a large reactor will require large amounts of energy 
to maintain the high temperature for the duration of the reaction.  
Another parameter to consider is atom economy and waste generation. Atom economy 
is a measure of the percent efficiency where the molecular mass of the desired product 
Figure 2.8. Typical route of drug development focusing on process development. LO: lead optimization, PAI: pre-
approval inspection
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is divided by the molecular mass of all of the reactants.25 First introduced by Barry Trost 
in 1995, atom economy is considered a metric for how “green” a process is. Therefore, 
when considering the reaction sequence in Figure 2.7d, which is the most commonly used 
method of Boc-imine formation, the atom economy is 54% due to the addition then 
subsequent elimination of benzenesulfinate which doesn’t contribute to the mass of the 
final product. It also results in a stoichiometric amount of waste generated, which must 
be separated from the product and treated. One strategy to reduce waste is to run the 
reaction as concentrated as possible. Therefore, there is less solvent waste to handle. 
For example, the reaction in Figure 2.6e has an atom economy of 95%. It is also 
considered very green because the reaction is run neat, where no solvent is required, 
minimizing waste. Many little considerations can add up to an efficient drug campaign in 
process development. 
2.1.5.2 Literature Precedent for Transimination 
 In 1982, Polt and O’Donnell reported the first application of transimination via ketiminium 
salts (Fig. 2.9).26 The typical condensation between ketone and amine was not practical 
in this reaction due to concerns of epimerization. The reaction was, on average, very high 
yielding. It occurred at ambient temperature and required neither acid, base, nor any other 
additive. Although this method was reported for ketiminium salts with alkyl amines, it was 
worth exploring whether the reaction could occur with ketiminium salts and sulfinamides. 
If successful, this method could 
bypass the titanium requirement 
in the Ellman method of 
generating N-sulfinyl ketimines. 
Ph Ph
NH2Cl
H2N CO2Me
R
+
Ph Ph
N CO2Me
R
 avg. 90%
Figure 2.9. First transimination reported in 1982
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Furthermore, if the synthesis of N-sulfinyl ketimines via transimination succeeded, it 
raises the question: could the same method be used for N-tosyl, -phosphinyl, and –
carbamoyl imines? Although the electronics of an alkyl amine and sulfinamide are vastly 
different, it was appealing to investigate if transimination could occur on different 
substrates. 
 
2.2 RESULTS AND DISCUSSION 
2.2.1 Research Objectives 
The goals of this study were to  
1. Generate a library of ketiminium salts 
2. Optimize the synthesis of N-sulfinyl ketimines via transimination with Ellman- and 
Davis-type sulfinamides 
3. Use optimized reaction conditions to generate N-tosyl, -phosphinyl, and  
–carbamoyl ketimines 
 
2.2.2 Synthesis of Ketiminium Library 
2.2.2.1 Retrosynthetic Strategy  
The retrosynthesis of N-sulfinyl ketimines (1) is straightforward (Fig. 2.10). As mentioned, 
the plan was to access 1 via transimination with a ketiminium salt 2 and a commercially 
available sulfinamide. Following a known procedure, an iminium salt can be achieved via 
addition into a nitrile using an organolithium reagent followed by acidification.27  
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2.2.2.2 Ketiminium Library  
The synthesis of the HCl ketiminium salts followed the same protocol, changing the nitrile 
and organo-lithium reagent, with quantitative yields for the most part (Fig. 2.11).27 
Phenyllithium was added to the corresponding nitrile at -78 C for 2a-j. n-Butyllithium was 
added to benzonitrile for 2k, and methyllithium was used for 2l-n. The compound library 
contained benzophenone imine-derived ketimines to observe the different effects due to 
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Figure 2.11 Generation of a ketiminium library
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Figure 2.10. Retrosynthetic strategy for N-sulfinyl ketimines 
via transimination
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substitution on one phenyl group. Some parameters considered were the position (ortho 
versus para, or both ortho and para), the size (sterically bulky versus small), and the 
electronics (electron withdrawing versus donating) of the substituent. Another subset of 
ketiminium salts looked at the effect of aromatic versus alkyl substituents. The library 
contains salts that have one aromatic and one alkyl group on the imine (2h-m) and one 
doubly alkyl ketiminium salt (2n). The alkyl substituents were chosen specifically to 
monitor if the reaction works better with small alkyl groups versus sterically bulky 
substituents. 
It was expected that the benzophenone-type ketimines and ketimines with smaller 
substituents would undergo transimination more easily. The ketiminium salt 2h was 
chosen as the first substrate for optimization. Because it contains t-butyl, the reaction 
might be hindered due to steric effects. Therefore, if the reaction could succeed with a 
less active substrate, the other ketiminium salts should react easily under the optimized 
conditions.  
 
2.2.3 Solvent Screen 
Because transimination occurs by stirring the iminium salt and sulfinamide together with 
no additives or catalysts, the solvent and temperature play an important role in the 
reaction. Therefore, the optimal solvent had to be chosen (Table 2.1). Each reaction 
was run on a 0.5 g scale with 1.2 eq. of (S)-TBSA with the reaction conversion 
monitored via high performance liquid chromatography (HPLC) every hour until the 
conversion stalled. The solvents chosen were polar aprotic, because protic solvents 
could solvolyze or hydrolyze the starting material salt (Entry 8). At room temperature, 
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the reactions proceeded very slowly, with 
less than 50% conversion for all solvents. 
Dichloromethane (DCM) and ethyl acetate 
(EtOAc) reaction conversions stalled at 
45% and 35%, respectively (Entries 6 and 
7). The reactions in N-methyl-2-pyrrolidone 
(DMP), 1,3-Dimethyl-3,4,5,6-tetrahydro-2-
pyrimidinone (DMPU), and acetonitrile 
(MeCN) all produced a byproduct 
observed via HPLC that increased as the 
reaction continued. Therefore, dimethyl 
sulfoxide (DMSO) and dimethylformamide 
(DMF) were chosen as the best solvents. DMF was ultimately selected due to the ease 
of removal in workup. Even upon aqueous workup, DMSO was still present in the crude 
material (via 1H NMR). Because the traditional Ellman method of generating N-sulfinyl 
ketimines with Ti(OEt)4 usually requires heat, the reaction in DMF was also heated 
(Entry 1). Upon heating the reaction mixture to 60 C then 80 C, the reaction 
conversion increased dramatically with 80 C being the optimal temperature. Because 
process methods seek to reduce as much waste as possible, the ideal concentration of 
the reaction was also investigated under the described conditions. It was anticipated 
that more concentrated reactions would work better because the more dilute the 
reaction, the less the reactants can interact with each other. This hypothesis was 
confirmed when it was found that five volumes of DMF produced the best reaction 
Table 2.1 Solvent screen for transimination
2h
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conversions. This means that if the reaction is run on a 0.5 g scale, 2.5 mL of DMF is 
used. Therefore, the reaction works best in five volumes DMF at 80 C, with 1.2 eq. of 
sulfinamide. A strange observation was noted however, when the reaction was allowed 
to stir overnight, the conversion would dramatically decrease. It seemed as though 
something in the reaction was causing the desired product to decompose over time.  
2.2.4 Ammonium Salt Assay 
Due to the simplicity of the reaction, there aren’t many components in the system that can 
destroy the desired product. When considering the mechanism, the only chemical present 
in the reaction other than the two starting materials and product, is ammonium chloride 
which is displaced in order to form the product (Scheme 2.1a, chloride ion not shown for 
clarity). Perhaps, the last step in the mechanism is reversible and ammonium chloride 
can add back into the desired product. If this were the case, an equilibrium between 
starting material and product would be established (Scheme 2.1b). In the worst-case 
scenario, the chloride ion from the ammonium chloride byproduct can add into the sulfinyl 
Ph tBu
NH2Cl
H2N
S
O
Ph tBu
N HN
S
O
H
H H
Ph tBu
H3N
HN
S
O
Ph
HN
tBu
S
ONH3
Ph
N
tBu
S
O
NH4Cl
Scheme 2.1 Proposed mechanism of transimination with TBSA
a.
b.
Ph
N
tBu
S
O NH3H
Ph
HN
tBu
S
O
NH3
Ph tBu
H3N
HN
S
O
Ph tBu
NH2Cl
c.
Ph
N
tBu
S
O NH3H
Ph
N
tBu
S
OH Cl-
Ph
N
tBu
S
OH
Cl
Ph tBu
NH
+ (S)-TBSA
+ Cl
S
O
 112 
group, breaking the N-S bond in the product. If this were to happen, the free base imine 
and sulfinyl chloride would form. 
In order to test whether the ammonium chloride 
is destroying the product, a test reaction was 
performed where ammonium chloride was 
added to a Davis-type N-sulfinyl ketimine that 
was prepared in lab via the Ellman method 
(Entry 1, Table 2.2). Because the HPLC column 
is slightly acidic, the free base imine and 
hydrolyzed ketone were observed and 
measured to indicate loss of starting material. After stirring overnight at room temperature, 
over half of the starting material was destroyed. After much consideration on how to 
actively remove ammonium chloride from the reaction, it was decided that instead of 
attempting to remove the salt byproduct, other ammonium salts should be investigated 
for how easily they destroy N-sulfinyl imine. Chloride was the worst perpetrator. This trend 
was thought to be due to either the acidity of the corresponding acid: HCl (pKa -7), or to 
the nucleophilicity of the chloride anion. Other ammonium salts explored were milder and 
had less nucleophilic counterions. Although the results of ammonium tetrafluoroborate 
were the most promising (Entry 5) had the most promising results, the other ammonium 
salts also had a significantly reduced effect on the N-sulfinyl ketimine than ammonium 
chloride and weren’t ruled out.  
  
Ph Ph
N
S
O
NH4X
DMF, rt, 18h Ph Ph
NH
Ph Ph
O
+
Entry X % starting material
1
2
3
4
5
Cl
OAc
PO4H2
PhCO2
BF4
40
88
89
92
>97
Table 2.2 Ammonium salt assay
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2.2.5 Counterion Screen 
Once it was determined that most ammonium salts were less reactive towards N-sulfinyl 
ketimines than ammonium chloride, a counterion screen was performed. Eight 
benzophenone ketiminium salts were generated using the method in Table 2.1. The acids 
chosen were based on what was available in the lab. The ketiminium salts then underwent 
Ph Ph
N
S
OPh Ph
NH2X Davis sulfinamide
Entry X
1
2
3
4
5
Salicylic Acid
Fluoroboric Acid
Benzenesulfonic Acid
Oxalic Acid
Phosphoric Acid
Salt Comments
Benzoic Acid
Picolinic Acid
Mandelic Acid
6
7
8
Ph
NH2
Ph
OH
CO2
Ph
NH2BF4
Ph
Ph
NH2PhSO3
Ph
Ph
NH2CO2HCO2
Ph
Ph
NH2PO4
Ph
Ph
NH2PhCO2
Ph
Ph
NH2
PhN
CO2
Ph
NH2
Ph
OH
CO2
35% conv.
95% conv.
85% conv.
DMF
overnight
low solubility in DMF
salt too hygroscopic
salt did not crystallize
salt did not crystallize
low conv. 
significant byproducts
Table 2.3 Counterion Screen
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transimination with Davis sulfinamide. p-Toluene sulfinamide was chosen not only to stay 
consistent with the ammonium salt assay, but also because Davis-type N-sulfinyl ketimine 
formation occurs much faster than Ellman-type and doesn’t require heating so the 
reactions could be run and monitored at ambient temperature. The results of the 
counterion screen are summarized in Table 2.3. Some salts did not crystallize making 
isolation of the iminium salt impossible (Entries 6 and 7). As a result, the reaction could 
not be performed on those substrates. The phosphoric acid iminium salt was extremely 
hygroscopic and quickly decomposed due to water hydrolysis (Entry 5). Due to the high 
reactivity with water, this salt was not a viable choice. Of the eight salts tested, the 
benzenesulfonic acid salt and tetrafluoroboric acid salt performed best (Entries 2 and 3). 
This result was not surprising considering how well ammonium tetrafluoroborate did in 
the ammonium salt assay (see Table 2.2). Although benzensulfonic acid performed well 
in the screen, tetrafluoroboric acid was chosen for future study based on its consistently 
good results in the assays and the generally high crystallinity of the iminium salts with this 
counterion.  
 
2.2.6 Davis Sulfinamide Screen 
While the new library of HBF4 ketiminium salts was being assembled, formation of the  
Davis-type N-sulfinyl ketimines via HCl ketiminium salts was investigated. Because these 
reactions occur rapidly at room temperature, it was thought that perhaps the ammonium 
chloride would have neither the time nor energy required to react with the product. The 
reactions were worked up after only one hour (versus overnight for reactions with Ellman 
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sulfinamide). For this substrate scope, only the 
benzophenone imine-derived salts were 
examined (Fig. 2.12). After one hour, the 
reaction seemed to be proceeding rapidly based 
on the percent conversion monitored by HPLC. 
One interesting observation was made with the 
CF3-substituted benzophenone imine substrate. 
The reaction conversion was only 50% after one 
hour. Because the trifluoromethyl group is highly 
electron withdrawing, one would think the imine 
carbon would be activated for nucleophilic 
addition, and the reaction would occur easily. 
The question remained: why did the most activated iminium salt have the lowest 
conversion? When the reaction was run a second time and monitored every ten minutes, 
it was found that the reaction occurred so rapidly that after an hour, ammonium chloride 
was already destroying the product at room temperature. Therefore, the most activated 
substrates cannot avoid the ammonium chloride addition when the hydrochloric acid salt 
is used. For the rest of the substrates, the reactions were stopped after one hour, worked 
up, and purified. Despite the overall good conversions, the isolated yields were quite low: 
ranging from 10-20%. Once the tetrafluoroboric acid ketiminium salt library was complete 
however, attempting transimination reactions with the hydrochloric acid salts were 
abandoned. The focus turned instead to a substrate scope with the new starting materials 
(Fig. 2.13).  
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Figure 2.12 Transimination with Davis 
sulfinamide
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2.2.7  Water Effects in Transimination 
With the new ketiminium salts in hand, transiminations with both the Ellman and Davis 
sulfinamide were performed. As described earlier, reactions with tert-butanesulfinamide 
were run at 80 C and reactions with p-toluenesulfinamide ran at room temperature. Once 
again, percent conversions were high (observed via HPLC) yet isolated yields were low. 
The question remained: why don’t the reaction conversions correlate to the isolated 
yields? One consideration is the work up. Because the reaction runs in DMF, the first 
work up involved diluting the reaction in EtOAc, and quenching it with aqueous 
ammonium chloride. Once the ammonium chloride problem was discovered, the work up 
switched to quenching with deionized water (dI water). If the reaction is not complete 
before work up, the remaining starting material hydrolyzes to the corresponding ketone 
in the aqueous work up. Therefore, the next factor to investigate was whether the product 
can also be hydrolyzed in the work up, which would explain inconsistency in reaction 
conversion and yield. Once again, the Davis-type benzophenone N-sulfinyl ketimine was 
used as a sample substrate. The product was dissolved in DMF at room temperature, 
Ph
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NH2BF4
Ph
NH2BF4OMe
Ph Ph
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Figure 2.13. Tetrafluoroboric acid ketiminium 
salt library
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stirred for 30 min, then monitored via HPLC (Table 2.4). When using reagent grade DMF 
that is marketed as anhydrous, 6% hydrolysis of product was observed after 30 min (Entry 
1). A sample of the DMF was run through Karl Fischer titration to determine the water 
content.28 Although the DMF purchased was supposed to be anhydrous, it contained 500 
ppm of water. That trace amount of 
water was able to hydrolyze 6% of the 
desired product in only 30 min. If a 
reaction is allowed to run for multiple 
hours, both the starting material and 
product will be hydrolyzed due to 
solvent’s water content. Worse still, 
when DMF was doped with 5% water, a quarter of the product hydrolyzes in 30 min (Entry 
2). Not surprisingly, aqueous ammonium chloride was the worst offender destroying 
nearly 40% of the product in 30 min (Entry 3). Therefore, even when the work up was 
switched to dI water with the first round of substrates (HCl iminium salts), the product was 
essentially being washed with aqueous ammonium chloride anyway. These results would 
explain why the test reactions in Figure 2.12 failed.  
  
Ph Ph
N
S
O
conditions
DMF, rt, 30 min Ph Ph
O
+
NH2
S
O
Entry Conditions % Hydrolysis
1
2
3
“anhydrous” DMF
500 ppm H2O
6
5% H2O in DMF 26
395% NH4Cl(aq) in DMF
Table 2.4 Product hydrolysis rates in various conditions
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2.2.8 Optimal Conditions for Transimination and Substrate Scope 
It was established that ammonium chloride and water are the major factors causing the 
transiminations to fail. Therefore, the optimal reaction conditions were implemented. First, 
as mentioned earlier, the iminium salts were switched from the hydrochloric acid salts to 
the tetrafluoroboric acid salts to prevent any product destruction due to byproduct 
reactions. The reaction conditions had to also be truly anhydrous. Therefore, 
transiminations were attempted with both the Ellman and Davis type sulfinamide under 
the optimal conditions. Each reaction was run on a 1.0 g scale in 5.0 mL DMF. The stock 
DMF was dried with activated molecular sieves, and the water content was measured via 
Karl Fischer titration. The new DMF water content was 13 ppm, significantly less than 
what was used previously. Crushed activated molecular sieves were also added to each 
reaction prior to sulfinamide addition. This protocol was performed to try to eliminate any 
water that might have been absorbed by the ketiminium salts. As before, reactions with 
Davis sulfinamide were run at room temperature with 1.2 equivalents of the sulfinamide. 
Because the Ellman sulfinamide reactions required much more heat to turnover, it was 
found that starting with 2 equivalents of the sulfinamide helped reaction rates, and adding 
more equivalents over time allowed the reaction to reach higher percent conversions. 
This trend was thought to be due to the Ellman sulfinamide degrading over time at such 
a high temperature. Once the reaction was complete or the highest reaction conversion 
was observed, the reaction was diluted with EtOAc as before, and quickly washed with 
aqueous sodium bicarbonate to try to prevent any acid-mediated hydrolysis of the desired 
N-sulfinyl ketimine product.  
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Due to time constraints, a limited substrate scope was performed (Fig. 2.14). Because 
transimination with the Ellman sulfinamide was more time-consuming and involved, only 
four substrates were completed (Fig. 2.14a). These four compounds however, exhibit the 
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success of the reaction for different types of ketimines. Benzophenone imine 1a showed 
that not only does the reaction work on doubly aromatic ketimines, but also that there 
essentially no epimerization (98.4% enantiomeric excess by chiral column). For ketimine 
1b and 1c, the reaction worked despite the sterically bulky t-butyl and adamantyl 
substituents. What is interesting about 1d is that the reaction worked on a substrate that 
has two alkyl substituents, which was thought to be more difficult due to electronic effects. 
It is also important to note that the numbers reported are isolated yields that were not as 
high as the reaction conversion, but were much higher than was observed by the previous 
reaction methods.  
In transimination reactions involving the Davis sulfinamide, once again the benzophenone 
imine ketimine was generated in a moderate yield (4a, Fig. 2.14b). Substrates with 
sterically bulky groups were attempted and worked with ranging degrees of success. As 
before, the t-butyl substituent (4b) had an excellent yield. Ketimine 4c is a benzophenone 
imine-type substrate with a 2,4-dimethyl substitution that had a moderate yield. 
Surprisingly, 4d with a large adamantyl group was also generated, albeit with a modest 
yield of 53%. Another steric effect to consider is on the sulfinyl group. Therefore, another 
transimination reaction was performed on the benzophenone iminium salt with (R)-
triisopropylphenyl sulfinamide (TIPPS). The synthesis and use of (R)-TIPPS was 
developed in order to fine-tune stereoselectivity when the Ellman and Davis sulfinamide 
failed.29,30 The yield for 5a was modest and required heating similar to the Ellman 
sulfinamide transimination reactions. Although the yields range from excellent to 
moderate, this is the first reported synthesis of N-sulfinyl ketimines that does not require 
Ti(OEt)4 or any other Lewis acid additives.  
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2.2.9 Synthesis of N-Phosphinyl, -Tosyl, and -Carbamoyl Ketimines via 
Transimination 
Using the same conditions outlined in section 2.2.8, the synthesis of N-phosphinyl, -tosyl, 
and -carbamoyl ketimines was 
attempted with the corresponding 
phosphinamide, sulfonamide, and 
carbamate, respectively (Fig. 2.15). 
Unfortunately, in all three cases, no 
product was observed. It is unclear 
why the reaction only worked for 
sulfinamides and should be 
investigated further. These reactions 
were attempted at room temperature 
and monitored via HPLC. Perhaps with more fine-tuning of the reaction conditions product 
would be able to form, but due to time restrictions, another method was investigated. 
 
2.2.10  Mildly Basic Method of Generating N-Phosphinyl and –Tosyl 
Ketimines 
2.2.10.1 N-Phosphinyl Ketimines 
As mentioned, the HCl ketiminium salts could not be used for transimination due to the 
ammonium chloride byproduct. Because they were still available in the lab, the HCl 
ketiminium salts were chosen as test substrates for a novel reaction to generate the 
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tosyl, and -carbamoyl ketimine synthesis via 
transimination. N.R.: no reaction
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various substituted imines. It was hypothesized that the acidic iminium proton could be 
deprotonated upon treatment with a mild base. This would in turn create a nucleophilic 
imine that could attack a good electrophile such as an anhydride or acyl chloride. 
Therefore, instead of using a phosphinamide or sulfonamide as the nucleophile that would 
attack the electrophilic ketiminium salt, the imine could act as a nucleophile to a 
corresponding electrophile. At room temperature, the HCl ketiminium salts were dissolved 
in 2.5 equivalents of Et3N and seven volumes of acetonitrile.  Diphenylphosphinic chloride 
(1.2 equivalents) was added and the reactions were monitored via HPLC. Most reactions 
were completed in one hour with some reactions taking as long as four hours. The 
products were easily purified via column chromatography to generate N-phosphinyl 
ketimines in good to excellent yields (Fig. 2.16). The benzophenone imine-derived 
substrates worked best with electron donating groups producing the highest yield (6b). 
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Because the reactions are under basic conditions, the enolizable substrates (6e and 6g) 
had lower yields. Although 6e had the poorest result, it was surprising to see any product 
at all on the doubly alkyl-substituted substrate. This method is also much simpler and 
milder than those outlined in Figure 2.5 for N-phosphinyl ketimines. The atom economy 
of these reactions is also favorable for process chemistry with an average of 84%.  
 
2.2.10.2 N-Tosyl Ketimines 
 Using the same conditions for N-phosphinyl ketimines, the corresponding N-tosyl 
ketimines were generated using p-toluenesulfonic anhydride as the electrophile (Fig. 
2.17). The yields were consistent with the phosphinyl imines for the most part with some 
differences. The doubly alkylated ketimine 7e had a slightly better yield for the tosyl imine. 
The other enolizable substrate 7g had a significantly lower yield compared to the 
phosphinyl imine (70% and 29%, respectively). As expected, the benzophenone imine-
derived substrates reacted better than the alkyl-containing salts. Once again, this new 
method is less time-consuming and milder than previously reported methods (see Fig. 
2.6). It is also much more process-friendly with little concerns in scalability. Although the 
concentration of the reaction and equivalents may need to be optimized for large-scale 
reactors, these reactions require no tedious work up such as filtering titanium byproduct, 
and purification is trivial. That these reactions are complete in a short period of time and 
are performed at room temperature is an added bonus. The atom economy for this 
reaction is not as favorable as the N-phosphinyl ketimine reaction due to the nature of 
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tosyl anhydride being pseudo-two equivalents of tosyl. Unlike the previous methods 
however, this new reaction does not require heat, additives, or any type of catalysts. 
 
 
2.2.10.3 N-Carbamoyl Ketimines 
 As mentioned earlier, N-carbamoyl ketimines are synthetically useful intermediates but 
can be difficult to generate in an efficient manner (see Fig. 2.7). Therefore, the new mildly 
basic method with ketiminium salts was attempted with benzyl chloroformate to produce 
Cbz-protected ketimines (Fig. 2.18). As before, the limited substrate scope performed 
focused on aromatic versus alkyl substituents and sterically small versus bulky groups. 
Although product was observed via HPLC and NMR, Cbz-protected imines are not stable 
to column chromatography on silica gel. When one sample was subjected to purification 
via column chromatography, no product was isolated, and the corresponding ketone was 
recovered. Therefore, the yields noted in Figure 2.18 are determined by NMR assay of 
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Figure 2.17. Preliminary substrate scope of N-tosyl ketimine formation
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the crude material. This minor drawback can 
be overcome by performing the next reaction 
on the crude material. The crude NMR had 
very few impurities as the minor excess of 
benzyl chloroformate is removed upon work 
up of the reaction. Another solution would be 
to recrystallize the product. It is suspected 
that the product could be a solid despite the 
crude material being an oil. The state of the 
crude could be due to hydrolyzed unreacted 
starting material, which would be the 
corresponding ketone and most likely an oil. 
Due to time restrictions, these solutions could 
not be investigated. It should be noted that in 
the methods described in Figure 2.7, purification was typically not performed either. 
Regardless of the purification obstacles, this is the first reported method of generating 
Cbz-protected ketimines using ketiminium salts under mildly basic conditions.  
 
2.2.11 Conclusions 
A library of N-sulfinyl ketimines was generated through a novel use of transimination with 
ketiminium salts and chiral sulfinamides under optimal conditions. This method is much 
more process chemistry-oriented due to the cheap starting materials, ease of generating 
the ketiminium salts, and elimination of the titanium reagent requirement. These reactions 
R R’
NH2Cl
R R’
NCbz
Et3N, MeCN
rt, 1-4 h
Cl OBn
O
Ph
NCbz
8a, 89%
MeO
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Ph
NCbz
8e, 92%
Yields determined by NMR assay of the 
crude material
Figure 2.18. Preliminary results of 
Cbz-imine formation reactions
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also have good atom economy, with an average of 73% for the Ellman-type sulfinimines 
and 75% for the Davis-type. Despite the many obstacles that had to be overcome for the 
reaction to work, this is the first reported successful, Lewis acid and titanium-free 
synthesis of N-sulfinyl ketimines via transimination. 
Although transimination was not successful with phosphinamides or sulfonamides yet, a 
new method was developed by switching the roles of nucleophile and electrophile in the 
reaction under basic conditions. N-tosyl, -phosphinyl, and -carbamoyl ketmines were 
produced with varying degrees of success. This method is also process-friendly as the 
reactions do not require heat, catalysts, or unstable intermediates. The starting materials 
and reagents are also cheap, stable, and easy to make. These methods show great 
promise in developing N-substituted ketimines for the synthesis of pharmaceutically 
interesting compounds. 
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2.3 EXPERIMENTAL 
General experimental. All reactions, unless specified, were conducted under an 
atmosphere of N2. Where appropriate, control of temperature was achieved with a solid 
CO2/acetone bath, an ice-bath, or a heated oil bath. All commercially available reagents 
were purchased from Sigma-Aldrich. 
1H NMR spectra were recorded at 400 MHz and/or at 500 MHz and calibrated to the 
residual CHCl3 peak at 7.26 ppm. The following abbreviations are used for peak 
multiplicities: br s (broad singlet), s (singlet); d (doublet); t (triplet); q (quartet); quintet 
(quin); m (multiplet); dd (doublet of doublets); ddd (doublet of doublet of doublets); dt 
(doublet of triplets). 13C NMR spectra were recorded at 100MHz and/or at 125 MHz and 
calibrated to the CDCl
 
peak at 77.23 ppm. Chemical shifts are reported in units of parts 
per million (ppm). Coupling constants, J, are reported in Hertz (Hz). Flash 
chromatography was performed on Combi-Flash Rf+ automated system with silica 
columns at Boehringer Ingelheim in Danbury, Connecticut. 
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General procedure for transimination with (S)-tert-butanesulfinamide using 1a as 
example:  
(S)-N-(Diphenylmethylene)-2-methylpropane-2-sulfinamide (1a) 
 (Diphenyl)methaniminium tetrafluoroborate (3d) (1.00 g, 3.72 mmol) and (S)-tert-
butanesulfinamide (0.902 g, 7.44 mmol) were combined in DMF (5.0 mL) and stirred at rt 
for 15 h with 1 eq. of (S)-TBSA added every two hours for the first six hours. The reaction 
mixture was diluted with EtOAc (50 mL) and washed with aqueous NaHCO3 (25 mL). The 
organic phase was dried with Na2SO4 and concentrated in vacuo. Purification of the crude 
residue by silica column chromatography using 10% MTBE/hexane as eluent afforded 
(S)-N-(diphenylmethylene)-2-methylpropane-2-sulfinamide 1a (0.754 g, 71% yield) as 
white solid. 1H NMR (400 MHz, DMSO-d6)  7.83−7.18 (m, 10H), 1.20 (s, 9H).31  
Note: Modifications (if any) on the above general procedure are detailed in the following 
reactions. 
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(S)-N-(2,2-Dimethyl-1-phenylpropylidene)-2-methylpropane-2-sulfinamide (1b) 
According to the general procedure, using 2,2-dimethyl-1-phenylpropan-1-iminium 
tetrafluoroborate (3e) (1.00 g, 4.02 mmol), (S)-TBSA (0.973 g, 8.03 mmol), and DMF (5.0 
mL) stirred for 1 h at 80 °C, followed by purification by chromatography on SiO2 (10% 
MTBE/hexanes) provided (S)-N-(2,2-dimethyl-1-phenylpropylidene)-2-methylpropane-2-
sulfinamide (0.800 g, 75% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6)  
7.53−7.32 (m, 3H), 7.18−7.03 (m, 2H), 1.17 (s, 9H), 1.10 (s, 9H).31  
 (S)-N-(Adamantyl-1-phenylmethylene)-2-methylpropane-2-sulfinamide (1c) 
 According to the general procedure, using adamantyl(phenyl)methaniminium 
tetrafluoroborate 3f (1.00 g, 3.06 mmol), (S)-TBSA (1.48 g, 12.2 mmol), and DMF 
(5.0 mL) stirred for 1 h at 80 °C, followed by purification by chromatography on SiO2 (10% 
MTBE/hexanes) provided (S)-N-(adamantyl-1-phenylmethylene)-2-methylpropane-2-
sulfinamide (0.410 g, 39% yield) as a white solid.  1H NMR (400 MHz, CDCl3)  7.36 (m, 
Ph
N
S
O
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N
S
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3H), 7.03 (br, 2H), 2.02 (m, 3H), 1.84 (m, 6H), 1.68 (d, J = 12.6 Hz, 3H), 1.66 (d, J = 12.6 
Hz, 3H), 1.18 (s, 9H); 13C NMR (100 MHz, CDCl3)  192.1, 136.4, 128.2, 127.6, 126.5, 
44.3, 39.5, 36.3, 28.1, 22.1. 
 
(S)-N-(1-(4-Chlorophenyl)cyclopropyl)ethylidene-2-methylpropane-2-sulfinamide 
(1d) 
According to the general procedure, using (1-(4-chlorophenyl)cyclopropyl)ethaniminium 
tetrafluoroborate 3h (1.00 g, 4.34 mmol), (S)-TBSA (2.10 g, 17.4 mmol), and DMF (5.0 
mL) stirred for 2 h at 80 °C, followed by purification by chromatography on SiO2 (10% 
MTBE/hexanes) provided (S)-N-(1-(4-chlorophenyl)cyclopropyl)ethylidene-2-methyl- 
propane-2-sulfinamide (0.759 g, 63% yield) as a white solid.  1H NMR (400 MHz, CDCl3) 
 7.27 (m, 4H), 2.17 (s, 3H), 1.61 (m, 1H), 1.54 (m, 1H), 1.18 (m, 2H), 1.17 (s, 9H); 13C 
NMR (100 MHz, CDCl3)  186.4, 139.7, 133.0, 131.7, 128.5, 56.4, 35.7, 22.0, 21.5, 17.2, 
17.0. 
  
N
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General procedure for transimination with (S)-p-toluenesulfinamide using 4a as 
example:  
(S)-N-(Diphenylmethylene)-4-toluenesulfinamide (4a) 
(Diphenyl)methaniminium tetrafluoroborate (3d) (1.00 g, 3.72 mmol) and (S)-p-
toluenesulfinamide (0.692 g, 4.46 mmol) were combined in DMF (5.0 mL) and stirred at 
rt for 2 h. The reaction mixture was diluted with EtOAc (50 mL) and washed with aqueous 
NaHCO3 (25 mL). The organic phase was dried with Na2SO4 and concentrated in vacuo. 
Purification of the crude residue by SiO2 column chromatography using 10% 
MTBE/hexane as eluent afforded (S)-N-(diphenylmethylene)-4-toluenesulfinamide 4a 
(0.820 g, 69% yield) as white solid. 1H NMR (500 MHz)  7.88 (d, J = 7.6 Hz, 2 H), 7.72 
(d, J = 8.2 Hz, 2 H), 7.47 (t, J = 6.7 Hz, 1 H), 7.39 (t, J = 8.0 Hz, 2 H), 7.32 (d, J = 8.2 Hz, 
2 H), 2.78 (s, 3 H).15 
 
Note: Modifications (if any) on the above general procedure are detailed in the following 
reactions. 
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 (S)-N-(2,2-Dimethyl-1-phenylpropylidene)-4-toluenesulfinamide (4b) 
According to the general procedure, 2,2-Dimethyl-1-phenylpropan-1-iminium tetrafluoro-
borate 3e (1.00 g, 4.02 mmol), (S)-p-toluenesulfinamide (0.748 g, 4.82 mmol), and DMF 
(5.0 mL) stirred at rt for 15 h followed by purification by chromatography on SiO2 (10% 
MTBE/hexane) provided (S)-N-(2,2-dimethyl-1-phenylpropylidene)-4-toluenesulfinamide 
(1.04 g, 86% yield) as yellow solid. 1H NMR (400 MHz, CDCl3)  7.49-7.47 (m, 2H), 7.40-
7.39 (m, 3H), 7.26-7.24 (m, 2H), 6.95 (br s, 2H), 2.39 (s, 3H), 1.19 (s, 9H); 13C NMR (100 
MHz, CDCl3)  188.9, 143.8, 142.2, 137.1, 129.7, 128.7, 128.1, 126.1, 125.5, 42.0, 27.9, 
21.6. 
 
(S)-N-(2,4-Dimethylphenyl(phenyl)methylene)-4-toluenesulfinamide (4c) 
According to the general procedure, (2,4-dimethylphenyl)(phenyl)methaniminium 
tetrafluoroborate 3a (1.00 g, 3.53 mmol), (S)-p-toluenesulfinamide (0.658 g, 4.24 mmol), 
and DMF (5.0 mL) stirred at rt for 15 h followed by purification by chromatography on SiO2 
Ph
N
S
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(10% MTBE/hexane) provided (S)-N-(2,4-dimethylphenyl(phenyl)methylene)-4-toluene-
sulfinamide (0.891 g, 76% yield) as yellow solid. 1H NMR (400 MHz, CDCl3)  7.72 (d, J 
= 7.4 Hz, 2H), 7.49 (d, J = 7.9 Hz), 7.44 (m, 1H), 7.32 (m, 2H), 7.27 (d, J 7.6 Hz, 1H), 
7.23 (d, J = 8.1 Hz, 2H), 7.16 (d, J = 7.6 Hz, 1H), 7.00 (d, J = 7.6 Hz, 1H), 2.36 (s, 3H), 
2.25 (s, 3H), 1.50 (s, 3H); 13C NMR (100 MHz, CDCl3)  175.8, 143.4, 142.4, 136.4, 135.9, 
134.1, 134.1, 132.6, 129.6, 129.2, 128.6, 127.7, 127.3, 125.6, 21.5, 20.0, 19.4. 
(S)-N-(Adamantyl-1-phenylmethylene)-4-toluenesulfinamide (4d) 
According to the general procedure, using adamantyl(phenyl)methaniminium 
tetrafluoroborate 3f (1.00 g, 3.06 mmol), (S)-p-toluenesulfinamide (0.570 g, 3.67 mmol), 
and DMF (5.0 mL) stirred for 4 h, followed by purification by chromatography on SiO2 
(10% MTBE/hexanes) provided (S)-N-(adamantyl-1-phenylmethylene)-4-toluene-
sulfinamide (0.695 g, 53% yield) as a white solid.  1H NMR (400 MHz, CDCl3)  7.48 (d, J 
= 8.2 Hz, 2H), 7.40 (m, 3H), 7.25 (d, J = 8.2 Hz, 2H), 6.92 (br, 2H), 2.40 (s, 3H), 2.00 (m, 
3H), 1.82 (m, 6H), 1.67 (d, J = 12.6 Hz, 3H), 1.64 (d, J = 12.6 Hz, 3H); 13C NMR (100 
MHz, CDCl3)  188.1, 143.5, 141.7, 136.1, 129.3, 128.3, 127.6, 125.8, 125.0, 43.3, 38.9, 
35.9, 27.7, 27.7, 21.2. 
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(R)-N-(Diphenylmethylene)-2,4,6-triisopropylphenyl-2-sulfinamide (5a) 
According to the general procedure, using (diphenyl)methaniminium tetrafluoroborate 3d 
(1.00 g, 3.74 mmol), (R)-2,4,6-triisopropylphenylsulfinamide (1.20 g, 4.49 mmol), and 
DMF (5.0 mL) stirred for 4 h at 80 C, followed by purification by chromatography on SiO2 
(10% MTBE/hexanes) provided (S)-N-(diphenylmethylene)-2,4,6-triisopropylphenyl-2-
sulfinamide (0.936 g, 58% yield) as a white solid. 1H NMR (400 MHz, CDCl3)  8.00-6.80 
(m, 10H), 7.02 (s, 2H), 3.81 (br, 2H), 2.91-2.81 (m, 1H), 1.24-1.21 (m, 12H), 1.18-1.16 
(m, 6H); 13C NMR (100 MHz, CDCl3)  174.5, 152.7, 150.0, 138.6, 137.2, 128.3, 122.6, 
34.4, 28.8, 25.4, 23.8, 23.8. 
 
General Procedure for Synthesis of N-H Imine Hydrochloride Salts (2) 
A round-bottom flask was charged with nitrile (5.00 g, 1 eq.) and THF (1 M). The mixture 
was cooled to −78 C and PhLi (1.1 eq., 1.8 M in di-n-butyl ether) was added dropwise 
over 0.5 h. After addition, the resulting mixture was stirred for 2 h and quenched with 
anhydrous MeOH (10 mL). The mixture was then stirred at rt for 2 h. The suspension was 
filtered through celite, and the filtrate was concentrated under vacuum. The residue was 
dissolved in MTBE (1 M) and treated with HCl/Et2O (1.1 eq., 1 M). The slurry was stirred 
for 30 min and filtered to obtain the product as free-flowing off-white to yellow solids.27,32  
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Note: Modifications (if any) on the above general procedure are detailed in the following 
reactions. 
 
 
 
(2,4-Dimethylphenyl)(phenyl)methaniminium chloride (2a) 
According to the general procedure, 2,4-dimethylbenzonitrile (5.00 g, 38.1 mmol) and 
PhLi (23.3 mL) were combined in THF (38 mL). The reaction was quenched with MeOH, 
filtered through celite, and concentrated. The crude material was dissolved in MTBE (38 
mL) and treated with HCl/Et2O (34.7 mL). The filtered solid was off-white. 1H NMR 
(MeOD, 500 MHz)  7.90-7.94 (m, 3H), 7.71-7.74 (m, 2H), 7.59 (d, J = 10 Hz, 1H), 7.43 
(m, 1H), 7.37 (d, J = 10 Hz, 1H), 2.41 (s, 6H). 
 
Phenyl(o-tolyl)methaniminium chloride (2b)  
According to the general procedure, o-tolubenzonitrile (5.00 g, 42.7 mmol) and PhLi (26.1 
mL) were combined in THF (43 mL). The reaction was quenched with MeOH, filtered 
through celite, and concentrated. The crude material was dissolved in MTBE (43 mL) and 
treated with HCl/Et2O (47.0 mL). The filtered solid was off-white. 1H NMR (DMSO-d6, 400 
Ph
NH2Cl
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NH2Cl
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MHz)  13.45 (br s, 2H), 7.89 (d, J = 7.2 Hz, 2H), 7.83 (t, J = 7.2 Hz, 1H), 7.65−7.57 (m, 
3H), 7.47-7.40 (m, 3H), 2.12 (s, 3H). 
 
 
 
(2-Methoxyphenyl)(phenyl)methaniminium chloride (2c) 
According to the general procedure, 2-methoxybenzonitrile (5.00 g, 37.6 mmol) and PhLi 
(23.0 mL) were combined in THF (37.6 mL). The reaction was quenched with MeOH, 
filtered through celite, and concentrated. The crude material was dissolved in MTBE (38.0 
mL) and treated with HCl/Et2O (41.3 mL). The filtered product was a yellow solid. 1H NMR 
(DMSO-d6, 400 MHz)  13.20 (br s, 2H), 7.86 (d, J = 7.6 Hz, 2 H), 7.79 (t, J = 7.6 Hz, 1 
H), 7.75−7.70 (m, 1H), 7.61 (m, 2H), 7.45−7.42 (m, 1H), 7.31 (d, J = 8.4 Hz, 1 H), 7.16 (t, 
J = 7.6 Hz, 1 H), 3.72 (s, 3H). 
 
(4-Methoxyphenyl)(phenyl)methaniminium chloride (2d) 
According to the general procedure, 4-methoxybenzonitrile (5.00 g, 37.6 mmol) and PhLi 
(23.0 mL) were combined in THF (37.6 mL). The reaction was quenched with MeOH, 
filtered through celite, and concentrated. The crude material was dissolved in MTBE (38.0 
mL) and treated with HCl/Et2O (41.3 mL). The filtered product was a yellow solid. 1H NMR 
Ph
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(DMSO-d6, 400 MHz)  13.20 (br s, 2H), 7.86 (d, J = 7.6 Hz, 2 H), 7.79 (t, J = 7.6 Hz, 1 
H), 7.73 (m, 1H), 7.61 (m, 2H), 7.44 (m, 1H), 7.31 (d, J = 8.4 Hz, 1 H), 7.16 (t, J = 7.6 Hz, 
1 H), 3.72 (s, 3H). 
 
(2-Bromophenyl)(phenyl)methaniminium chloride (2e)  
According to the general procedure, 2-bromobenzonitrile (5.00 g, 27.5 mmol) and PhLi 
(16.8 mL) were combined in THF (27.5 mL). The reaction was quenched with MeOH, 
filtered through celite, and concentrated. The crude material was dissolved in MTBE (27.5 
mL) and treated with HCl/Et2O (30.2 mL). The filtered product was a yellow solid. 1H NMR 
(MeOD, 500 MHz)  7.90-7.93 (m, 2H), 7.83 (m, 2H), 7.67-7.73 (m, 5H). 
 
Phenyl(2-(trifluoromethyl)phenyl)methaniminium chloride (2f)  
According to the general procedure, 2-(trifluoromethyl)benzonitrile (5.00 g, 29.2 mmol) 
and PhLi (17.9 mL) were combined in THF (29.2 mL). The reaction was quenched with 
MeOH, filtered through celite, and concentrated. The crude material was dissolved in 
MTBE (29.2 mL) and treated with HCl/Et2O (32.1 mL). The filtered product was a yellow 
solid. 1H NMR (MeOD, 500 MHz)  8.05-8.06 (m, 1H), 7.95-8.00 (m, 2H), 7.90-7.93 (m, 
1H), 7.78-7.81 (m, 3H), 7.68-7.71 (m, 2H). 
Ph
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(Diphenyl)methaniminium chloride (2g) 
Commercially available benzophenone imine (5.00 g, 27.5 mmol) was dissolved in MTBE 
(27.5 mL) and treated with HCl/Et2O (30.4 mL). The filtered product was a white solid. 1H 
NMR (MeOD, 400 MHz)  7.62-7.48 (m, 6H), 7.67-7.88 (m, 4H). 
 
2,2-Dimethyl-1-phenylpropan-1-iminium chloride (2h) 
According to the general procedure, trimethylacetonitrile (5.00 g, 60.2 mmol) and PhLi 
(36.8 mL) were combined in THF (60.2 mL). The reaction was quenched with MeOH, 
filtered through celite, and concentrated. The crude material was dissolved in MTBE (60.2 
mL) and treated with HCl/Et2O (66.2 mL). The filtered product was a tan solid. 1H NMR 
(DMSO-d6, 400 MHz)  12.74 (br s, 2H), 7.66−7.61 (m, 1H), 7.56−7.55 (m, 4H), 1.33 (s, 
9H).  
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Adamantyl(phenyl)methaniminium chloride (2i) 
According to the general procedure, 1-adamantanecarbonitrile (3.00 g, 18.6 mmol) and 
PhLi (11.4 mL) were combined in THF (18.6 mL). The reaction was quenched with MeOH, 
filtered through celite, and concentrated. The crude material was dissolved in MTBE (18.6 
mL) and treated with HCl/Et2O (20.5 mL). The filtered product was a tan solid. 1H NMR 
(CDCl3, 400 MHz)  7.55−7.13 (m, 5H), 2.03 (m, 5H), 1.85 (m, 4H), 1.68 (m, 6H).33 
 
Cyclopropyl(phenyl)methaniminium chloride (2j) 
Cyclopropanecarbonitrile (3.00 g, 45.0 mmol) in diethyl ether (3.0 mL) was added 
dropwise to PhLi (27.5 mL, 1.8 M in di-n-butyl ether) over a 5 min period, and when the 
exothermic reaction had ceased the brown solution was allowed to stir an additional 1 h. 
The reaction was quenched with MeOH, filtered through celite, and concentrated. The 
crude material was dissolved in MTBE (45.0 mL) and treated with HCl/Et2O (49.5 mL). 
The filtered product was a white powder. 1H NMR (MeOD, 400 MHz)  7.77 (m, 5 H), 2.05 
(quin, J = 7.0 Hz, 1H), 0.94 (d, J = 7.0 Hz, 4H).34 
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1-Phenylpentan-1-iminium chloride (2k) 
According to the general procedure, benzonitrile (5.00 g, 48.5 mmol) and n-butyllithium 
(21.3 mL, 2.5 M in hexanes) were combined in THF (48.5 mL). The reaction was 
quenched with MeOH, filtered through celite, and concentrated. The crude material was 
dissolved in MTBE (53.3 mL) and treated with HCl/Et2O (53.3 mL). The filtered product 
was a white solid. 1H NMR (DMSO-d6, 400 MHz)  12.77 (br s, 2H), 8.12−8.10 (m, 2H), 
7.85−7.81 (m, 1H), 7.70−7.66 (m, 2H), 3.24 (t, J = 7.6 Hz, 2 H), 1.61-1.53 (m, 2H), 1.40-
1.31 (m, 2H), 0.89 (t, J = 7.6 Hz, 3 H).  
 
 
1-Phenylethaniminium chloride (2l) 
According to the general procedure, benzonitrile (5.00 g, 48.5 mmol) and MeLi (33.4 mL, 
1.6 M in diethyl ether) were combined in THF (48.5 mL). The reaction was quenched with 
MeOH, filtered through celite, and concentrated. The crude material was dissolved in 
MTBE (48.5 mL) and treated with HCl/Et2O (53.3 mL). The filtered product was a white 
solid. 1H NMR (MeOD, 400 MHz) 8.07−8.04 (m, 2H), 7.86−7.82 (m, 2H), 7.70−7.65 (m, 
2H), 2.91 (s, 3H).  
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(1-(4-Chlorophenyl)cyclopropyl)ethaniminium chloride (2n)  
According to the general procedure, the nitrile (5.00 g, 31.8 mmol) and MeLi (21.9 mL, 
1.6 M in diethyl ether) were combined in THF (31.8mL). The reaction was quenched with 
MeOH, filtered through celite, and concentrated. The crude material was dissolved in 
MTBE (31.8 mL) and treated with HCl/Et2O (35.0 mL). The filtered product was a white 
solid. 1H NMR (DMSO-d6, 400 MHz)  7.55 (br, 2H), 7.36 (s, 4H), 1.90 (s, 3H), 1.47 (dd, 
J = 4.0, 7.1 Hz, 2H), 1.12 (dd, J = 4.0, 7.1 Hz, 2H); 13C NMR (DMSO-d6, 100 MHz)  207.2, 
140.1, 132.9, 132.3, 128.8, 37.1, 28.4, 18.0. 
 
General Procedure for Synthesis of N-H Imine Tetrafluoroboric Salts (3) 
The procedure for compounds 3a-3h is identical to the procedure for the N-H imine 
hydrochloride salts (2) with the following changes: Upon formation of the imine, the crude 
material was dissolved in MTBE and treated with tetrafluoroboric acid diethyl ether 
complex (1.1 eq.) to produce the N-H imine tetrafluoroboric salts (3).  
 
General procedure for phosphinic and tosyl imine formation using 6a as example:  
NH2Cl
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 N-((Diphenyl)methylene)-P,P-diphenylphosphinic amide (6a) 
(Diphenyl)methanimine HCl 2g (0.500 g, 2.30 mmol) was dissolved in MeCN (7.5 mL) 
and. Et3N (1.59 mL, 11.5 mmol). Diphenylphisphinic chloride (0.653 g, 2.76 mmol) was 
added and the reaction mixture stirred at rt. After 3 h, the reaction was diluted with CH2Cl2 
(100 mL) and washed with H2O (100 mL). The organic phase was dried with Na2SO4 and 
concentrated in vacuo. Purification of the crude residue by silica column chromatography 
using 35% EtOAc/hexane as eluent afforded phosphinic N-((diphenyl)methylene)-P,P-
diphenylphosphinic amide 6a (0.816 g, 93% yield) as white solid. 1H NMR (CDCl3, 400 
MHz):  7.92 (ddd, J = 11.8, 8.0, 1.4 Hz, 4H), 7.57-7.55 (m, 4H), 7.49 (t, J = 7.4 Hz, 2H), 
7.45 - 7.36 (m, 10H).35 
 
Note: Modifications (if any) on the above general procedure were detailed in the following 
reactions. 
 
N-((4-Methoxyphenyl)(phenyl)methylene)-P,P-diphenylphosphinic amide (6b)  
According to the general procedure, (4-methoxyphenyl)(phenyl)methanimine HCl 2d 
(0.500 g, 2.02 mmol) and diphenylphisphinic chloride (0.573 g, 2.42 mmol) were 
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combined in MeCN (7.5 mL) and Et3N (1.40 mL, 10.1 mmol). After 3 h, the reaction was 
worked up and purified by column chromatography using 35% EtOAc/hexane as eluent 
to afford N-((4-methoxyphenyl)(phenyl)methylene)-P,P-diphenylphosphinic amide 6b 
(0.815 g, 98% yield) as yellow oil. 1H NMR (400 MHz, CDCl3)  7.87 (m, 4H), 7.63 (d, J = 
8.8 Hz, 2H), 7.34 (m, 10H), 7.15 (m, 1H), 6.85 (d, J = 8.8 Hz, 2H), 3.81 (s, 3H); 13C NMR 
(100 MHz, CDCl3)  181.2 (d , J = 7.9 Hz), 162.7, 135.7, 134.4, 132.2, 131.4 (d, J = 9.1 
Hz), 131.2 (d, J = 9.1 Hz), 130.9 (d, J = 2.5 Hz), 130.6 (d, J = 1.8 Hz), 130.3, 129.5, 128.9, 
128.1 (d, J = 12.4 Hz), 127.8 (d, J = 13.1 Hz), 127.5, 113.2, 55.3; 
 
N-((2,4-Dimethylphenyl)(phenyl)methylene)-P,P-diphenylphosphinic amide (6c)  
According to the general procedure, using (2,4-dimethylphenyl)(phenyl)methaniminium 
chloride 2a (0.500 g, 2.02 mmol), diphenylphosphinic chloride (0.578 g, 2.44 mmol), and 
Et3N (1.4 mL, 10.2 mmol) in MeCN (7.5 mL) stirred for 6 h, followed by purification by 
chromatography on SiO2 (35% EtOAc/hexanes) provided N-((2,4-
dimethylphenyl)(phenyl)methylene)-P,P-diphenylphosphinic amide 6c (0.582 g, 73% 
yield) as a light orange oil.  1H NMR (400 MHz, CDCl3)  7.95 (m, 6H), 7.54 (t, J = 7.0 Hz, 
1H), 7.42 (m, 8H), 7.23 (t, J = 7.5 Hz, 1H), 7.01 (d, J = 7.0 Hz, 2H), 1.88 (s, 6H); 13C NMR 
(100 MHz, CDCl3)  181.9 (d, J = 7.4 Hz), 138.2, 137.9, 137.8, 134.9, 133.9, 133.6, 
132.8, 131.6 (d, J = 8.8), 131.1 (d, J = 2.4), 128.7 (d, J = 18.5 Hz), 128.4, 128.1, 128.0, 
126.9, 19.5; 
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N-((2-Methylphenyl)(phenyl)methylene)-P,P-diphenylphosphinic amide (6d)   
According to the general procedure, using phenyl(o-tolyl)methaniminium chloride 2b 
(0.500 g, 2.16 mmol), diphenylphosphinic chloride (0.613 g, 2.59 mmol), and Et3N (1.5 
mL, 10.8 mmol) in MeCN (7.5 mL) stirred for 2 h, followed by purification by 
chromatography on SiO2 (35% EtOAc/hexanes) provided N-((2-
methylphenyl)(phenyl)methylene)-P,P-diphenylphosphinic amide (0.789 g, 96% yield) as 
a yellow oil.  1H NMR (400 MHz, CDCl3)  7.89 (m, 6H), 7.54 (t, J = 7.0 Hz, 1H), 7.42 (m, 
8H), 7.30 (t, J = 7.5 Hz, 1H), 7.15 (m, 2H), 7.02 (d, J = 7.6 Hz, 1H), 1.88 (s, 3H); 13C NMR 
(100 MHz, CDCl3)  182.3 (d, J = 7.3 Hz), 138.8 (d, J = 22.6 Hz), 138.1 (d, J = 12.0 Hz), 
135.3, 134.3, 134.0, 132.8, 131.6 (d, J = 9.0 Hz), 131.2 (d, J = 2.5 Hz), 129.7, 129.5, 
128.9, 128.5, 128.2, 128.1, 127.1, 125.1, 19.6; 
 
 
N-(1-(4-Chlorophenyl)cyclopropyl)ethylidene)-P,P-diphenylphosphinic amide (6e)   
According to the general procedure, using (1-(4-Chlorophenyl)cyclopropyl)ethaniminium 
chloride 2n (0.500 g, 2.17 mmol), diphenylphosphinic chloride (0.617 g, 2.61 mmol), and 
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Et3N (1.5 mL, 10.9 mmol) in MeCN (7.5 mL) stirred for 2.5 h, followed by purification by 
chromatography on SiO2 (35% EtOAc/hexanes) provided N-(1-(4-
chlorophenyl)cyclopropyl)ethylidene)-P,P-diphenylphosphinic amide (0.283 g, 33% yield) 
as a light yellow oil.  1H NMR (400 MHz, CDCl3)  7.78 (m, 4H), 7.38 (m, 6H), 7.29 (m, 
2H), 7.23 (m, 2H), 2.30 (d, J = 1.9 Hz, 3H), 1.71 (dd, J = 7.0, 4.1 Hz, 2H), 1.26 (dd, J = 
6.8, 3.8 Hz, 2H); 13C NMR (100 MHz, CDCl3)  192.6 (d, J = 7.8 Hz), 139.9, 135.3, 134.0, 
133.0, 132.0, 131.3, 131.2, 131.1, 131.1, 128.4, 128.2, 128.1, 37.2 (d, J = 24.3 Hz), 24.8 
(d, J = 12.3 Hz), 18.9; 
 
N-(Adamantan-1-yl)(phenyl)methylene)-P,P-diphenylphosphinic amide (6f)  
According to the general procedure, using adamantyl(phenyl)methaniminium chloride 2i 
(0.500 g, 1.82 mmol), diphenylphosphinic chloride (0.517 g, 2.18 mmol), and Et3N (1.3 
mL, 9.10 mmol) in MeCN (7.5 mL) stirred for 1.5 h, followed by purification by 
chromatography on SiO2 (35% EtOAc/hexanes) provided N-(adamantan-1-
yl)(phenyl)methylene)-P,P-diphenylphosphinic amide (0.471 g, 59% yield) as a light 
orange oil.  1H NMR (400 MHz, CDCl3)  7.85 (m, 4H), 7.41 (m, 6H), 7.32 (m, 1H), 7.25 
(m, 2H), 6.90 (m, 2H), 2.10 (m, 3H), 1.96 (d, J = 2.5 Hz, 6H), 1.74 (dd, J = 27.8, 12.3 Hz, 
6H); 13C NMR (100 MHz, CDCl3)  196.5 (d¸ J = 12.1 Hz), 138.5 (d, J = 12.7 Hz), 135.1 
(d, J = 129.0 Hz), 131.4 (d, J = 9.1 Hz), 130.9 (d, J = 2.7 Hz), 128.1, 128.0, 127.9, 127.1, 
125.8, 39.6, 36.3, 28.1; 
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P,P-Diphenyl-N-(1-phenylpentylidene)phosphinic amide (6g)  
According to the general procedure, using 1-phenylpentan-1-iminium chloride 2k (0.500 
g, 2.53 mmol), diphenylphosphinic chloride (0.713 g, 3.04 mmol), and Et3N (1.8 mL, 12.65 
mmol) in MeCN (7.5 mL) stirred for 4 h, followed by purification by chromatography on 
SiO2 (35% EtOAc/hexanes) provided P,P-diphenyl-N-(1-phenylpentylidene)phosphinic 
amide (0.662 g, 70% yield) as a colorless oil.  1H NMR (400 MHz, CDCl3)  8.01 (m, 6H), 
7.46 (m, 9H), 3.42 (m, 2H), 1.56 (m, 2H), 1.40 (sex, J = 8.5 Hz, 2H), 0.86 (t, J = 7.5 Hz, 
3H); 13C NMR (100 MHz, CDCl3)  185.7 (d, J = 8.4 Hz), 136.4 (d, J = 22.5 Hz), 135.7, 
134.4, 132.1, 131.5 (d, J = 9.1 Hz), 131.2 (d, J = 2.4 Hz), 128.5, 128.4, 128.2 (d, J = 7.3 
Hz), 35.7 (d, J = 11.7 Hz), 30.9, 22.8, 13.7; 
 
 
N-((Diphenyl)methylene)-4-methylbenzenesulfonamide (7a)  
According to the general procedure, using iminium salt 2g (0.500 g, 2.30 mmol), p-
toluenesulfonic anhydride (0.901 g, 2.76 mmol), and Et3N (1.59 mL, 11.5 mmol) in MeCN 
(7.5 mL) stirred for 4 h, followed by purification by chromatography on SiO2 (30% 
MTBE/hexanes) provided 7a (0.741 g, 96% yield) as a white solid. 1H NMR (CDCl3, 400 
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MHz):  7.84 (d, J = 8.2 Hz, 2H), 7.62-7.35 (m, 10H), 7.29 (d, J = 8.1 Hz, 2H), 2.43 (s, 
3H).36 
 
N-((2-Methoxyphenyl)(phenyl)methylene)-4-methylbenzenesulfonamide (7b) 
 According to the general procedure, using (diphenyl)methanimine HCl 2g (0.500 g, 2.02 
mmol), p-toluenesulfonic anhydride (0.791 g, 2.42 mmol), and Et3N (1.4 mL, 10.1 mmol) 
in MeCN (7.5 mL) stirred for 4 h, followed by purification by chromatography on SiO2 (30% 
MTBE/hexanes) provided N-((2-Methoxyphenyl)(phenyl)methylene)-4-methyl- 
benzenesulfonamide (0.441 g, 60% yield) as a yellow oil.  1H NMR (400 MHz, CDCl3)  
7.70 (dd, J = 17.6, 8.2 Hz, 4H), 7.49 (m, 1H), 7.43 (ddd, J = 7.7, 1.4 Hz, 1H), 7.33 (m, 
3H), 7.24 (dd, J = 7.7, 1.8 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 3.59 (s, 3H), 2.39 (s, 3H); ); 
13C NMR (100 MHz, CDCl3)  176.6, 155.9, 143.1, 137.8, 137.0, 133.3, 131.4, 129.8, 
129.1, 129.0, 128.3, 127.5, 120.1, 110.7, 55.4, 21.5. 
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N-((2,4-Dimethylphenyl)(phenyl)methylene)-4-methylbenzenesulfonamide (7c)  
According to the general procedure, using (2,4-dimethylphenyl)(phenyl)methaniminium 
chloride 2a (0.500 g, 2.02 mmol), p-toluenesulfonic anhydride (0.796 g, 2.44 mmol), and 
Et3N (1.4 mL, 10.2 mmol) in MeCN (7.5 mL) stirred for 4 h, followed by purification by 
chromatography on SiO2 (30% MTBE/hexanes) provided N-((2,4-
Dimethylphenyl)(phenyl)methylene)-4-methylbenzenesulfonamide (0.330 g, 45% yield) 
as a yellow oil.  1H NMR (400 MHz, CDCl3)  7.83-7.80 (m, 2H), 7.70-7.68 (m, 2H), 7.53-
7.49 (m, 1H), 7.37-7.33 (m, 2H), 7.28-7.26 (m, 3H), 7.08-7.06 (m, 2H), 2.41 (s, 3H), 2.10 
(s, 6H); 13C NMR (100 MHz, CDCl3)  178.9, 143.6, 138.0, 135.9, 135.2, 134.7, 133.9, 
129.63, 129.60, 129.4, 129.3, 128.9, 127.6, 127.2, 127.1, 21.6, 19.9 
  
N-((2-Methylphenyl)(phenyl)methylene)-4-methylbenzenesulfonamide (7d)  
According to the general procedure, using phenyl(o-tolyl)methaniminium chloride 2b 
(0.500 g, 2.16 mmol), p-toluenesulfonic anhydride (0.845 g, 2.59 mmol), and Et3N (1.5 
mL, 10.8 mmol) in MeCN (7.5 mL) stirred for 4 h, followed by purification by 
chromatography on SiO2 (30% MTBE/hexanes) provided N-((2-
methylphenyl)(phenyl)methylene)-4-methylbenzenesulfonamide (0.694 g, 92% yield) as 
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a white solid. 1H NMR (400 MHz, CDCl3)  7.78-7.76 (m, 2H), 7.67-7.65 (m, 2H), 7.53-
7.49 (m, 1H), 7.39-7.33 (m, 3H), 7.29-7.20 (m, 5H), 2.41 (s, 3H), 2.05 (s, 3H); 13C NMR 
(100 MHz, CDCl3)  179.1, 143.5, 138.1, 136.7, 135.2, 134.9, 133.7, 130.0, 129.7, 129.4, 
128.7, 127.52, 127.46, 125.3, 21.6, 19.9. 
 
 
N-(1-(4-Chlorophenyl)cyclopropyl)ethylidene)-4-methylbenzenesulfonamide (7e)  
According to the general procedure, using (1-(4-Chlorophenyl)cyclopropyl)ethaniminium 
chloride 2n (0.500 g, 2.17 mmol), p-toluenesulfonic anhydride (0.851 g, 2.61 mmol), and 
Et3N (1.5 mL, 10.9 mmol) in MeCN (7.5 mL) stirred for 2 h, followed by purification by 
chromatography on SiO2 (10% MTBE/hexanes) provided N-(1-(4-chlorophenyl)-
cyclopropyl)ethylidene)-4-methylbenzenesulfonamide (0.720 g, 48% yield) as a white 
solid.  1H NMR (400 MHz, CDCl3)  7.78 (d, J = 8.3 Hz, 2H), 7.30 (m, 4H), 7.24 (m, 2H), 
2.43 (s, 3H), 2.39 (s, 3H), 1.64 (dd, J = 6.9, 3.9 Hz, 2H), 1.27 (dd, J = 6.9, 3.9 Hz, 2H); 
13C NMR (100 MHz, CDCl3)  191.5, 143.3, 138.7, 133.6, 132.0, 130.4, 129.3, 128.9, 
126.8, 36.0, 23.6, 21.5, 20.2, 18.7. 
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N-(Adamantan-1-yl)(phenyl)methylene)-4-methylbenzenesulfonamide (7f)  
According to the general procedure, using adamantyl(phenyl)methaniminium chloride 2i 
(0.500 g, 1.82 mmol), p-toluenesulfonic anhydride (0.713 g, 2.18 mmol), and Et3N (1.3 
mL, 9.10 mmol) in MeCN (7.5 mL) stirred for 4 h, followed by purification by 
chromatography on SiO2 (30% MTBE/hexanes) provided N-(adamantan-1-
yl)(phenyl)methylene)-4-methylbenzenesulfonamide (0.410 g, 57% yield) as a white 
solid.  1H NMR (400 MHz, CDCl3)  7.68 (m, 2H), 7.36 (m, 2H), 7.28 (m, 1H), 7.21 (d, J = 
8.2 Hz, 2H),  7.06 (dd, J = 7.7, 1.3 Hz, 2H), 3.22 (q, J = 7.3 Hz, 1H), 2.40 (m, 3H), 2.01 
(m, 2H), 1.79 (d, J = 2.6 Hz, 3H), 1.64 (dd, J = 37.1, 12.3 Hz, 4H), 1.12 (t, J = 7.3 Hz, 2H); 
13C NMR (100 MHz, CDCl3)  192.6, 143.0, 138.4, 134.8, 129.5, 129.2, 128.6, 127.2, 
127.1, 126.9, 2126.2, 44.6, 41.9, 39.1, 27.9, 21.4, 21.4, 14.1; 
 
 
N-(1-Phenylpentylidene)-4-methylbenzenesulfonamide (7g)  
According to the general procedure, using 1-phenylpentan-1-iminium chloride 2k (0.500 
g, 2.53 mmol), p-toluenesulfonic anhydride (0.991 g, 3.03 mmol), and Et3N (1.75 mL, 12.7 
mmol) in MeCN (7.5 mL) stirred for 4 h, followed by purification by chromatography on 
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SiO2 (30% MTBE/hexanes) provided N-(1-phenylpentylidene)-4-methyl- 
benzenesulfonamide (0.231 g, 29% yield) as a white solid.   
 152 
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